Lantibiotic Smb: Characterization of the immunity protein, identification of a novel receptor-like protein, and a new perspective on regulation by Biswas, Saswati
 
LANTIBIOTIC SMB: CHARACTERIZATION OF THE IMMUNITY PROTEIN, 
IDENTIFICATION OF A NOVEL RECEPTOR-LIKE PROTEIN, AND A NEW PERSPECTIVE 
ON REGULATION 
 
By 
                                                                    SASWATI BISWAS 
March 13, 2014 
Submitted to the graduate degree program in Microbiology, Molecular Genetics and Immunology, and the 
Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy. 
 
 
 
 
.    
                                              Chairperson:  Thomas Yankee, Pharm. D., Ph.D. 
 
Joe Lutkenhaus, Ph.D. 
 
 Wolfram Zueckert, Ph.D. 
 
Liskin Swint-Kruse, Ph.D. 
 
Mohammad Mir, Ph.D. 
 
 
                                                          Date Defended: March 13, 2014  
ii 
 
The Dissertation Committee for SASWATI BISWAS 
certifies that this is the approved version of the following dissertation:   
 
 
 
 
 
LANTIBIOTIC SMB: CHARACTERIZATION OF THE IMMUNITY PROTEIN, 
IDENTIFICATION OF A NOVEL RECEPTOR-LIKE PROTEIN, AND A NEW PERSPECTIVE 
ON REGULATION 
         
 
 
 
 
 
 
 
 
  
                                                           
                                                                                           Chairperson:   Thomas Yankee, Pharm. D., Ph.D. 
 
 
                                            Date approved:  March 13, 2014 
  
iii 
 
 
 
This is to attest that the work represented in this dissertation was performed by Saswati Biswas in my 
laboratory, except where indicated. 
 
 
 
 
 
__________________ 
Indranil Biswas, Ph.D. 
Professor 
Department of Microbiology, Molecular Genetics and Immunology 
The University of Kansas Medical Center 
iv 
 
Abstract 
Dental caries, commonly known as tooth decay, is a chronic disease that develops slowly and requires 
formation of biofilm on tooth surfaces, commonly known as dental plaque.  Dental plaque is a highly 
complex multispecies biofilm containing over ~700 different microorganisms. In this microbiota, 
Streptococcus mutans is considered to be the primary etiological agent for cariogenesis.  To colonize and 
maintain its dominance over competing non-cariogenic species, S. mutans secretes various antimicrobial 
peptides called bacteriocins.  S. mutans produces two types of bacteriocins: linear unmodified peptides 
known as non-lantibiotics and extensively modified nonlinear peptides called lantibiotics.  S. mutans GS-5 
strain is a highly virulent isolate that has been extensively used for genetic and biochemical studies.  This 
strain produces a broad-spectrum lantibiotic called Smb.  This lantibiotic is one of the arsenals that S. 
mutans GS-5 uses to shift the established bacterial flora associated with dental health towards the flora 
associated with dental caries.    
A lantibiotic producer strain must contain a self-protection mechanism to protect itself from the lantibiotic-
mediated damage.   Immunity mechanisms against Smb have not been identified. A previous report by 
Kuramitsu's group described SmbG, a putative ABC transporter with a peptidase domain, as the immunity 
protein for Smb.  This proposed function of SmbG in providing immunity is not supported by their 
experimental data.   In this study we show that an ABC-transporter encoded by SmbFT functions as an 
immunity complex.   We show that GS-5 becomes sensitized to Smb upon deletion of smbT, which makes 
the ABC transporter non-functional.  We demonstrate that SmbFT can confer protection against Smb when 
expressed heterologously in four different sensitive streptococci.  We also demonstrate that SmbFT can 
confer protection against structurally similar two-petide lantibiotics such as haloduracin.  We conclude that 
SmbFT truly displays immunity function and confers protection against Smb and structurally similar 
lantibiotics.   
Lantibiotics are potent bactericidal agents and usually functional at nanomolar range, whereas other 
antimicrobial peptides are effective at micromolar concentrations.  This fact indicates that the interplay 
between the lantibiotics and the target organisms must be specific and perhaps it occurs through receptor-
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mediated interaction.  However, to date, no such receptor molecules have been identified for any 
lantibiotics.   In this study we identify in S. pyogenes (a human pathogen) a membrane-bound protein that 
exhibits a receptor-like function for Smb.  This protein, which we named LsrS, belongs to CAAX-protease 
family.  LsrS is widely present in streptococci including S. mutans and is highly conserved.  Deletion of the 
LsrS homolog in sensitive S. mutans strains makes them refractory to Smb inhibition.  However, neither 
LsrS nor its homolog can recognize other structurally similar two-peptide lantibitics.  Nevertheless, this is 
the first protein that displays a receptor-like function for any lantibiotics. 
It is of great importance to understand how the producer strain regulates the expression of its immunity 
protein to counteract the cognate lantibiotic produced by the cell as well as by the neighbours.  An auto-
sensing mechanism may exist to maintain a constant ratio of the immunity protein and the lantibiotic.  Little 
is known about the transcriptional regulation of the smb operon.  Unlike most of the other lantibiotic loci 
that encode their own regulatory factors, smb locus does not encode any factor that can function as an auto-
regulator.  We provide experimental evidences that Smb peptides function as signaling molecules and auto 
regulate the smb operon through some yet to be discovered regulators.  We attempted to identify the 
unknown regulators by transposon mutagenesis and identified an operon that seems to be involved in 
activation of smb operon.  Further analysis indicated that a transcriptional regulator encoded within the 
operon indeed regulates smb production.  Our results show that a new regulator and perhaps a new 
regulatory pathway might control smb expression. 
 Lantibiotics, such as Smb, are highly potent, stable, and active at nanomolar concentrations.  Because of 
the stability and potency lantibiotics are widely used in food industry as preservative. Few other lantibiotics 
are in clinical trials with the prospective to be used as antimicrobial agents in the healthcare industry.  Since 
Smb can inhibit many pathogenic streptococci, it has the potential to be used as an antimicrobial agent in 
food and/or healthcare industry. 
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Chapter 1:  Introduction    
 
1.1.      Streptococcus mutans: the pathogen and its community  
 
The oral cavity, which is sterile at birth, is immediately colonized by bacteria acquired primarily from the 
mother or other family members of the infant.  Right after the eruption of the first tooth, the oral cavity 
microbial community diversifies and eventually becomes a complex consortium of bacteria with more 
than 700 species [1].  In healthy individuals, this community provides protection against pathogens by 
inhibiting their survival as well as interfering with their colonization in the oral cavity.  However, some 
potential opportunistic pathogens are members of this community and can cause diseases when the 
conditions become favorable.  Although bacteria can adhere to different mucosal surfaces in the oral 
cavity, they are periodically shed during epithelial cell turnover.  One exception is the tooth, where 
bacteria can colonize firmly and form biofilms, unless proper hygiene is maintained.  Biofilms formed on 
the tooth surfaces are known as dental plaques.  Dental plaque formation is a prerequisite to dental caries, 
which is one of the most prevalent and somewhat benign human diseases.  In 1924, Clarke and colleagues 
have isolated Streptococcus mutans, a Gram-positive and chain forming cocci, from cariogenic tooth of 
humans [2].  The prevalence of this organism in human dental caries entitled the bacterium the name of 
the causative agent for the tooth decay.  S. mutans has exceptional ability to adhere to tooth surfaces and 
to produce high amount of acid to de-mineralize the tooth enamel causing dental caries.  Although, S. 
mutans and few other streptococci are the predominant species during initial stages of dental plaque 
formation, other Gram-positive rods such as Actinomyces oris and filamentous bacteria such as 
Fusobacterium nucleatum start accumulating with the progression of the dental caries.  Other species of 
bacteria such as Actinomyces spp. and Veillonella spp. are also associated with caries formation; however 
their exact role in the disease pathogenesis is not well understood.  
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1.1.1. The oral environment 
The diverse community of oral bacteria often shows distinct tissue-specific tropisms. Various bacteria 
colonize different surfaces of the oral cavity, such as the tooth enamel, tongue, soft and hard palate, 
gingiva and buccal mucosa [3].  Several studies have been conducted to characterize which biological 
surfaces in oral cavity are colonized by which group of bacteria. For example, Actinomyces spp. seem to 
colonize on tooth surfaces, while Prevotella melaninogenica and Veillonella parvula colonize soft tissue 
surfaces in higher proportions [3].  Other Gram-negative organisms such as Capnocytophaga gingivalis 
and V. parvula primarily colonize the tongue, which is also a soft tissue [3].    Gram-positive organisms, 
specifically streptococci such as S.mitis, S. oralis, and S. salivarius predominantly colonize the soft 
tissues and are found in higher proportion in the saliva as compared to other organisms [4].  Other 
pathogenic streptococci, such as S. agalactiae, S. dysgalactiae, and S. pyogenes are all able to colonize 
the human nasopharynx [5].   The rate of colonization of S. pyogenes in the oral cavity specifically in the 
oropharynx of children can reach as high as 10% [6]. The dominance of certain bacterial species in the 
specific regions of the oral cavity is due to the fact that various organisms express different cell-surface 
associated adhesins that determine the tissue tropism [3].   
Dental plaque formation requires extensive bacterial colonization on the tooth surfaces.  Colonization by 
oral bacteria in biofilms requires attachment to a surface such as to teeth, epithelial cells, or to the 
bacterial surface.  This initial adherance is the most crucial step in building dental plaque.  The best-
studied oral biofilms are the two types of dental plaques.  The first one is the dental plaque that develops 
on the tooth enamel and known as supragingival plaque.  The second one is the plaque below the gum line 
on the root surface known as subgingival plaque.  Development of a mature dental plaque occurs in four 
successive stages involving different colonizing bacteria (Fig. 1).  The bacteria involved in these four 
stages are called initial, early, mid, and late colonizers.  These bacteria either directly interact with the 
epithelial cell or to tooth surfaces through adhesin-receptor interaction, or to another bacteria by specific 
protein-protein interaction known as coaggregation.   
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Figure 1:  Pictorial representation of oral bacterial colonization and biofilm formation on pellicle coated 
tooth surface. This colonization is detected within few hours of oral hygiene procedure.  Streptococcus 
oralis (Sor), Streptococcus gordonii (Sgo),  Streptococcus snaguinis (Ssa),   Streptococcus mitis (Smi) 
Actinomyces oris (Aor), and Actinomyces naeslundii (Ana) bind to salivary receptors or coadhere to the 
other initial colonizers.  Early colonizers Veillonella spp. (Vei), Prevotella spp. (Pre), and 
Porphyromonas spp. (Por) appear within four hours of dental hygiene.  Growth of initial colonizers is 
shown by increased numbers of streptococci and actinomyces.  Mid-colonizers such as Fusobacterium 
nucleatm (Fus), Capnocytophaga spp. (Cap), and Streptococcus mutans (Smu) coadhere with the already 
present initial and early colonizers.  Late colonizers such as Tanerella forsythia (Tan), Treponema 
denticola (Tre) coaggregate with the bacteria in the already established biofilm. The color scheme follows 
the Socransky classification of dental bacteria. [Adapted from Kolenbrander and Periasamy, Oral 
Microbial Communities]  
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The initial colonization step is perhaps the most crucial stage in biofilm development since it dictates the 
community structure of the matured dental plaque.  The initial colonizers of dental plaque are capable of 
directly binding to the salivary glycoproteins in pellicle, which immediately coats the tooth surface after 
oral hygiene measures [7,8].  Results from culturing bacteria in dental plaque indicated that streptococcal 
species belonging to the viridians group, primarily S. mitis and S. oralis dominated the initial stage.  Two 
other streptococci, S. sanguinis and S. gordonii, were also found but at a lesser frequency and 
Actinomyces spp. were also present in the initial development [8-10].  After the establishment of the 
initial community, coaggregation and coadherence between different bacterial species continues as a 
result biofilm microflora becomes more complex [9].  Surface component mediated cell-cell interactions 
of two species have been extensively studied and various adhesins that promote co-aggregation have been 
identified [10].  For example, cell wall anchored adhesins SspA and SspB on different streptococci have 
been shown to mediate co-aggregation with Actinomyces naeslundii and S.  gordonii [10]. This interaction 
introduces genus diversity in early plaque formation.  Although S. gordonii is an initial colonizer, 
streptococcal adhesin SspA/B expressed by S. gordonii shown to interact with fimbriae of 
Porphyromonas gingivalis, involved in periodontal disease.  Initial colonization by streptococci is also 
influenced by the intrageneric coaggregation among all the initial colonizing bacteria [11].  Intrageneric 
coaggregation is widely observed among various oral streptococci and not so much with other species.  
However, other oral bacteria such as A. naeslundi and Actinomyces oris display intergenic coaggregation 
with the initial streptococcal colonizer and other genera, and diversify the initial developing community 
([12,13]; Fig 1).  
After coadherence and coaggregation, the initial colonizers start multiplying and provide a bacterial 
surface for the attachment of the early colonizing bacteria.  The early colonizing bacteria include genera 
such as Eikenella, Neiseeria, Porphyromonas, Prevotella, and Rothia all of them have the ability to 
coaggregate with the already attached cells.  However, an important group, Veillonella spp., has the 
ability to readily coaggregate with the attached streptococci and actinomyces.  Veillonella spp. can reach 
high proportion in the biofilm and can constitute between 2 to 9% of the microbiota in the early 
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colonizing stage [14,15].  This observation suggests that Veillonellae can efficiently exhibit both 
intergeneric and intrageneric interactions on tooth enamel.  Another importatnt trait is that Veillonellae 
cannot utilize sugars for their growth but are able to ferment organic acids such as lactic acid.  Both 
streptococci and actinomyces present in the early biofilm produce lactic acid as metabolic by product.  
This lactic acid provides a nutritional source for Veillonellae growth.  
Another notable coaggregation in the early biofilm community is between S. gordonii with S. oralis and 
P. gingivalis.  The coaggreation between S. gordonii and P. gingivalis is very well characterized.  The 
interaction involves Mfa, a short fimbriae present on the P. gingivalis cell and SspA/B on the S. gordonii 
cell [16].  This interaction is regulated by several factors including an auto inducer molecule, a LuxR 
family transcription factor, and involvement of arginine deiminase pathway [17-19].  Likewise, S. oralis 
is also an important contributor in the early biofilm community. A two-species biofilm study suggests that 
S. oralis can grow mutualistically with Veilonella sp. [20].  However, another two-species biofilm study 
involving S. oralis and P. gingivalis show no growth of either species [21].  By comparison, a three-
species biofilm study involving all three organisms (S. oralis, P.gingivalis, and Veillonella) show growth 
of all, indicating that the interfering effects observed in the two-species study can be overcome by the 
addition of a third species [20].   These in vitro studies indicate that intricate multispecies partnerships are 
the key for succession of species during dental plaque development.   
The mid-colonizing bacteria need to interact with both the initial and early colonizers as well as with the 
late colonizers.  These bacteria also need to compete with the numerous streptococci as well as other 
initial and early colonizers to establish themselves in the biofilm.  The mid colonizers include mainly two 
species:  Fusobacterium nucleatum and Capnocytophaga gingivalis.  These bacteria exhibit different 
community interactions and strategies than those employed by the initial and early colonizers.  For 
example, F. nucleatum has the ability to coaggregate with all the initial and early colonizers [22].  
Fusobacteria are also able to co-aggregate with the mid colonizer C. gingivalis [7,9].   This trait provides 
F. nucleatum an added advantage over already adherent all other species including C. gingivalis.  Both of 
these species are ubiquitously present in non-carious sites of healthy oral tissues.   However, both F. 
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nucleatum and C. gingivalis bacteria appear predominantly in the oral sites that are subsequently affected 
by periodontitis, these middle colonizers are called "the crossroads between health and disease."   
F. nucleatum expresses an arginine-sensitive adhesin, RadD, on its cell-surface that is used for 
coaggregation between F. nucleatum and other streptococci [23,24].    F. nucleatum can also form 
coaggregates with numerous Gram-negative species that are lactose-inhibitable.   However, one initial 
colonizer, S. oralis, appears to negatively influence the growth of F. nucleatum.  On the other hand, 
another initial colonizer, A. oris, appears to positively influence F. nucleatum growth.   Therefore, the 
relationship among the species in the mid colonization phase seems to be highly dynamic with some 
interactions being synergistic while others being antagonistic.   
It is important to mention here that while S. mutans is considered as an early colonizer and can directly 
interact with the tooth enamel via surface expressed adhesins (see below), as well as can form 
coaggregates with early colonizers such as Neisseria spp. and Actinomyces spp. [25],  some researcher 
believe that S. mutans may actually be a mid colonizer.   This is because some studies have found that S. 
mutans is noticeably absent from the initial and early biofilms, while many other streptococci, including 
S. mitis, S. oralis, S. gordonii, S. infantis, and S. sangunis are dominant in the early stages [26,27].  
Interestingly, these dominant streptococci produce hydrogen peroxide, which inhibits the growth of S. 
mutans.  Therefore, in healthy and non-cariogenic lesions, S. mutans may be outcompeted by other 
streptococci.   But situation is differnt in the cariogenic tooth where using multiple antagonistic 
approaches S. mutans establishes itself in the biofilm at the early stages and suppresses the growth of 
other competing species.   
As the microbial community develops and diversifies, late colonizers start to accumulate in the biofilm.   
These late colonizers are frequently associated with the periodontal disease.  Three organisms, Tannerella 
forsythia, Treponema denticolla, and P. gingivalis, are commonly classified as red complex and cause 
periodontal disease.  Another organism, Aggregatibacter actinomycetemcomitans, which is often involved 
in an aggressive form of periodontitis, is also a late colonizer [28].   As expected, all four species can 
efficiently coaggregate with fusobacter, the mid colonizer.  However, as mentioned before, P. gingivalis 
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is the exception among the red complex bacteria since it can coaggregate with the initial colonizer S. 
gordonii.   Red complex bacteria can also interact with each other in the oral biofilm.  P. gingivalis can 
coaggregate with T. denticola through the involvement of fimbriae and treponema PrtP protease [29].   
 
Established biofilm communities are found not only on the tooth surfaces but also in the mucosal surfaces 
of the tongue, buccal mucosa, and gingival crevices.   The population structure of the bacterial flora in 
these established biofilms is highly complex and dynamic.  Competitive and mutualistic interactions 
among the species determine the ultimate composition of the biofilm.  However, the population structure 
is subjected to changes by parameters such as diet and underlying health conditions [30].   Environmental 
factors such as nutrient availability and red-ox potential as well as host factors such as presence of 
receptors and immune chemicals (cytokines and antibodies) determine the composition of the biofilm at a 
given niche.   Most bacteria in the biofilm display commensalism, which benefits both host and the 
bacteria.   However, as mentioned before, among the innocuous bacterial flora, some opportunistic 
pathogens with virulence capability exist and can cause disease within and beyond the confines of oral 
cavity.  When the condition is shifted from healthy state to a disease state, the entire consortia of bacterial 
population changes.  There are no bacterial species that are exclusively associated with the healthy oral 
environments.  The proper balance between pro-healthy and pro-disease causing bacterial community is 
critical and the balance can be disturbed due to nutritional variations, exposure to antibacterial agents, 
underlying health conditions, and other factors.   Oral diseases such as dental caries occur when the pro-
disease causing bacterial community increases in abundance relative to the pro-healthy microbiota.  The 
exact reasons responsible for the emergence of certain disease causing pathogens and the shift from 
heathy state to disease state are not very well understood. 
 
1.1.2. Diseases caused by S. mutans  
Changing diet to a more sugar-based (carbohydrates), more frequent feeding, and consumption of acidic 
drinks shift the bacterial flora to more acidogenic population.   In this acidogenic population, S. mutans is 
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the dominant species and is considered to be the principal etiological agent in human dental caries. S. 
mutans encodes for different virulence factors that help them to cause diseases (Fig 2).  Apart from S. 
mutans, various lactobacilli, S. sobrinus and F. nucleatum also show some association with dental caries; 
however, S. mutans is the predominant one.  It is believed that S. mutans, which is an early or mid 
colonizer, could out compete other bacteria in the dental plaque. Often, this organism is involved in 
causing infective endocarditis (IE) and S. mutans accounts for more than 20% of cases of viridians 
streptococcus-induced endocarditis.  The induction of dental caries and the development of endocarditis 
are discussed below.  
 
1.1.2. a. Dental caries  
Dental caries is initiated by a breach in the tooth enamel caused by bacteria present in the dental plaque.   
These acidogenic bacteria produce lactic acid from dietary sugars during carbohydrate metabolism, which 
demineralizes the tooth enamel [31,32].  The disease develops from this initial area of deminaralization 
that exposes the underlying dentine to the condition where bacteria gain access to the tubular network of 
dentine reaching to dental pulp.   There are at least three major hypotheses behind the development of 
dental caries that includes the specific plaque hypothesis, the non-specific plaque hypothesis, and the 
ecological plaque hypothesis [2,33-35].  In 1924, Clarke [2] first proposed the specific plaque hypothesis  
suggesting that only a few species of bacteria, such as S. mutans, are involved in the caries development.  
Towards this end, several studies have indicated the presence of higher levels of S. mutans at human 
carious lesions compared to other organisms and for this reason, S. mutans is attributed as the principal 
etiological agent of caries formation [31,32,36,37].    
Miller in the late 1800s [33] proposed the non-specific plaque hypothesis.  He suggested that all bacteria 
in the mouth have the potential to be cariogenic and few reports indicate several non-mutans bacteria can 
successfully produce caries lesions [35,38,39].   The non-specific plaque hypothesis is an attractive and 
highly accepted alternative explanation for dental caries formation. Finally, the ecological plaque 
hypothesis suggests that dental caries and other plaque-related diseases are formed by imbalances in the 
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resident community microflora.  For example, imbalances due to high acidic conditions may favor 
emergence of a plaque community enriched in cariogenic streptococci [40].  This hypothesis proposes 
that any acidogenic organisms in the oral cavity, such as S. mutans and others, can initiate caries 
formation provided that the local environmental conditions support the overall process.  Several recent 
microbiome studies as well as other targeted studies [41] involving children with healthy and cariogenic 
tooth suggest that complex cariogenic community might be responsible for dental caries.  Nevertheless, 
most of the studies, whether microbiome based or targeted, have always identified S. mutans in the 
cariogenic population.  Therefore, S. mutans truly involved in development of dental caries in human.  
Cariogenic lesions on the tooth surfaces progresses rather slowly.   The pH inside oral plaque is always in 
constant flux.  The pH can rapidly decrease due to acid production by acidogenic bacteria following 
intake of dietary carbohydrate and can rise due to alkali production by other plaque bacteria under 
nutrient limited condition [35,39,42].  Since S. mutans can metabolize a diverse range of carbohydrates, 
this organism has the innate ability for initiation and progression of dental caries [43-45].  Carbohydrates 
such as fructose, glucose, galactose, and sucrose can be easily fermented by S. mutans via the glycolytic 
pathway to produce lactic acid from pyruvate [31].   Lactic acids generated by S. mutans and other 
acidogenic plaque bacteria such as lactobacilli and S. sobrinus, acidify the local environment below the 
pH 5.5; the critical point required for remineralisation of tooth enamel [32,43,46].  Extended period of 
exposure to low pH leads to continuous demineralisation of the tooth enamel causing caries formation 
[47].   
 
1.1.2.b. Infective endocarditis (IE)  
S. mutans is also responsible for the induction of infective endocarditis.  IE is a bacterial infection of the 
endocardium (a lining that covers the inside of the heart) and the heart valve [48,49].  Predominantly, IE 
is caused by Gram-positive cocci, which account for more than 80% of all endocarditis in humans [49].  
The viridans group of streptococci are the most common players of endocarditis involving native heart 
valves in patients with congenital heart disease [48].  IE results from a combination of systemic infections 
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including bacteremia following oral surgery or various dental procedures and a predisposing condition of 
damaged heart valve [50,51].  S. mutans accounts for about 20% of IE cases attributed to viridans 
streptococci [47,52].  Viridans streptococci are a group of streptococci that produce greeninsh halo on 
blood agar plate (see later).  Success in causing the diseases depends on two strategies: adherence to 
cardiac tissue and evasion of host immune response. To adhere to cardiac tissue, S. mutans expresses 
various cell surface associated adhesins.  The serotype specific rhamnose-glucose polysaccharide (RGP) 
acts as a putative adhesins for binding of S. mutans cells to human monocytes, fibroblasts, and platelets 
[53].  Recently, two surface associated collagen-binding proteins Cnm and Cbm are also shown to be 
involved in adhesion and invasion human endothelial cells [54]. Once the organism reaches to heart 
valve, the next step is to facilitate growth of a coagulum at the site of adherence.  Within this protective 
niche covered by platelets, bacteria multiply and damage host tissues that lead to formation of thrombotic 
vegetation.   The dynamic or sequential events of bacteria-platelet interactions during colonization and 
vegetation formation on the heart valves are currently unclear.   
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Figure 2:  Schematic representation of different communications and virulence strategies employed in 
dental plaque by S. mutans.   S. mutans ferments different sugars to produce acid and uses ATPase pump 
for acidifying its environment while maintaining neutrality inside the cell.    S. mutans also extracellularly 
synthesizes different polysaccharides such as glucan and fructan to adhere to tooth surface. These bacteria 
express different surface antigens, WapA, PavA, and SpaP.   These proteins are help in coaggregation 
with other bacteria.   S. mutans employs both AI-2 and CSP mediated quorum sensing mechanisms to 
communicate in a multispecies community.   S. mutans produces inhibitory molecules mutanobactin and 
bacteriocins to destroy competing species.  
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1.1.3. Classification of streptococci and diseases caused by major streptococcal pathogens 
The genus streptococcus is a heterogeneous group of bacteria containing about 103 different species; 
many of them are involved various human and animal associated diseases.  Based on 16S ribosomal RNA 
sequences, streptococci are phylogenetically divided into six groups: anginosus, bovis, mitis, mutans, 
pyogenic, and salivarius (Fig 3).   This phylogenetic classification is further supported by numerous 
genome sequences and is the current method of choice for classifying streptococci.    
There are two other traditional methods of classifications, one that uses Lancefield group antigens that are 
present on the cell surface and the other one is based on bacterial ability to lyse red blood cells.  
Lancefield classification contains twenty described serotypes named Lancefield groups A to H and K to 
V.  There are some streptococci that have no described Lancefield group antigens and some with new 
antigens.  Among the various Lancefield groups, group-A and group-B are by far the most common 
human pathogens.  Streptococci are also classified into three hemolytic groups: α, β, and γ. The α-
hemolytic group includes the viridans group of streptococci (oral streptococci) and produces partial 
hemolysis or green color around the colony by oxidizing the hemoglobin of the red blood cells.  The β-
hemolytic group includes mostly group-A and group-B streptococci that produce complete lysis of the red 
blood cells.  Finally the γ-hemolytic group does not lyse the red blood cells at all; bacteria such as 
enterococci, lactococci (both of which are not considered as streptococci anymore), S. salivarius, and S. 
thermophilus are included in this group.  It is important to mention that Lancefield group antigen does not 
always correlate with the species and the classification based on hemolysis is also not accurate.   
Among the various streptococci, S. pyogenes (classified as group-A), S. agalactiae (classified as group-
B), and S. pneumonia belonging to non Lancefield group antigen are perhaps the major human pathogens.  
S. pyogenes causes variety of diseases in humans ranging from mild to severe in nature.  Infections such 
as pharyngitis (strep-throat) and impetigo (skin infections) are self-limiting and mild.  In contrast, 
invasive diseases such as faciitis, bacteremia, and toxic-shock are more severe and life threatening.  
Although, S. pyogenes is generally found on the skin as commensal organism, it is often isolated from the 
oral cavity and saliva along with the other oral bacteria. The rate of colonization of S. pyogenes in the oral 
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cavity specifically in the oropharynx of children can reach as high as 10%.   Perhaps less frequently, S. 
pyogenes can cause infective endocarditis along with the primary causative agents such as S. mutans and 
other viridans streptococci.  
 
On the other hand, S. agalactiae is generally colonized in the female genital tract. Occasionally, S. 
agalactiae can be found in the nasopharynx.   This organism commonly causes pneumoniae, meningitis, 
and sepsis in the newborns.  S. agalactiae is also an important animal pathogen and can cause bovine 
mastitis.  And finally, S. pneumoniae is an upper respiratory tract pathogen and the carrier rate of S 
pneumoniae in the normal human nasopharynx is as much as 20-40%. This capsular coccus has over 90 
different serotypes. Although usually commensal, it is capable of causing pneumoniae, sinusitis, 
conjunctivitis, meningitis, bacteremia, sepsis, osteomyelitis, and endocarditis in immunocompromised 
individuals.   
 
Apart from the streptococci that are discussed above, a few others streptococci can cause various human 
diseases.  For example, viridans group of strptococci are the causative agents in 40-60% of endocarditis.  
Viridans streptococci are a heterogeneous group containing mainly α-­‐hemolytic streptococci.  The most 
important clinical representatives, other than S. mutans, are: S. oralis, S. mitis, S. sanguinis, and S. 
gordonii.  Because these streptococci are part of the normal oral flora and are relatively avirulent, the 
course of endocarditis caused by these streptococci is slow as opposed to endocarditis caused by other 
bacteria.  Streptococci belonging to bovis group also cause endocarditis.  In particular, S. gallolyticus is 
often cuases IE in patients with colon cancer [55]. S. gallolyticus is an emergent pathogen and recently it 
has been shown to be associated with colon cancer as well as bacteremia, meningitis, and other illnessess 
[56]. 
Interestingly, there are many streptococci that are beneficial to humans as they play a protective role 
when present in the microbiota. For example, S. salivarius, an oral bacterium, can antagonize caries 
formation and pharyngitis because it produces antimicrobial peptide called bacteriocins.  Oral 
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streptococci in general are a prolific producer of various bacteriocins (see below).  Bacteriocins produced 
by commensal streptococci are of major interests in the drug industry because they have the potential to 
inhibit many important pathogens including the pathogenic streptococci. 
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Figure 3: Classification of streptococci based on 16S rRNA analysis.  Phylogenetic relationship among 
various streptococci species is depicted here. S. suis and S. acidominimus could not be placed into any of 
these six groups.  Not all streptococci are listed. [Adapted from Kawamura et. al., 1995 [26]]    
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1.1.4. Cell-cell signaling in dental plaque 
Multispecies colonization initiates from direct molecular interaction between two organisms, which 
eventually establishes a community.  In this community of dental plaque recycling of metabolic 
byproducts among various bacterial species takes place.   Community supplied metabolic byproducts can 
be potentially used as a source of nutrition by another organism [57].  For example, Veillonellae are 
unable to utilize sugar but can ferment lactic acid which is a common metabolic end product produced by 
different streptococci as well as actinomyces [57,58].   A similar symbiotic interaction between S. oralis 
and A. naeslundii was observed. When nutrient-limited saliva was provided as the sole energy source both 
species could grow together, suggesting that these species are fitted for each other. However, when 
cultivated independently neither of these two could survive [59].  This observation is reinforced in the 
case of P. gingivalis, which stimulates biofilm formation by F. nucleatum.  Surprisingly, S. sanguinis, an 
early colonizer produces para-aminobenzoic acid that is utilized as a source of vitamin by S. mutans 
during anaerobic growth [58].   Various physiological parameters such as pH, oxygen, metabolites, and 
toxins of the dental plaque can govern the composition of microbial diversity in the biofilm.  Different 
incompatible microorganisms can coexist within the heterogeneous environment of the oral biofilm and 
facilitates the creation of complex symbiotic networks [60]. 
Bacterial cells also communicate within and across the species using various signaling molecules (Fig 2).  
Although, the majority of the studies were done to understand the intrasepcies communication using 
monospecies culture, only a few studies have been reported about the interspecies communication using 
multispecies systems.   In this section we will focus on how the interspecies communication occur in oral 
biofilm between S. mutans and other organisms, as well as how S. mutans senses and responds to 
different environmental cues using two-component signal transduction systems.  
Bacterial communication that depends on cell density is generally termed as quorum sensing.  Quorum 
sensing usually occur when an organism senses and responds to a critical concentration of small 
extracellular molecules, generally termed as autoinducer (AI).  Autoinducers are either small chemical 
moieties or small peptides that are produced constitutively as the cell population grows.  When a 
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threshold concentration is achieved, autoinducer molecules trigger a change in expression of various 
genes in the population.  In this way, a bacterial population can behave in a highly coordinated fashion, 
similar to multicellular organisms.  Quorum sensing can control antibiotic production, expression of 
virulence genes, formation of biofilm, competence development, sporulation, and several other biological 
processes [61].  Three different signaling molecules mediate quorum sensing: AI-1, AI-2, and small 
peptides.  AI-1 signaling is restricted to only Gram-negative bacteria and is involved in intraspecies 
communication.  Hence, we will only discuss the function of AI-2 in the following section. 
 
1.1.4. a. Auto inducer (AI)-2 signaling 
Both Gram-positive and Gram-negative organisms produce AI-2.  AI-2 is generally referred as 
LuxS/autoinducer-2 system.  They are generated from a common metabolite SAM by the action of LuxS 
enzyme.  AI-2 is a collection of interconvertable forms of 4, 5-dihydroxy-2, 3-pentadione (DPD), which 
undergoes structural changes depending on the environmental cues.  In dental biofilm, actinomyces, 
fusobacterium, porphyromonas, and streptococcus are producers of AI-2.  In S. mutans, AI-2 signal 
production occurs at mid-exponential growth phase. A total of 585 genes (30% of total genes) were 
differentially expressed among the wild type, a luxS mutant, and chemically complemented mutant strains 
[62].  These genes are involved in cell division, cell growth and stress response.  Moreover, the luxS 
mutant was also biofilm defective [63].   Interestingly, this defect in biofilm formation by S. mutans luxS-
deficient strain can be restored by the addition of diffusible molecules produced by S. anginosous, S. 
gordonii, and S. sobrinus; but not by S. salivarius, S. sanguinis, or S. oralis [63].   The luxS gene appears 
to be well conserved among many oral bacteria and can be involved across the species signaling.  Another 
phenotype assigned to an S. mutans luxS mutant is the production of a particular type of bacteriocin, 
called mutacin I [64].  Bacteriocins are small antimicrobial peptides used for intra- and interspecies 
competition by inhibiting the growth of competing bacteria (See section 1.2).  Deletion of luxS 
completely abolished the mutacin I expression; however the molecular mechanisms by which LuxS 
represses mutacin expression is yet to be uncovered.  The control of bacteriocin expression in the dental 
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plaque by AI-2 signaling is highly significant in the context of competition because it can determine 
which species will be successfully establised in the oral biofilm. 
 
1.1.4.b. Two-component signal transduction systems 
Oral bacteria need to constantly adapt to various fluctuations in their surrounding environments. They 
also need to compete with other organisms within the complex multispecies biofilm for nutrient 
acquisition by responding to available dietary products.  To survive in the oral cavity, bacteria employ 
various sensory systems commonly known as two-component signal transduction systems (TCS) to 
monitor and respond to the environmental cues.   This system is composed of two protein molecules, one 
of which is a membrane-bound sensor kinase and the other one is a cytoplasmic response regulator.  The 
function of sensor kinases is to perceive the environmental signals where as the response regulators 
integrate that information by changing the gene expression pattern as an adaptive response.  The number 
of TCS varies greatly depending on the organism.  One recent comprehensive study of TCSs from eight S. 
mutans strains revealed that total 18 orthologs of TCSs, two orphan sensor kinases, and two orphan 
response regulators are present in S. mutans [65].  Not all the TCSs are present in every S. mutans 
isolates.  Some key TCSs, necessary for surviving in the oral cavity, are present in all the isolates.  Most 
of the S. mutans strains contain about 14 TCSs of which eight are common to all the isolates.   These 
eight TCSs are involved in various stress responses, competence development, various virulence gene 
expression, biofilm formation, and bacteriocin production [66,67] 
 
1.1.4.c. Competence-stimulating peptide (CSP) mediated signaling 
S. mutans and streptococci encode a peptide mediated quorum sensing pathway that also requires a TCS.  
This system is required for development of competence in many streptococci.  Central to this pathway is a 
small peptide called competence-stimulating peptide (CSP).  In S. mutans the CSP, which is encoded by 
the comC gene, is synthesized as a 46-mer prepeptide.  NlmTE, an ABC transporter, processes this 
prepeptide to a mature 21-mer peptide during secretion.  In S. mutans, but not in other streptococci, this 
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21-mer peptide is further processed to a 18-mer active peptide by an extracellular protease named SepM 
[68].  When this active 18-mer peptide reaches a critical dentisty, it acts as a signal to induce ComD, a 
histidine kinase.  ComD then activates the cognate response regulator ComE, which then activates 
expression of various genes including those required for competence development.  The genes encoding 
comC, comD, and comE are organized in an operon and this operon is under the positive feedback 
regulation.  In S. mutans and some other streptococci, CSP also activates expression of various 
bactertiocin and bacteriocin-like genes. CSP mediated signaling is also ubiquitous among early colonizers 
in the dental plaque.  This includes S. mitis, S. oralis, S. gordonii, S. sanguinis from the mitis group, and 
S. constellatus, S. intermedius, S. anginosus from the anginosus group.  Notably, CSP signals are highly 
variable among different streptococcal strains including S. mitis, but in the anginosus group, CSP signals 
are highly similar.  Thus, it indicates that CSP might be involved in interspecies communication at least in 
the anginosus group of streptococci.   Since CSP is involved in the expression of bacteriocin genes to 
inhibit the growth of other competing species, this signaling pathway is also crucial for the establishment 
of a species in the dental plaque.  
 
1. 2.  Bacteriocins produced by Gram-positive organisms 
In order to survive in a competitive multispecies environment such as in the dental plaque, many bacteria 
produce different antimicrobial peptides that are active against other bacteria.  These ribosomally 
synthesized small antimicrobial peptides produced by bacteria are called “bacteriocins”.  These 
bacteriocins can be either broad or narrow spectrum.  When the bacteriocins are active against a diverse 
species, they are called broad spectrum and the bacteriocins that are only active against related species are 
called narrow spectrum. The first bacteriocin, colicin, was identified from the Gram-negative organism E. 
coli in 1925.  Bacteriocins produced by Gram-negative bacteria are generally narrow spectrum and only 
active against its own species or very closely related species.  On the other hand, bacteriocins produced 
by Gram-positive organisms including lactic acid bacteria (LAB) are of prime interest in the 
pharmaceutical industry because these bacteriocins are usually broad spectrum.   
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In order to get FDA approval of any bacteriocin to be used in food industry the producer strain is required 
to be nonpathogenic in nature.  The GRAS (generally recognized as safe) status assigned by FDA to lactic 
acid bacteria made them an attractive choice as bacteriocin producer for industrial application.  LAB used 
in cheese production is believed to secrete bacteriocins that determine the complex nature of the 
microflora needed for cheese manufacturing and prevent the growth of spoilage and pathogenic 
organisms.  
A large, diverse array of Gram-positive bacteriocins has been discovered and their structures have been 
reported [69],  along with their mode of action, synthesis, and self-immunity mechanisms.  Furthermore, a 
growing interest to modify the existing bacteriocin by using different modification enzymes is highy 
apparent.  This approach might improve the stability and efficacy of the exsiting bacteriocins already 
tested for commercial application.  Although, naturally occurring modified bacteriocins are more resistant 
to heat and protease degradation than the unmodified bacteriocins, nevertherless they are unstable under 
alkaline pH and are degraded by proteases present in stomach.  Therefore, unless the stability is improved 
by bioengineering, even the modified bacteriocins are only good to be used for topical applications in the 
pharmaceutical industry.  In the food industry a modified bacteriocin, nisin, has been used over 50 years 
to inhibit spoilage bacteria mainly Clostridium difficile and Listeria monocytogenes. The encouraging 
news is that there is no resistance against nisin is observed till today and nisin is the most used 
commercial food preservetive.  This phenomenon suggests that bacteria do not develop resistance easily 
against bacteriocins and remain susceptible to the bacteriocin inhibitions.  Therefore, overall bacteriocins 
have a potential to be used as an alternative to antibiotics in the era when multidrug resistant bacteria such 
as methicillin resistant S. aureus (MRSA) and vancomycin resistant E. faecalis (VRE) are highly 
prevalent.  Recently, few modified bacteriocins showed promising activity against MRSA and VRE.  
Bacteriocins have two properties that prevent the development of resistant organism.  First, the mode of 
inhibition by bacteriocins towards susceptible organism is highly rapid therefore the time required to 
generate resistant organims is not enough.  Second, since the bacteriocins are protineaceous in nature, 
they are easily degraded inside the human body leaving little chance for resistance development in the 
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environment.  In the following section, we will describe how various bacteriocins are classified. 
 
1. 2.1. Classification of bacteriocins 
Bacteriocins produced by Gram-positive organisms are broadly classified into two distinct categories. The 
class I bacteriocins are post-translationally modified bacteriocins and are called lantibiotics because they 
contain polycyclic thioether amino acids lanthionine or methyl lanthoinine. The class II bacteriocins are 
unmodified linear or cyclic and are called nonlantibiotics.  Table-1 summarizes the classification of 
various bacteriocins. 
1.2.1. a. Lantibiotics 
Lanthionine or methyl lanthionine containing bacteriocins are called lantibiotics.  The characteristic 
properties of lantibiotics are the presence of post-translationally modified unusual amino acids. The most 
common modifications are serine residue modified to dehydroalanine and threonine modified to 
dehydrobutyrine.  These two modified residues are present in almost all lantibiotics.  The chemical bonds 
between dehydroalanine and dehydrobutyrine to cystine are called lanthionine and methyl lanthionine 
bonds, respectively.  These modifications and ring structures make those lantibiotics more tolerant to 
heat, proteolysis, and oxidation.  These lantibiotics are further classified into two groups depending on 
their modified structure type-A (I) and type-B (II) [70].  Type-A lantipeptides are elongated in nature 
whereas type-B lantipeptides are globular ([71]).   Nisin produced by L. lactis and pep5 produced by S. 
epidermidis are two examples of type-A lantibiotics.  Globular mersasidin from B. subtillis and actagerdin 
from Actinoplanes sp. are examples of type-B lantibiotics. Additionally, lantibiotics can consist of a 
single peptide (one-peptide) or two separate peptides (two-peptide).  One-peptide lantibiotic can be either 
type-A or type-B.  As mentioned above, nisin, which is a type-A and mersasidin, which is a type B, are 
both one-component lantibiotics.  On the other hand the two-component lantibiotics usually contain one 
of each type-A and type-B components.  Lacticin 3147 is a well-known example of two-peptide 
lantibiotics, which comprises of globular Ltnα (type-B) and elongated Ltnβ (type-B) components.  
Another classification scheme is devised on the basis of the pathway of modification of the peptide 
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lantibiotics [71]. This scheme is simple and flexible enough to include all lantithionine-containing 
peptides.  Moreover, this inclusive method may accommodate the lantibiotics that are yet to be 
discovered.  
Class-I lantibiotics are modified by two modification enzymes, one is specific for serine/threonine 
dehydration and the other one is specific for thioether cyclization.  In general the dehydratase and cyclase 
enzymes are termed as LanB and LanC enzymes, respectively.  The modified peptides generated by these 
two enzymes are more linear in nature than the class-II peptides.  Class-II lantibiotics are modified by a 
single bifunctional enzyme termed as LanM that posses both dehydratase and cyclase activity in their N- 
and C-terminal domains, respectively.  However, the homology between LanM with LanB or LanC is not 
significant.  Class-II group is structurally more diverse and represents a larger body of members than 
class-I lantibiotic.  The unique members of class-II lantibiotics are the two-component lantibiotics.  
Lantibiotics belonging to class-III are modified by a trifunctional enzyme containing a lyase domain, a 
kinase domain, and a cyclase domain; however, this enzyme lacks many conserved active site residues 
found in LanC/LanM.  And finally, class-IV lantibiotics are synthesized by LanL enzyme, which is 
similar to class-III enzyme, except that the cyclase domain is analogous to LanC.  The classifications just 
described above are based on the modification on the lantithionine peptides (Fig 4).   However, there is 
one other classification exists where the latibiotics are subdivided into 11 groupes based on the sequence 
homology with the unmodified lantibiotics [72].  The groups are named after the 11 representatives from 
each group and they are: cinnamycin, cytolysin, epidermin, lacticin 481, lactocin S, LtnA, mersacidin, 
nisin, pep5, streptin, and sublancin.  To date, seven two-peptide lantibiotics have been identified; among 
them six are mersacidin-like systems (lacticin 3147 produced by L. lactis DPC3147, staphylococcin C55 
produced by S. aureus C55, plantaricin W produced by Lactobacillus plantarum, Smb prodcced by S. 
mutans GS-5, BhtA produced by S. rattus BHT, and haloduracin produced by Bacillus halodurans). The 
seventh two-component lantibiotic is cytolysin, produced by E. faecalis.  Both the components of 
cytolysin are similar to each other and it is the only example of this type.   
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Table 1: Classification of bacteriocins produced by Gram-positive bacteria  
_____________________________________________________________________________________ 
Classification    Description    Examples 
_____________________________________________________________________________________ 
Class I   Post-translationally modified peptide lantibiotic 
             Type Ia  Elongated peptide with net positive charge   Nisin, Pep5  
 Type Ib  Globular peptide net negative or no charge  Mersacidin, actagardin 
 Type Ic  Multi component                           Lacticin3147, SmbAB 
       
Class II  Unmodified, non-lanthionine, heat stable 
             Type IIa Monopeptide with YGNGVGVXC motif            PediocinPA1, Leucocin A       
 Type IIb Two peptide GxxxG motif              NlmAB, Lactococcin G 
 Type IIc Heterogeneous                             Lactococcin A, Lacticin Q 
 
Class III  Large heat labile   
            Type IIIa Bacteriolytic                Lysostaphin 
 Type IIIb Nonbacteriolytic               Helveticin J  
 
Class IV  Cyclic peptide; no sub-class             Enterocin AS-48,  
                   Gassericin A 
_____________________________________________________________________________________ 
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Figure 4: Representative examples of lantibiotics, a class I bacteriocin. (A) Examples of one-peptide 
lanticbiotics belonging to class Ia (net positive charge containing elongated lantibiotiics) and class Ib 
(globular lantibiotics). (B) Examples of some two-peptide lantibiotics belonging to class Ic are shown 
here.  Positively charged residues are colored blue, negatively charged residues are colored maroon, 
where as lanthionine and methyl lanthionine are colored as light and dark grey [Adapted from Suda et. al. 
2010, [73]].  
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1.2.1. b. Non-lantibiotics 
Bacteriocins belonging to class-II are not post-translationally modified; in other words, they are non-
lanthionine containing bacteriocins.  It is important to point out that class-II lantibiotics, which are just 
described, and class-II bacteriocins are entirely different. Class-II bacteriocins are relatively simple in 
structure and mostly linear peptides, although some of them can be circular (Table 1).  Class II 
bacteriocins are subdivided into four groups: class IIa, class IIb, class IIc, and class IId. Class IIa 
bacteriocins are called pediocin-like bacteriocins becuase pediocin, the first bacteriocin in this class, is 
prouced by Pediococcus sp.  All pediocin-like bacteriocins, of which more than 20 have been identified, 
contain an N-terminal consensus sequence YGNGVXC, called "pediocin-box" motif.   Pediocins-like 
bacteriocins are highly active against listeria and are used as bioperservative [72]. Class IIb bacteriocins 
are two-peptide bacteriocins.  Lactococcin G produced by L. lactis and mutacin IV produced by S. mutans 
are the member of class IIb bacteriocin family.  Class IIc bacteriocins are circular bacteriocin where the 
N- and the C- terminals are covalently linked by a peptide bond.  Enterococcin AS-48 produced by a 
variety of enterococci was the first class IIc bacteriocin identified. The last group of unmodified 
bacteriocins (class IId) constitutes the remaining linear, non pediocin-like, one-component bacteriocins.  
This group of bacteriocins is highly diverse in nature both in terms structure wise and activity wise, and 
therefore it requires further sub-classification.   Some members of this group have a leader peptide that is 
processed during their transport by the Sec dependent mechanism. For example, the plasmid-encoded 
lactococcin 972 that is produced by certain strains of L. lactis utilizes Sec dependent pathway for 
secretion.   In contrast, there are a group of class IId peptides that do not contain a leader sequence and 
are called leaderless bacteriocins. Two prominant examples are lacticin Q and lacticin Z, both secreted by 
different L. lactis strains. Despite the differences in structure (linear, cyclic, or circular), biochemical 
properties (dehydrated residues, thioether bonded residue, or presence of motifs), as well as the 
composition (one-component or two-component), most of the bacteriocins function in a quite convergent 
manner and they all interfere with the bacterial cell-wall or membrane integrity. 
 
31 
 
1.2.2. Mode of action of lantibiotics 
As mentioned before, bacteria employ bacteriocins as a weapon to inhibit other competing species.  These 
antimicrobial peptides are very potent and active at a nanomolar concentration.  Modes of action of a 
given bacteriocin can be predicted from the primary structure of the peptides.  In this section, we will 
mainly focus on the mechanisms of inhibition by lantibiotics (Fig 5). 
Type-A lantibiotic is elongated, amphillic, or hydrophobic peptide and often contains a net positive 
charge.  Nisin is one such kind whose mode of action was experimentally characterized.  Nisin and 
related lantibiotics have activity against a wide range of Gram-positive bacteria.  Studies using artificial 
and physiological membrane revealed that nisin adheres to the membrane by electrostaic interaction with 
the membrane lipids (Fig 5A).  Mutagenesis studies suggested that the initial interaction of nisin with the 
membrane is through the C-terminal of the peptide that contains most of the cationic residues.  Nisin 
inserts into the membrane mediated by hydrophobic residues on the N-terminal side of the peptide.  The 
first ring or ring A on the N-terminal side is involved in insertion in the membrane; any change in that 
ring region interferes with the insertion and eventual decrease in antimicrobial activity.  However, C-
terminal side of nisin has no effect in the membrane insertion process.  Not only the modified part but 
also the linear or the hinge region of nisin (ie. region between the ring C and ring D) is required for 
membrane insertion.  Finally, nisin molecules oligomerize to form a pore complex at the membrane. 
Lipid II is a conserved precursor of bacterial cell wall biosynthesis. Nisin can form pores at a much lower 
concentration and more efficiently if lipid II is present at the artificial membrane.  Afterwards, NMR 
analysis revealed that nisin interacts with the lipid II moiety at the pyrophosphate bridge between the lipid 
carrier and the disaccharide.  Moreover, for this interaction, only first ten amino acids (ring A and ring B) 
are necessary for binding (Fig 6).  A conserved binding sequence, CTxTxEC, was identified among a 
number of lantibiotics that target lipid II.  Some lipid II binding lantibiotics such as mersacidin, 
plantaricin C, or actagerdin do not have ability to cross the membrane bilayer to form pore, rather they 
inhibit cell wall biosynthesis by interfering with lipid II avalability (Fig 5B).  In contrast, epidermin like 
lantibiotics such as gallidermin, epidermin, and mutacin 1140 bind to lipid II, but can only cross thin 
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layer of membrane as shown in some in vitro studies.  Interestingly, gallidermin is active against only 
micrococcus and staphylococcus but not against lactococcus.  Evidently, it was reported that short chain 
lipids are present in micrococcus and staphylococcus membranes but not in lactococcus.   A new member 
of lipid II binding lantibiotic, michiganin, contains the conserved CTxTxEC motif, but it is not inside the 
ring structure as in the case of mersacidin or actagardin.  However, the mode of action for this new type 
has not been evaluated. 
 
In the case of two-peptide lantibiotics, the α-peptides are the type-B globular peptides and the β-peptides 
are the type-A elongated peptides.   The α-peptides contain the lipid II binding motif.  A concerted effort 
involving both the component peptides is required for the antimicrobial activity.  A three-step model has 
been proposed to explain the mode-of-action of the two-component lantibiotics (Fig 5C).  In this model, 
the inhibition process is initiated by the α-peptide, which first binds to lipid II molecule.  Next the β-
peptide recognizes the complex of α-peptide bound lipid II and forms a tripartite complex.  This tripartite 
complex formation helps the β -peptide to get inserted inside the membrane and subsequently to form 
pores.  It has been shown that the two ring structures present at the C-terminal end of the α-peptide of 
lacticin 3147 are involved in lipid II binding as well as binding to the β-peptide.  This C-terminal domain 
is necessary for the activity of the peptide complex.  Type-B lantibiotic cinnamycin and most likely 
duramycin also bind to phospholipid phosphatidylethanolamine and inhibit phospholipase activity.  At 
present, it is not clear why the efficient inhibitory activity against the peptidoglycan synthesis as well as 
pore formation capacity of the lantibitics function only against certain strains or species instead of all the 
strains or species.  
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Figure 5:  Proposed models for the mode of action of different classes of lantibiotics. (A) Class Ia 
lantibiotic such as nisin, adsorbs to the membrane of the target cell and eventually interacts with the lipid 
II molecule.  While bound to lipid II nisin not only sequesters this cell wall precursor it also forms pore 
complex at the target site. (B) Class Ib lantibiotic like mersacidin also binds to the lipid II and inhibits 
wall synthesis of the target cell, but do not for pore. (C) Class Ic two-peptide lantibiotic such as lacticin 
3147 contains a globular component, lacticinA1, which interacts with the lipid II molecule and inhibit cell 
wall synthesis.  The second peptide, lacticinA2, interacts with lipid II bound lacticinA1 and forms pore in 
the target cell membrane.  
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Most of the nonlantibiotic bacteriocins form pores but the size of the pore varies depending on the type of 
bacteriocins. The mode of action for class IIa bacteriocins, such as pediocin, involves mannose 
phosphotransferase system (Man-PTS), which acts as a recruiter for the bacteriocins to membrane to form 
pore on the susceptible organisms.  These pores are relatively small but allow loss of proton gradient to 
occur that ultimately leads to death of the sensitive strains. Class IIb two-peptide bacteriocin consisting 
two different unmodified peptides functions at equimolar ratio.  Class IIb bacteriocin such as lactococcin 
G and lactococcin Q permeabilize membrane of the sensitive strain by pore formation [74]. The α- and β- 
components of the above mentioned bacteriocins are interchangeable without significant loss of activity.  
The pore formed by these two-peptide bactericins is relatively large that allows leakage of monovalent 
cations, phosphate ions, and ATP through the pore leading to death of the susceptible bacteria.  A similar 
mechanism has been proposed for class IIc bacteriocins.  As mentioned before, class IId bacteriocins are 
structurally diverse.  Lactococcin A and lactococcin B both are suggested to form pores in the membrane 
and loss of solutes kills the susceptible bacteria.  Lacticin Q, on the other hand is a leaderless bacteriocin, 
and it interacts with the lipid II molecule to form a relatively large peptide-lipid pore [75].  It is the first 
example of a nonlatibiotic that interacts with the lipid II molecule.  Another class-IId bacteriocin, 
lactococcin 972 (lcn972), interacts with lipid II and inhibits cell wall biosynthesis.  Although it interacts 
with lipid II, Lcn972 does not contain N-terminal ring structure like nisin.  The binding site of Lcn972 
might divulge a novel lipid II binding mechanism.  For class-IV bacteriocin, enterocin AS-48 forms 
nonselective pores that allow loss of low molecular weight substances leading to cell death [76].  In 
contrary, carnocyclin A, another class-IV bacteriocin, forms anion specific pores and causes 
depolarization of the membrane.   Thus, while most of the nonlantibiotic peptides form pores on the target 
cell membrane, the size of the pore and solutes that escaped through them varies significantly. 
 
1.2.3. Immunity proteins 
Bacteriocin producer strains are usually protected from their own antimicrobial activity by concomitant 
expression of one or more immunity protein complexes. Three different immunity mechanisms that are 
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present in the producer strain: an ABC transporter complex that exports out bacteriocins, a membrane 
protein that sequester the bacteriocins before they reach to the membrane, and antagonizing the receptor 
of the bacteriocins.  Immunity proteins for nisin and lacticin 3147 have been well characterized and they 
function in somewhat similar manner.  In case of lacticin 3147, an ABC transporter complex, LanFEG, 
and a membrane bround protein LanI or LanH that sequesters bacteriocin, provide self-immunity [77].  
LanF of the ABC-transporter complex has nucleotide-binding domain and functions as ATPase 
component of the complex. This complex is known to scavenge out the self-produced lantibiotic from its 
own membrane.  This type of immunity provided by ABC-transporter is very common.  For instance, 
SpaFEG of subtilin producer B. subtilis and NisFEG of nisin producer L. lactis both function in similar 
manners.   
The LanI proteins are subdivided into three groups: lipoproteins such as NisI and SpaI, immunity peptides 
residing on the membrane or at the extracellular space such as PepI and EciL, and transmembrane 
proteins such as LtnI, CylI, and SunI.  The degree of immunity provided by these proteins can vary 
greatly and the exact mechanisms of their function are not well studied.   For example, LanI or LanH 
cannot provide complete protection against lacticin 3147 in the absence of corresponding ABC 
transporter complex.   For one LanI member, NisI, the C-terminal domain is involved in the binding of 
lantibiotics (nisin) and the N-terminal domain is involved in interacting with the NisFEG complex.  In 
contrast, PepI has been shown to attach to the outer side of the membrane and shields the target from the 
lantibiotic action. 
In case of nonlantibiotic bacteriocins, sequences of the immunity protein and their sizes vary significantly 
and the detail mechanisms of protection are also not well understood [78].  However, studies on 
lactococcin A revealed the detail mechanism of how the immunity protein LciA confers immunity.  
During purification, LciA was found to be associated with the membrane fraction of the producer strain.  
It was demonstrated that in the presence of the cognate bacteriocin lactococcin A, the immunity protein 
associates tightly with the membrane components IIC and IID of man-PTS system; but in the absence of 
the bacteriocin, LciA remained mostly unassociated [79].  Although there are variations in the sequence 
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and in the size of the immunity proteins, for class IIa bacteriocins most of the immunity proteins function 
in similar manners [80]. For class IIb bacteriocins the lactococcin G immunity protein, LagC, was 
predicted to bind with a yet to be indentified membrane-associated receptor to interact the lactococcin G 
[81].  Recently, it has been shown that immunity protein might use protease activity to confer immutnity 
[80]. In particular, a CAAX family protease, called as Abi-family protein, is a putative transmembrane 
associated protein involved in the immunity function against sakacin [82]. The immunity protein, SkkI, 
was isolated from Lactobacillus sakei, which also produces sakacin (a class IIb bacteriocin).  It was 
shown that the immunity function is lost if the putative protease active site residues are mutated in SkkI 
[82].  Though class II bacteriocin family immunity proteins are somewhat specific, Abi-family immunity 
proteins are observed to confer cross-immunity [82].  It is hypothesized that a common proteolytic 
mechanism may confer the immunity; however the bacteriocin itself is not the substrate.  Therefore, the 
exact mechanism by which the Abi-family proteins confer immunity in bacteria is currently unknown.  
For class IIc and class IId family bacteriocins the immunity proteins are suggested to be either ABC 
transporters or other hydrophobic peptides. Further elucidation is needed to understand these diverse 
mechanisms of bacteriocin immunity in bacteria. 
 
1.2.4. Protein receptors for bacteriocins 
An organism is susceptible to a given bacteriocin because they carry a receptor protein.  Initial studies 
with bacteriocin resistant mutants of E. faeccalis and L. lactis indicated that man-PTS might act as a 
receptor for class IIa bacteriocins [83].  The bacterial man-PTS system contains three proteins: IIAB, IIC, 
and IID, encoded by a single operon.  When the entire locus encoding man-PTS was deleted from a 
sensitive lactococci strain, the strain became resistant to the lactococcin A bacteriocin [83].  Moreover, 
introduction of IIC and IID together in a resistant L. sakei strain made the cells sensitive to lactococcin A.  
Other pediocin-like bacteriocins, enterocin P, sakacin A, pediocin PA1, and penocin A have inhibitory 
activity against L. sakai but not against L. lactis IL1403 while both contains man-PTS.  However, when 
the man-PTS from L.sakai was expressed in L. lactis, it became sensitive to the bacteriocin [83].  This 
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observation confirms that in general for class II bacteriocin, components of man-PTS function as potential 
receptor.  The consensus sequence at the N-terminal of pediocin-like bacteriocins probably interacts with 
the receptor.  Subsequently, the C-terminal α-helix gets inserted in the membrane and interacts with the 
man-PTS.  This interaction causes structural changes in the man-PTS and the permease opens as a pore.  
This eventually leads to the loss of solutes that ultimately kills the bacteria.  Understanding the motif 
present on bacteriocin molecule involved in man-PTS interaction will aid in designing more potent 
bacteriocin by bioengneering method.  Since man-PTS is absent in eukaryotes, use of this target by class 
II bacteriocin will not have any adverse effect on the host.   
So far no lantibiotics receptors have been identified for lantibiotics.  However, for some lantibiotics, lipid 
II has been proposed as a docking molecule (i.e. receptor), but how the initial interaction between the 
lipid II and the lantibiotics at the membrane happens is currently not known.    
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Figure 6: Schematic diagram of nisin processing and maturation. The leader peptide of the precursor 
nisin directs this peptide to the modification machinery and to the transporter for processing and 
secretion. Specific serine and threonine residues are dehydrated by NisB and converted to dehydroalanine 
(Dha) and dehydrobutyrine (Dhb), respectively.  Next, NisC cyclase forms lanthionine bond between Dha 
and cyscteine, and methyllanthionine bond between Dhb and cysteine.  NisT transports out this fully 
modified nisin and NisP protease removes the leader peptide to generate active nisin [Adapted from  
Cotter et. al.  2005, [72]].  
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Figure 7. Diagrammatic presentation of all the mechinary needed for lantibiotic production. Nisin is 
encoded by a locus containing 11 genes needed for nisin production, maturation, export, immunity, and 
regulation of biosynthesis.  Yellow color represents modification and transport machinery, blue color 
represents immunity machinery, purple color represents the regulatory molecules and the red color 
represents nisin molecule.  
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1.2.5. Regulation of bacteriocin production 
Bacteriocin production is regulated by genetic as well as environmental factors.  Two-component systems 
are known to regulate the expression of both lantibiotics and nolantibiotics. The lantibiotic synthetic 
genes are encoded in a gene cluster that sometime encodes regulatory proteins. The gene clusters for 
nisin, salivaricin A, and subtilin all harbor a two-component regulatory system that regulates the gene 
expression of the respective lantibiotic and the associated immunity proteins (Fig. 7).  Many lantibiotics 
encode orphan regulators in their gene clusters.  For example, lacticin 3147, mersacidin, and epidermin all 
contain regulators in the biosynthetic operon.  Growth and culture conditions also influence the lantibiotic 
production for some lantibiotics.  Subtilin (produced by B. subtilis) is regulated by SpaRK two-
component system, which is expressed by σH a stationary phase sigma factor, but σH did not influence the 
production of mersacidin.  Epidermin is active in stationary phase like subtilin but controlled by the agr 
two-component system.  The drop in pH can also induce bacteriocin production such as Lacticin 481 
production.  The presence of some host factors can also regulate bacteriocin production such as cytolysin 
expression by E. faecalis.  Finally, some bacteriaocins can act as signaling molecules to induce their own 
expression, as in the case of nisin (Fig 8).  A number of class II bacteriocins such as curvacin A, sakacin 
P, and plantaricin E/F are also regulated by two-component regulatory systems that are activated by 
peptide pheromones.  Regulation of some bacteriocins produced by S. mutans is discussed in the 
following section. 
 
1.3. Mutacins: Bacteriocins produced by S. mutans 
S. mutans is not only a prolific producer of bacteriocin they produce multiple types of bacteriocin as well. 
Bacteriocins produced by S. mutans were first studied by Kelstrup and Gibson [84] and named mutacins 
by Hamada and Ooshima [85]. Mutacin production frequency in S. mutans can vary from 70 to 100% 
depending on the conditions of the tests and the indicator strains used [86].   A population based study by 
Kamiya and colleagues [87] showed that over 70% clinical isolates from caries-active and caries-free 
individuals produced one or more bacteriocin like activities in vitro.   Most S. mutans bacteriocins 
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characterized to date are lantibiotics.  Mutacin I, II, III, BNy266, K8, H29B, and 1140 are lantibiotic 
monopeptide, where as Smb (produced by S. mutans strain GS-5) and BHT (produced S. ratti) are 
examples of dipeptide lantibiotic [88].  Mutacins I and III are the most thoroughly characterized members 
of all mutacins.  Mutacin I is encoded by S. mutans UA140 and CH4 strains and the biosysnthesis locus 
encodes 14 ORFs (See Fig. 8).  On the other hand, mutacin III is produced by S. mutans UA787 and the 
biosynthetic operon encompasses eight genes.   Mutacin I and III harbor significant sequence similarities 
and can confer similar antibacterial activities.   For both, the alanine t-RNA synthetase (SMU.650) gene is 
found upstream of the biosynthetic operon, suggensting that some strains might have acquired the genes 
by horizontal gene transfer.  Furthermore, the sequence of the genes encoding mutacin 1140 produced by 
S. mutans JH1140 is identical to mutacin III.  Similarly, the primary sequences for mutacin II produced 
by S. mutans T8 and mutacin H29B peptides are completely identical.   However, while the biosynthetic 
locus is known for mutacin II (Fig. 8), the locus is not identified for H29B; therefore a direct comparison 
between these two loci is not possible. Apart from mutacin I, II, and III, mutacin B-Ny266 produced by S. 
mutans Ny266 is somewhat well studied.  It is the first lantibiotic mutacin to be completely sequenced.  
Subsequent studies were carried to to detremine the MIC and in vivo acticities of B-Ny266.  S. mutans K8 
strain produces another lantibiotic called mutacin- K8.  The biosyntheis locus for mutacin K8 consists of 
13 genes and shows high homology with the genes encoding lantibiotic SA-FF22 produced by S. 
pyogenes (Fig. 8).   
 
The only two-component lantibiotic produced by S. mutans is Smb.  Smb was originally identified by 
Paul and Slade [89] as mutacin GS-5.  Later Yonezawa and Kuramitsu [90] identified a biosynthesis locus 
for two-component lantibiotic and named as “Smb” (S. mutans bacteriocin).  The Smb peptides were 
subsequently purified from culture supernatant as suggested by Petersen and colleagues [91].  Hyink and 
colleagues [92] also purified a variant of Smb that is produced by S. ratti strain BHT, and named as BHT-
A. Like most lantibiotic mutacins, very little is known about the biochemical properties or the mode of 
action for Smb. 
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S. mutans also produces several monopeptide non lantibiotics such as mutacin V, mutacin N, IT-9, and a 
dipeptide non-lantibiotic mutacin IV.  These mutacins are not well characterized and for many the 
inhibitory spectra are unknown.   Apart from these above-mentioned non-lantibiotics, the first S. mutans 
sequenced strain UA159 encodes at least eight additional genes with putative non-lantibiotics like 
sequences designated as bsm.  A recent study suggests that these uncharacterized bsm genes are more 
frequent than the characterized mutacin genes in the clinical isolates.  Furthermore, some of these bsm 
genes are highly expressed in many clinical isolates.  Interestingly, the study by Kmaiya and colleagues 
(2008) have indicated that over 12% clinical isolates do not encode any known mutacin encoding genes, 
yet they produce antimicrobial substances that kill other bacteria.  This observation suggests that there 
could be many more mutacin encoding genes that are yet to be discovered. 
Expression of mutacins is highly coordinated and is regulated by several genetic and environmental 
factors [93].  At least three types of regulatory systems have been described for mutacin expression.  The 
first category is Rgg-like stand-alone regulators referred to as MutR.  The genetic loci for mutacin I, II, 
and III, each encodes a MutR like transcriptional activator.  In fact MutR is an essential activator for 
mutacin operon expression and mutacin activity is undetected when MutR is inactivated.  Rgg family 
proteins require a small peptide that acts as a signal.  However, no such small peptides have been 
identified in the mutacin operons.  The second category regulators belong to LytTR family.  So far only 
two such systems, HdrRM and BrsRM have been described for S. mutans.  A LytTR regulatory system 
consists of a membrane bound inhibitory portein that antagonizes the activity of a cognate trasncription 
factor that activates the gene expression.  At present the signals that induce HdrRM and BrsRM pathways 
are unknown.  However, inactivation of the membrane-bound inhibitory proteins lead to increase mutacin 
gene expression and production.  The third regulatory systems that control mutcin expression are the two-
component signal transduction systems.  Among the 14 two component systems, perhaps the ComDE is 
the most important and best-studied system.  ComDE plays a direct role in the expression of mostly non-
lantibiotics such as mutacin IV. A direct interaction of the ComE response regulator with the mutacin 
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encoding gene promoters has been demonstrated.  The two peptide lantibiotic Smb is also regulated by 
ComDE system as shown by Kuramitsu's group.  Some of the other two-component systems involved in 
mutacin gene regulation are CiaRH, VicRK, and LiaRS systems.  However, a direct regulation of mutacin 
genes by these systems has not been shown.  Interestingly, the locus that encodes mutacin K8 contains 
both an Rgg-like activator MukR and a two-component system MukRK.  Perhaps both these regulatory 
systems involved in mutacin K8 regulation.  An analogous to MukRK system known as ScnRK 
(SMU.1814-SMU.1815) is also present in UA159, a strain that does not produce lantibiotics.  The role of 
ScnRK and other two-component systems in mutacin production has not been evaluated.    
Mutacin production is also modulated by environmental conditions. How environmental conditions 
regulate mutacin expression has not been demonstrated, but it is assumed that the regulatory pathways 
mentioned above might be involved.   The two most important environmental factors are cell density and 
nutritional conditions.  Studies with mutacin I (lantibiotic) and mutacin IV (non-lantibiotic) have shown 
that transcription of both of these mutacins is relatively weak in liquid culture but is increased drastically 
if the cells are grown on solid media or cells are incubated as cell pellet. As for the nutrient conditions are 
concerned, phosphate seems to have a negative effect on mutacin gene expression.  On the other hand, 
easily fermentable carbohydrates and yeast extract seem to stimulate various mutacin production.  The 
exact molecular mechanisms by which nutritional conditions exert their effect on mutacin production are 
currently unknown.  However, mutacin production is induced when the cells experience stresses.  In the 
dental plaque, S. mutans encounters multiple types of stress conditions that might induce mutacin 
production.  This leads to the inhibition of competing species within the biofilm and proliferation of S. 
mutans.  
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Figure 8: Genetic organization of the biosynthetic gene cluster for various mutacins produced by S. 
mutans isolates.  Various colored block arrows represent the following:  red, structural genes; dark blue,  
immunity genes; yellow, modification genes; light blue, transporter genes; and purple, regulatory genes.  
Other genes not involved with mutacin biosynthesis or regulation are shown with either brown or gray 
arrows [Adapted from Merritt et. al. 2012, [93]]  
48 
 
Lantibiotic mutacin
Non-lantibioticmutacin
Mutacin I	  and	  III:
Mutacin II
Smb
Mutacin K8
Mutacin 1140
Mutacin B-­‐Ny266
Mutacin IV
Mutacin V
Mutacin VI
Mutacin N
alaS mutR
mutA
mutB mutP
mutG
mutA’ mutC mutD mutT
mutF
orfX spaR
mutE
spaKorfY orfZ
mutRpyrG tra
mutA mutM mutT
mutGmutF
mutE
fbaA
smbBsmbG smbAsmbM1leuRS smbF smbT smbM2 tra
mukR mukK tra tra mukA1 mukA3
mukA2 mukA’
mukM mukT mukE mukG
mukF
orfX lanA
orfY
lanB
lanA
lanA’
lanB
nlmT nlmE SMU.925 comC comD comEtra nlmA
nlmB
SMU.152
nlmD
rbfA copY
nlmC
mutN
tra blpI
comC comD comE
49 
 
1.4. Scope of the study   
 S. mutans strain GS-5 was originally isolated from a cariogenic tooth and was first reported by Gibbons 
RJ in 1966.  Initially this strain was widely used for the characterization of virulence and physiologic 
properties of S. mutans.  GS-5 was also the strain of choice to study bacteriocin production.  However, 
only recently Kuramitsu and colleagues (2005) reported the presence of a two-component lantibiotic Smb 
in GS-5 strain.  Currently, Smb is the only known two-component lantibiotic encoded by S. mutans.   A 
lantibiotic producer strain must contain a self-protection mechanism to protect itself from the lantibiotic-
mediated damage.  The self-protection is achieved by three mechanisms: sequestration by a membrane 
protein, efflux by an ABC transporter, or proteolytic activity.  Immunity mechanisms against Smb have 
not been identified.  A previous report by Kuramitsu's group described SmbG, a putative ABC transporter 
with a peptidase domain, as the immunity protein for Smb.  This proposed function of SmbG in providing 
immunity is not supported by their experimental data.  For example, the authors found that SmbG 
deficiency alone has no effect on immunity or protection against Smb.  However, the authors observed 
that deletion of the entire smb locus makes the strain susceptible to the lantibiotic. This observation 
implies that SmbG is not the authentic immunity protein; rather another gene present in the operon may 
encode the immunity function.  Interestingly, smb locus encodes another ABC transporter complex, 
SmbFT, whose function is not yet characterized.  Therefore, it is possible that SmbFT might function as 
an immunity complex.  The multispecies biofilm community in the dental plaque provides a favorable 
environment for horizontal gene exchange because of spatial proximity and constant selection pressure. 
Therefore, an Smb non-producer strain can easily acquire the immunity function by horizontal gene 
transfer and become resistant to Smb.  It will be interesting to examine if the immunity protein can 
function in a heterologous hosts and can provide protection against Smb.   
Lantibiotics have more potent bactericidal activity compared to the mammalian antimicrobial peptides 
such as defensin.  Lantibiotics usually function at nanomolar range, whereas other antimicrobial peptides 
are effective at micromolar concentrations.  This fact indicates that the interplay between the lantibiotics 
and the target organisms must be specific and likely it occurs through receptor-mediated interaction.  So 
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far, only two receptor proteins have been identified for non-lantibiotics.  However, to date, no receptor 
molecules have been identified for any lantibiotics.   Since Smb is a broad-spectrum lantibiotic, we 
speculate that the receptor protein (or its homologs) is widely expressed in bacteria and present in all the 
susceptible organisms that were tested.  
It is of great importance to understand how the producer strain regulates the expression of its immunity 
protein to counteract the cognate lantibiotic produced by the cell as well as by the population in the 
biofilm.  An auto-sensing mechanism must exist to maintain a constant ratio of the immunity protein and 
the lantibiotic.  Little is known about the transcriptional regulation of the smb operon.  Recent studies 
have shown that a two-component system, ComDE, encoded elsewhere in the genome, is required for the 
smb expression.  However, ComDE might not be the regulatory system for the auto-sensing.  Unlike most 
of the other lantibiotic loci that encode their own regulatory factors, smb does not encode any factor that 
can function as an auto-regulator.  We speculate that Smb peptides function as signaling molecules and 
auto regulate the smb operon through some yet to be discovered regulators.  
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1.5. Hypothesis 
 
Based on the current knowledge of immunity protein and receptor functions we hypothesize that 
inactivation of the putative immunity protein (ABC transporter) will make the producer strain sensitive to 
Smb.  And, Smb itself coordinates the immunity protein expression to facilitate the protection of the 
organism against its own antimicrobial activity.   Moreover we predict that Smb recognizes specific 
receptors that are present on the target strains.  Inactivation of the receptor encoding genes will generate 
resistance against Smb.   
 
Above hypotheses will be tested by means of the following three specific aims: 
 
Aim 1: Identify the self-immunity proteins in GS-5 that are specific to Smb and evaluate their activity in 
heterologous organisms, since there is a possibility that immunity functions can be transferred by 
horizontal gene transfer to other streptococci in the densely packed dental biofilm. 
Aim 2:  Identify the putative receptor molecule(s) from a medically important streptococcus and evaluate 
its function. 
Aim 3: Identify new regulators for smb locus and test whether Smb could induce the operon. 
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Chapter 2:  Materials and Methods 
2.1. Bacterial strains and growth conditions 
Escherichia coli strains DH5α[(F- φ80lacZΔM15 Δ (lacZYA-argF) deoR recA1 endA1 hsdR17 (rk-, 
mk+) phoA supE44 thi-1 gyrA96 relA1 λ-)] (NEB) and Top10 [F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 araD139 ∆(ara- leu)7697 galU galK rpsL (StrR) endA1 nupG 
(Invitrogen) were used for cloning.  E. coli TG1Rep+ [(supE hsd-5 thi Δ(lac-proAB) F'(traD6 proAB+ 
lacIq lacZΔM15) (repA from pWVO1)] was use for propagation of pGhost9::ISS1 at 37°C.  These strains 
were grown in Luria-Bertani (LB) medium, and when necessary, ampicillin (100 µg ml–1, Ap), 
erythromycin (100 µg ml-1, Em), and kanamycin (100 µg ml–1, Km) were included.  
Streptococci and other Gram-positive bacteria (Table 4) were routinely grown at 37°C in Todd-Hewitt 
medium (BBL, Becton Dickinson) supplemented with 0.2% yeast extract (THY) under microaerophilic 
condition.  Some organisms were also grown in BHI under microaerophilic condition.  For Bacillus 
subtilis LB medium was used and cultured aerobically at 37°C. When needed, erythromycin (10 µg ml–1) 
and kanamycin (300 µg ml–1) were included in the media.  Bacterial growth was measured using a Klett-
Summerson colorimeter with a red filter and the turbidity was expressed in Klett unit (KU).  
 S. gordonii, S. mutans, and S. sanguinis, strains were transformed by means of natural transformation 
according to previously described protocol. In brief, streptococcal strains were grown in presence of horse 
serum to an OD of 0.2 at A595 wavelength.  Transforming DNA and CSP (when necessary, at final 
concentration of 200nM) were added, incubated at 30°C for three hours, and plated on THY agar plates 
with appropriate antibiotics.  The plates were then incubated under microaerophilic condition at 37°C.  
Colonies appeared after two or three days of incubation.   
For S. pyogenes, electrotransformation was carried out as previously described.  Briefly, strains were 
grown to an OD of 0.25 at A560. Cells were harvested, washed twice with 0.5% sucrose solution, and 
resuspended to one hundredth of the original volume in the same buffer.  Electroporetion was carried out 
using ~500ng DNA in chilled cuvettes (gap width 1mm) at 1.8KV.  Transformed cultures were incubated 
for two hours at 37°C and plated on THY agar plates with antibiotics.  
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2.2. Inactivation of genes by gene replacement 
 A previously described fusion PCR method was used for construction of various mutant strains. In short,  
~500-bp upstream (up) and downstream (dn) flanking regions of the targeted genes were separately PCR 
amplified using appropriate primer pairs as listed in Table 2.  GS-5, UA159, or V403 genomic DNA was 
used as template when necessary.  A third fragment (middle) containing either erythromycin resistant 
cassette (Em) or kanamycin resistant cassette (Km) was amplified from pIBM01 or pIBD38, respectively, 
using primer pair NcoI-kanD7F and PstI-KanD7R (Table 2).  The 5' end of this middle PCR fragment has 
a 20-bp complementary sequence to the 3' end of the up fragments, whereas the 3' end of this middle 
fragment has a 20-bp complementary region to the dn fragments to generate fusion PCR products, equal 
molar ratios of up, dn, and the middle fragments were mixed and used as a template for the next round of  
PCR amplification with the flanking primers of the targeted genes.  The final PCR products were verified 
by gel electrophoresis for correct sizes and transformed in S. mutans strains.  Transformants were selected 
on THY agar plates containing either Em or Km. Gene replacement events were confirmed in the 
transformants by isolating genomic DNA and confirmed by PCR. 
 
2.3. Construction of Psmb-gusA reporter strains   
Plasmid pIB107 was used to construct this reporter fusion strain.  Plasmid pIB107 contains a promoter 
less gusA gene flanked by SMU.1405 locus to integrate into GS-5 chromosome by homologous 
recombination.  A fragment of ~200-bp containing the promoter of smb locus was amplified using the 
genomic DNA of GS-5 with the primers upPsmbBamF and upPsmbXhoR (Table 2). The amplified 
fragment was digested with BamHI and XhoI, and cloned into BamHI-XhoI digested pIB107 to create 
pIBA32 (Table 3). The promoter fusion construct was verified by DNA sequencing.  Plasmid pIBA32 
was linearized with NotI and transformed into GS-5 strain to create strain IBSA71.  The reporter construct 
was verified by PCR for the presence of the promoter fragment. 
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2.4. Construction of plasmids for complementation 
Plasmid pIB184-Km was used as vector for cloning [68]. This plasmid contains P23 promoter from 
lactococcal phage (pOri23).  To clone the smbFT genes, a fragment containing the coding regions was 
amplified from GS-5 genomic DNA.  The upstream primer was designed in such a way that it also 
includes the ribosome-binding site (Fig. 10).  The amplified fragment was digested with BglII and XhoI 
and cloned into BamHI-XhoI-digested pIB184-Km to generate pIBM09.  This plasmid and the vector 
were introduced into various streptococci. 
A PCR fragment containing the entire SPy1384 coding region plus 36-bp upstream sequence (containing 
ribosome binding site) was amplified from GAS JRS4 genomic DNA using the primers NewCBam-
1384F and NewCXho-1384R which introduced a unique BamHI site at the 5′-end and a unique XhoI site 
at the 3′-end.  The resulting ~0.7-kb fragment was digested with BamHI plus XhoI and ligated into 
BamHI-XhoI-digested pIB184-Km to create pIBA35.  This plasmid was also introduced into selected 
streptococci. 
 
2.5. Bacteriocin assay (zone of inhibition)   
GS-5 and its mutant derivatives were stabbed on THY-agar plates and incubated overnight under 
microaerophilic condition at 37⁰C [94].  The following day, the plates were overlaid with freshly grown 
indicator strain cultures by mixing with soft agar.  When the indicator strains contain plasmids, 
kanamycin was also included in the soft agar.  The overlaid plates were incubated again overnight under 
the same condition as above. The diameter of the clearing zone was measured afterwards.  Assays were 
repeated at least twice with four replicates. 
 
2.6. Antibiotic sensitivity assay 
Disk diffusion assays were performed to evaluate the antibiotic susceptibility of different S. pyogenes and 
S. mutans strains as described previously [95]. Briefly, antibiotic disks (6 mm diameter; Becton 
Dickinson) were placed on THY agar plates that were overlaid with 10 ml of THY soft agar containing 
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400µl of freshly grown cultures. The plates were incubated overnight at 37°C under microaerophilic 
condition, and the zones of inhibition were measured. For some chemicals such as nisin and tunicamycin, 
stock solutions were prepared at indicated strengths and 20µl was spotted directly or on an empty disk 
(6mm diameter).   
 
2.7. Transposon mutagenesis, screening and identification of ISS1 integration site    
The procedure described by Maguin et al. [96] was used to generate insertion mutants of GAS. Briefly, 
JRS4 strain was electroporated with pGhost9::ISS1 and transformants were selected on THY agar 
containing erythromycin at 30°C.  An overnight culture was made from a single transformed colony at 
30°C with erythromycin. Cultures were diluted 100-fold in the same medium without antibiotics, grown 
for 2 h at 30°C, and then shifted to 37°C for 2.5 h to select for transposition events.  This culture was then 
stored at -80°C with 20% glycerol as transposon library.  GS-5 was stabbed on THY-agar plates (about 
four to six stabs per plate) and incubated overnight under microaerophilic condition at 37⁰C [94].  The 
stabbed plates were overlaid with the 100µl of library that was freshly revived in 500µl THY.   Colonies 
that appeared inside the zone of inhibition were inoculated in THY broth containing erythromycin at 
37°C.  The location of the inserted ISS1 element was identified by one of two methods. A template 
generated by self-ligation of HindIII-digested chromosomal DNA was subjected to inverse PCR by using 
ISS1Rout2 and ISS1For4 primers. The PCR product was sequenced with primer ISS1-Rout2 to identify 
the flanking sequences.  The insertion sequences were identified by comparison to the serotype M1 
(SF370) and serotype M6 (MGAS10394) genome sequences.  
 
2.8. Identification of positive regulators for Psmb promoter 
Insertional mutagenesis was also performed with the plasmid pGhost9:ISS1.  S. mutans strain IBSA71 
was transformed with pGhost9:ISS1 and transformants were selected on THY agar containing Em, and 
incubated at 30°C.  An overnight-grown liquid culture was made from a single transformed colony. 
Cultures were diluted 100-fold in the same medium, grown for 2 hrs at 30°C, and then shifted to growth 
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at 37°C for 2.5 hrs to select for transposition events. Cultures were then plated on THY-Em plates 
containing X-gluc (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside; 300µg/ml) at 37°C.  
Approximately, 10000 colonies were evaluated and about 43 colonies were found to be white.  These 
colonies were further verified for color generation on THY-Em plate containing X-gluc (200µg/ml) and 
evaluated for Smb production using GS-5 and ΔsmbAB as controls.  Low or no Smb producing clones 
were selected and the location of ISS1 insertion sites were analyzed using inverse PCR as described 
above.  The flanking sequences obtained from sequencing of the inverse PCR product were mapped on 
the genomes of S. mutans UA159 and GS-5 by BLAST search. 
 
2.9. Curing of pGhost9::ISS1 from the selected mutants 
S. mutans or S. pyogenes cells carrying chromosomally inserted pGhost9:ISS1 were subjected to multiple 
growth cycles in liquid THY medium at permissive and nonpermissive temperatures, in the absence of 
antibiotic, to induce plasmid DNA excision. For each growth cycle, a saturated culture grown at 37°C was 
diluted 1,000-fold in fresh THY medium, followed by incubation at 30°C for 16 h. After 16 h the cells 
were diluted and plated on THY agar. Colonies were then replica-patched on THY agar with or without 
erythromycin to determine the efficiency of plasmid excision and to isolate pGhost9:ISS1-cured strain. 
Erythromycin sensitive colonies were confirmed for the loss of the plasmid sequence by PCR with 
primers homologous to the flanking regions. 
 
2.10. Isolation of RNA from bacterial cultures 
Total RNA was isolated from bacterial cultures according to the protocol described below.   S. mutans 
UA159 and its derivatives were grown in THY medium with appropriate antibiotics to mid-exponential 
phase (70 Klett units), and the cultures were harvested by centrifugation.   The cell pellets were then 
suspended in 10 ml of RNAprotect bacterial reagent (Qiagen) and incubated at room temperature for 10 
min. Total RNA was extracted using an RNeasy minikit (Qiagen) according to the manufacturer's 
instructions, with a modified bacterial-lysis step.   Briefly, cells were broken by the addition of an equal 
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volume of 0·10 mm glass beads (MP Biomedicals) and vortexing the suspensions for 45 sec. at speed 6 in 
a bead beater (Thermo Electron).   The supernatants were loaded onto RNeasy mini columns and purified 
using the manufacturer's protocol. The purified RNA samples were further treated with Turbo DNase 
(Ambion) according to the manufacturer's instructions to remove residual DNA contamination. The 
quality and integrity of the purified RNA samples were ascertained on a 1.2% agarose gel electrophoresis.  
Total RNA was quantitated in a UV spectrophotometer (Shimadzu) according to the optical density at 260 
nm (OD260) (1 unit = 40 µg/ml). 
 
2.11. Semi-quantitative RT-PCR  
Total RNA (DNA free) was used to prepare cDNA, using Superscript II reverse transcriptase (Invitrogen). 
Briefly, RNA samples (500 ng) were mixed with random decamer primer (100 ng) and deoxynucleotide 
triphosphates (dNTP) (0.5 mM), and the cocktail was heated at 65°C for 5 min, followed by quick chilling 
on ice. First-strand buffer (SuperScript-II reverse transcriptase; Invitrogen), 10 mM dithiothreitol (DTT), 
and RNase inhibitor (40 U; Roche) were added to the cocktail and incubated at room temperature for 2 
min, and the reverse transcriptase was added to the reaction mixture. The reaction mixture was further 
incubated at room temperature for 10 min, followed by incubation at 42°C for 50 min to synthesize 
cDNA. The reaction mixture was heat inactivated at 70°C for 15 min. To degrade the DNA-RNA hybrid, 
RNase H (2 U; Invitrogen) was added to the reaction mixture and incubated at 37°C for 45 min. Finally, 
the cDNA was purified using a PCR purification kit (Qiagen), and the cDNA concentration was 
determined using a UV spectrophotometer (Shimadzu). Five to 20 ng of cDNA was used to carry out the 
second-step PCR, using ReadyMix Taq PCR mix with MgCl2 (Sigma). Twenty to 22 PCR cycles were 
carried out to amplify the cDNA products of interest. The amplified PCR products were then 
electrophoresed on a 2% agarose gel.  As an internal control, the gyrA gene was used to ensure that equal 
amounts of cDNA were used in each reverse transcription (RT)-PCR. 
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2.12. Partial purification of Smb from culture supernatant of S. mutans 
Overnight cultures of GS-5 were prepared in 0.5 X APT broths supplemented with 4% yeast extract.  The 
supernatant was collected and the residual bacteria were removed from the supernatant by passing 
through 0.45µm filter.  After cooling at 4⁰C, ammonium sulphate was added to a final concentration of 
80% (w/v).  The precipitate was collected by centrifugation at 10,000g for 30 min.  The pellet was 
dissolved in PBS and dialyzed against PBS using a dialysis membrane with a 3000Da molecular weight 
cut-off.  The partially purified Smb was verified against S. salivarius. 
 
2.13. Site-directed mutagenesis of lsrS     
For site-directed mutagenesis of the putative CAAX protease domain, the coding region of Spy1384 was 
amplified by using the primers NewCBam-1384F and NewCXho-1384R using JRS4 genomic DNA as 
template and inserted into pGEMT-EZ by TA cloning, to generate pIBA40.  Site-directed mutagenesis 
was performed using high fidelity Pfu polymerase (Quick Change, Agilent Tech.) with the mutagenic 
primers that encode the mutations either EE145/146AA or H178M with an additional recognition site for 
BbvI (to facilitate screening by restriction digestion) to create intermediate plasmids either pIBA43 or 
pIBA42, respectively.  The mutations were confirmed by sequencing.  Spy1384 was then amplified from 
pIBA42 and pIBA43 with primers NewCBam-1384F and NewCXho-1384R, digested with BamHI plus 
XhoI and ligated into BamHI-XhoI-digested pIB184Km, to create pIBA45 and pIBA44, respectively.   
Sequencing the entire coding region reconfirmed the mutations in these constructs.  Plasmids pIBA44 and 
pIBA45 were transformed into S. pyogenes by electroporation and into S. mutans by natural 
transformation as described above. 
 
2.14. Membrane topology prediction for LsrS 
Various bioinformatic software searches such as TMHMM, HMMTOP, TMpred, ToPhred were used to 
determine the hydrophobic region of LsrR receptor protein.  We used β-galactosidase (lacZ) fusion to 
experimentally verify the LsrS membrane topology.  For this pNM480 plasmid was used as a vector to 
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clone various N-terminal regions of LsrS and constructed in-frame fusion with the LacZ gene encoded by 
pNM480.  β-galactosidase activity was measured as described by Miller.  Briefly, E. coli cells were 
grown in 10 ml LB until A600 was reached ~0.5 and cells were collected by centrifugation followed by 
resuspension in 1ml Z-buffer.  Cells were permeabilized with 0.1% SDS and chloroform.  Subsequently, 
4mg / ml 2-nitrophenyl- β-galactopyranoside (ONPG) was added to the permeabilized cells.  The mixture 
was incubated at 25⁰C until the development of yellow color and the reaction was stopped with 1M 
sodium carbonate.   Enzymatic activities were expressed in Miller units using the formula [(522xOD420 
of reaction mixture)/(OD600 of culture X volume per ml of culture used x time of reaction)].  
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Table 2:  List of oligonucleotides used in this study 
Name Sequence (5’!3’) Purpose 
FsnsmbAupF   GTTGGCGAAAGTGGTTCTGGTAAG                     Inactivation of smbA, smbB, 
smbAB (up)  
FsnsmbAupR GCCGCCATGGCGGCCGGGAGTAATAAATTACTTTTCATTTTA      Inactivation of smbA, smbAB 
(up) 
FsnsmbBdnF CGCGGCCGCCTGCAGGTCGACCGAATGCATGAGAAATTGTAG Inactivation of smbAB (dn) 
FsnsmbAdnR GACCGCTTTCATATTGTTCAGCAC                       Inactivation of smbA, smbB 
smbAB (dn) 
FsnsmbAdnF CGCGGCCGCCTGCAGGTCGACCGCACATCTCGCTGTATTAAC Inactivation of smbA ?(up)      
FsnsmbBupR GCCGCCATGGCGGCCGGGAGCCTGCTTTTTGAATCTCTTTC Inactivation of smbB (up) 
LocussmbAR GTTATTTGTTAATACAGCGAGATG smbA  amplification 
LocussmbBF  GGAGTAAATTATAATGAAAGAGATTC smbB  amplification 
LocussmbAF GGAAGGAATATAGGGTGAAAAG  smbA, smbAB amplification 
LocussmbdnR CGTATTACTTACTACAATTCTCATGC smbB, smbAB amplification 
LocussmbupF CTTGGTAAGGGGGAAGTTGTGGAAAC smb locus amplification 
NcoI-Kan D7 F CTCCCGGCCGCCATGGCGGCCGC       Antibiotic cassette (middle) 
PstI-Kan D7 R  GGTCGACCTGCAGGCGGCCGCG                         Antibiotic cassette (middle) 
FsnSmbTupF CCAGCCACATCTTACAAAATTTGGAGC Deletion of smbT (up) 
FsncrtSmbTupR GCGGCCGCCATGGCGGCCGGGAGGGTCCTTTTAAATTCTCAATAG Deletion of smbT (up) 
FsnSmbTdnF CGCGGCCGCCTGCAGGTCGACGCTGATTTGACTAAATATATTCC Deletion of smbT (dn) 
FsnSmbTdnR CCTTTGAATATAATTACAAATAACAAC Deletion of smbT (dn) 
SMBFT-XHO-R GCCCTCGAGCCACTATGCATAACCCCATTTACGATAAATC Complementation of smbFT 
SMBFT-BGLII-
RBSGTF- 
CGCAGATCTTGGAGGTTCCTAATGAGAATTTTAGACATTCAAAATT
TAAA 
Complementation of smbFT 
NewCBam1384F AGTGGATCCAGACAATTTTACCGTTAGCCTAAAAGG LsrS complementation 
NewCXho1384R  GTTCTCGAGCCGAAGCTTTTTATTATATGACTCC  LsrS complementation 
FSN662upF CAATTTTACTTTGTTTTGTTTTTCTGCCAAGAAG  SMU.662 deletion 
FSN662upR CGGCCGCCATGGCGGCCGGGAGCAAGTGATAATAAAATCAGTCCA
ATAAC  
SMU.662 deletion 
FSN662dnF CGCGGCCGCCTGCAGGTCGACCTACGGCGCTTTATTTCTTATTTAT
AGC 
SMU.662 deletion 
Fsn662dnR GGACATTGACAAAATGACTGGACTCTGACAAGACCTTGCC  SMU.662 deletion 
EE145AABbv1F GCTTTTATCGCTCCTATTATGGCAGCACTAGTCTTTAGAGGATTTC
CTATG 
EE146/146AA mutation 
LsrS 
EE145AABbv1R CATAGGAAATCCTCTAAAGACTAGTGCTGCCATAATAGGAGCGAT
AAAAGC 
EE146/146AA mutation of 
LsrS 
H178ABbv1F CTTGTTTTTGCTTTACCAGCAGCCACCAATAGTGTTGAA H178A mutation of LsrS 
H178ABbv1R TTCAACACTATTGGTGGCTGCTGGTAAAGCAAAAACAAG H178A mutation of LsrS 
PJRS-F TAAGGCTATTGGTGTTTATGGC  LsrS-LacZ fusion  
(upstream) 
M74LZHind-R CCTAAGCTTCCATTTTTTGCTGTTTAATAAAAGTGTCTTGCTTAGC LsrS-LacZ fusion  
(downstream) 
V148LzHindR CCTAAGCTTCGACTAGTTCTTCCATAATAGGAGCGATAAAAGCTAT LsrS-LacZ fusion  
(downstream) 
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Table 2:  Contd… 
 
 
 
Name Sequence (5’!3’)         Purpose 
PBam-smbAB CACGGATTCGTGACAAAATAATTGTTTTAAAAGACG SmbAB complementation 
PXho-smbAB CAGCTCGAGCTTTTCATTTTATATTCCTTCCTATTC SmbAB complementation 
SmbGsqF GCCAAACAGAATGTGGATTATGTG sQ-RT-PCR (smbG) 
SmbGsqR GTCCTCCGATTCTATAAGCGATGCC sQ-RT-PCR (smbG) 
SmbM1sqF GCATCGGTGCTTACAACGGAATAGCT sQ-RT-PCR (smbM1) 
SmbM1sqR CACACGATTATTTAAACAGTCACTC sQ-RT-PCR (smbM1) 
SmbTsqF GCAGCTATCAACGCCTTTGGTAGAGAG sQ-RT-PCR (smbT) 
SmbTsqR GCATAAACTAAGTAAGCCGGTACCAG sQ-RT-PCR (smbT) 
SmbwholelcsF CGTTGTCAATCCTGATGATGTTGTCG smb locus amplification 
SmbwholelcsR GCACATGAATAGAGCACTCAAGCAAACC smb locus amplification 
UpPsmbBam-F CAGGGATCCTGAAGGCTGAAATAGTC Psmb amplification 
UpPsmbXho-R CAGCTCGAGCAGTCCTTGTTTCCACA Psmb amplification 
ISS1 Rout2 AATAGTTCATTGATATATCCTCGCTGTCA Inverse PCR  for ISS1 
ISS1 For 4 GGTCTTAATGGGAATATTAGC Inverse PCR for ISS1 
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Table 3: List of plasmids used in this study 
 
Plasmid Relevant Characteristic(s) Source or 
Reference 
pGEM T-EZ Commercial TA cloning vector, Apr Promega 
pGhost9::ISS1 Thermosensitive delivery plasmid for ISS1, Kmr Maguin 
pIB184-Km E. coli – Streptococcus shuttle plasmid, Kmr Biswas 
pIBD38 pGEM T-EZ containing  loxP-Km cassette, Apr, Kmr Biswas 
pNM480 E. coli vector for lacZ fusion, Apr Milton 
pIB107 Vector for gusA reporter fusion Biswas 
pIBM01 pGEMT-EZ containing ermB gene, Apr, Emr This study 
pIBM08 pIB184Km containing smbFT with native RBS, Kmr This study 
pIBM09 pIB184Km containing smbFT with GtfB RBS, Kmr This study 
pIBA32 pIB107 containing Psmb promoter fused with gusA This study 
pIBA35 pIB184Km containing SPy1384, Kmr This study 
pIBA39 pNM480with lacZ-fused to SpPy1384 at codon 75 (M75), Apr This study 
pIBA40 pGEMT-T-EZ containing SPy1384, Apr This study 
pIBA41 pNM480 with lacZ  fused to SpPy1384 at codon 149 (V149), Apr This study 
pIBA42 pGEMT-T-EZ with H178A mutation in SPy1384, Apr This study 
pIBA43 pGEMT-T-EZ with EE145/146AA mutations in SPy1384, Apr This study 
pIBA44 pIB184Km with EE145/146AA mutations in SPy1384, Kmr This study 
pIBA45 pIB184Km with H178A mutation in SPy1384, Kmr This study 
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Table 4:  List of Gram-positive strains used in this study  
Name Genotypes and descriptions Reference 
or Source 
IBSA63 S. mutans GS5 with !smbAB,  Kmr This study 
IBSA66 S. pyogenes  JRS4::ISS1, clone #1, insertion not mapped, EmR This study 
IBSA67 S. pyogenes  JRS4::ISS1, clone #4, insertion in Spy1384, EmR This study 
IBSA68 S. pyogenes  JRS4::ISS1, clone #13, insertion in Spy1384, EmR This study 
IBSA69 IBSA67, pGhost 9 cured, EmS This study 
IBSA70 IBSA68, pGhost 9 cured, EmS This study 
IBSA71 S. mutans GS5 with Psmb-gusA reporter fusion, KmR This study 
IBSA72 S. mutans GS5 with !SMU.1704,  Emr This study 
IBSA73 IBSA71 with !smbAB,  Emr , KmR This study 
IBSA74 IBSA71 with !smbA,  Emr, KmR This study 
IBSA75 IBSA71 with !smbB,  Emr, KmR This study 
IBSA76 IBSA71 with !smbAB,  Emr, KmR This study 
IBSA77 S. mutans GS5 with !smbT,  Emr This study 
IBSA81 S. mutans GS5 with ![SMU.1704 – SMU1706],  Emr This study 
IBSA82 IBSA71 with !SMU.1704,  Emr , KmR This study 
IBSA83 IBSA71 with ![SMU.1704 – SMU1706], Emr , KmR This study 
IBSA89 S. mutans GS5 with !smbG,  Emr This study 
IBSA91 IBSA71 with !smbT,  Emr , KmR This study 
IBSA93 IBSA71 with !smbG,  Emr , KmR This study 
IBSA98 S. mutans with V403 with !SMU.662,  Emr This study 
IBSA99 S. mutans with UA159 with !SMU.662,  Emr This study 
OG1X Enterococcus faecalis ATCC 
MG1363 Lactococcus lactis INRA 
RB2006 Lactobcillus rhamnosos Clinical isolate 
1457 Staphylococcus epidermidis UNMC 
A909, NEM306 S. agalactiae ATCC 
CI-SA S. anginosus Clinical isolate 
CI-SC S. constellatus Clinical isolate 
AHT S. criceti Krasse 
ATCC33798 S. downeii ATCC 
CI-SD S. dysgalactiae Clinical isolate 
ATCC700410 S.equines ATCC 
43143,TX20005
BAA2069 
S. gallolytics ATCC and 
others 
ATCC10588, 
DL-1, M-5 
S. gordonii ATCC and 
others 
K388 S. iniae Clinical isolate 
CI-MT S. mitis Clinical isolate 
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Table 4:  Contd… 
Names Genotypes and descriptions Reference or 
source 
109c, 262RF, 
8VS3, DP1, 
GS-5,  NG-8, 
OMZ175, SJ32, 
SM3209, SP-2,  
T8, UA130, 
UA159, V1, 
V100, V403 
S. mutans ATCC and 
others 
NCTC7864 S. oralis NCTC 
ATCC6303, 
ATCC43079, 
ATCC49619 
S. pneumoniae ATCC 
   
AM3, JRS4, 
K32 
S. pyogenes Clinical 
isolates 
BHT, FA-1 S. ratii ATCC 
BAA491, 
ATCC25975 
S. salivarius ATCC 
SK36 S. sanguinis VCU 
6715, 
ATCC27352, 
ATCC33478 
S. sobrinus ATCC 
UT387 S. uberis UT 
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Chapter 3:  
 
SmbFT, a putative ABC transporter complex, confers protection against the lantibiotic Smb in 
streptococci 
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3.1. Abstract 
 
Streptococcus mutans, a dental pathogen, secretes different kinds of lantibiotic and non-lantibiotic 
bacteriocins.   For self-protection, a bacteriocin producer strain must possess one or more cognate 
immunity mechanisms.  Here we report the identification of one such immunity complex in S. mutans 
strain GS-5 that confers protection against Smb, a two-component lantibiotic.  The immunity complex 
that we identified is an ABC transporter composed of two proteins: SmbF (the ATPase component) and 
SmbT (the permease component); both the protein-encoding genes are located within the smb locus.  We 
show that GS-5 becomes sensitized to Smb upon deletion of smbT, which makes the ABC transporter 
non-functional.  To establish the role SmbFT in providing immunity, we heterologously expressed this 
ABC transporter complex in four different sensitive streptococci species and demonstrated that it can 
confer resistance against Smb.  To explore the specificity of SmbFT in conferring resistance we tested 
mutacin IV (a non-lantibiotic), nisin (a single peptide lantibiotics), and three peptide antibiotics 
(bacitracin, polymyxin B, and vancomycin).  We found that SmbFT does not recognize these structurally 
different peptides.  We then tested whether SmbFT can confer protection against haloduracin, another 
two-component lantibiotic that is structurally similar to Smb; SmbFT indeed conferred protection against 
haloduracin.  SmbFT can also confer protection against an uncharacterized but structurally similar 
lantibiotic produced by Streptococcus gallolytics.  Our data suggest that SmbFT truly displays immunity 
function and confer protection against Smb and structurally similar lantibiotics.   
67 
 
3.2. Introduction  
Oral biofilm is complex and diverse in nature.  As many as 700 different bacterial species colonize in our 
mouth; unfortunately the identity of many of them is still unknown [1,97].  The complexity of biofilm 
greatly depends on the interspecies interaction during early as well as maturing phase of biofilm 
formation.  The participation of these organisms is not restricted to dental disease only, as they can cause 
bacterimia and in some cases infective endocarditis [98-100].  Endocarditis is generally caused by 
viridans group of streptococci.  Some of these viridians streptococci are commensal in oral cavity and the 
others are involved in disease formation [100,101].   Some of the commensal streptococci have a 
protective role against oral disease development [102].  The exact in vivo mechanisms for this 
interspecies interference are currently not well understood, however several studies strongly suggest an 
important role for hydrogen peroxide and bacteriocin in this process [103-105]. 
In general, bacteriocins are ribosomally synthesized small peptides with bactericidal or bacteriostatic 
activity on other species.  Bacteriocins are broadly categorized into two groups: non-lantibiotic and 
lantibiotic.  The non-lantibitic group contains peptides that do not require any modifications for their 
biological activity [106].  In contrast, the lantibiotic groups contain peptides that require posttranslational 
modification for their antimicrobial activity [70,107].   In lantibiotics, most of the serine and threonine 
residues are dehydrated to dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively, by modifying 
enzymes encoded within the lantibiotic synthesis operon. With neighboring cysteine residues, Dha and 
Dhb can form thioetherlinked lanthionine and 3-methyl lanthinoine bridges, respectively.  Sometimes 
Dha, Dhb and other modified residues can be present as unlinked residues (for reviews see [70,71,108-
110]).  Based on the nature of the enzymes responsible for the modifications, lantibiotics are divided into 
three classes [70].  Class I lantibiotics (such as nisin and subtilin) are modified by two enzymes generally 
referred to as LanBC system. Class II lantibiotics (such as lacticin 481 and mersacidin) are modified by a 
single enzyme often referred to as LanM-type enzyme.  Class II lantibiotics also include two-component 
lantibiotics (such as lacticin 3147 and haloduracin) and the antimicrobial activity requires synergistic 
interaction of both peptides [111,112].   Lantibiotics that belong to class III are lanthionine peptides that 
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have no antimicrobial activity [113,114].  The advantage of bearing modified residues as well as 
cyclization is to make lantibiotics more stable against heat, pH, and protease degradation compared to 
non-lantibiotics [115].  This stable nature of lantibiotics makes them a major candidate for commercial 
application; for example, nisin is extensively used as a preservative in the food industry [72]. 
Lantibiotics are generally produced by Gram-positive bacteria and usually have a variable spectrum of 
inhibition [72,109,115-117].  The producer organisms usually encode specific immunity proteins that 
protect themselves from the deleterious effect of their own lantibiotics and the immunity protein encoding 
genes are often present within the same lantibiotic biosynthesis operon.  Currently, two types of immunity 
proteins have been identified.  The first type includes dedicated ABC transporters that presumably pumps 
lantibiotics out of the membrane and thus prevent accumulation to inhibitory levels (for reviews see, 
[108,118]).  The second type includes small proteins that are weakly associated with the membrane and 
often sequester specific lantibiotics at the cell surface before they could cause cell damage [119-121].  
Streptococcus mutans, an oral streptococci and a major etiological agent of human dental caries, often 
produces several kinds of bacteriocins, collectively known as mutacins.  A majority of the mutacins 
characterized to date belong to lantibiotics, such as mutacins I, II, III, K8, B-Ny266, Smb, and1140 
[64,122-128]. Based on their primary amino acid sequences, mutacins belonging to lantibiotics are further 
subdivided into two classes: AI and AII [88,129,130]. Subclass AI contains the most well-characterized 
peptides such as mutacin I and III (1140), which are similar to nisin and subtilin.  Detailed structural 
information of these mutacins is currently lacking.  Although the lanctibiotic mutacins are widely present 
in S. mutans [86,128], surprisingly the first sequenced reference strain UA159 does not encode any 
lantibiotic, it only encodes non-lantibiotics [44].  In contrast, another recently sequenced S. mutans strain 
GS-5 encodes both Smb and non-lantibiotics [126,131].  Majority of the mutacins encoding genes are 
acquired by the S.mutans by horizontal gene transfer mechanism.  For example, the strains that produce 
mutacin K8 contains the K8-encoding muk locus that is inserted in between SMU.1811 and SMU.1812 
genes of the corresponding UA159 genome [128].  Similarly, the smb locus, which contains all the genes 
necessary for Smb biosynthesis, is integrated in between SMU.1942 and syl locus.  Smb is the only two-
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component lantibiotic identified so far in S. mutans and appears to be encoded only by a handful of strains 
[128] 
The smb locus contains seven open reading frames in the following order: smbM1, -F, -T, -M2, -G, -A, 
and –B.  Putative transposase encoding genes are also present near the smb locus [126]. Two genes, smbA 
and smbB, are the structural genes for the Smb pre-peptides and two putative modification enzymes 
encoded by smbM1 and smbM2 are also present in the smb locus.  A recent report indicated that SmbG 
appears to play a role in Smb immunity and sensitivity to antimicrobial agents [132].  Two other genes, 
smbF and smbT, show homology with the ATP binding cassette transporter and were previously predicted 
to be involved in processing and secretion of Smb pre-peptides [126].  We noticed that this SmbFT ABC 
transporter complex does not have a signal peptidase domain, and hence might not be involved in the 
processing and secretion of the Smb pre-peptide.  We predicted that SmbFT might provide immunity to 
Smb producing S. mutans strains.  In this study we provide evidences that SmbFT indeed confer 
resistance towards Smb in the producer strain and show that deletion of smbT gene in GS-5 leads to 
sensitivity towards Smb. We also demonstrate that SmbFT can confer resistance to sensitive streptococci 
belonging to non-mutans group.  Furthermore, we show that SmbFT has a narrow specificity since it only 
recognizes structurally similar two-peptide lantibiotics. 
70 
 
3.3. Results 
3.3.1. Smb sensitive strains do not encode the smb locus.   Smb is the only lantibiotic that is secreted by 
S. mutans GS-5 [131] and a previous study suggested that Smb is active against many oral streptococci 
[91].  Since most of the lantibiotics including nisin have wider spectrum than the non-lantibiotics 
[106,115,130], we wanted to determine whether Smb could inhibit various streptococci belonging to 
different phylogenetic groups [133].  We first constructed a smbAB-deleted mutant strain (ΔsmbAB) to 
include in our inhibition assays to make sure that the activity that we will observe is due to lantibiotic 
Smb and not due to other bacteriocins.  We then used GS-5 and ΔsmbAB strains as tester against 18 
streptococci and 16 S. mutants isolates (Fig 9A). All the streptococci strains, except some S. mutans 
isolates (see below), were inhibited by Smb.  We divided the activity spectra in to two classes, a zone-of-
inhibition (ZOI) smaller than 10mm and larger than 10 mm (Fig 9A).  Two groups of streptococci, the 
pyogenic and the bovis groups, consistently produced larger ZOI than the other groups suggesting that the 
streptococci belonging to these groups are more susceptible to Smb than the other groups.  S. mutans 
strains generally do not inhibit the growth of other S. mutans strains.  However, we found that nine out of 
16 S. mutans also produced large ZOI (Table 5). Furthermore, two S. ratti strains were also produced 
some ZOI but FA strain produced small (~8mm) but clear ZOI while BHT strain produced diffused ZOI 
(~10mm).   Among the mitis group, most of the isolates produced smaller ZOI except S. sanguinis SK36, 
which produced a large ZOI (~20mm).  
It was surprising to observe that many of the S. mutans isolates were insensitive to Smb.  Since 
the lantibiotics have the potential to attack the producer strains, the producer strains must contain some 
self-protection mechanisms to protect against their own lantibiotics.   Therefore, it is possible that the S. 
mutans strains that were insensitive may actually encode the smb locus. To examine the presence of smb 
locus, we PCR amplified the smbAB structural genes from all the 16 S. mutans isolates.  Eleven of these 
isolate belongs to serotype c, including common laboratory strains (UA159, NG8, and GS5); one each 
from serotype e (V100) and serotype f (OMZ175); and the rest were taken from unknown serotypes.   
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Figure 9.  Smb activity spectrum and distribution of smb locus in various S. mutans strains  (A) Member 
species of different phylogenetic group of streptococci were tested against mutacin Smb produced by GS-
5. GS-5 and a ΔsmbAB mutant strain were stabbed on THY-agar plate and incubated overnight in 
microaerophilic condition at 37⁰C.  Next day, overnight grown culture of indicator strain was mixed with 
soft agar and overlaid on the plate. The overlaid plates were incubated again overnight under the same 
condition. The following day the diameter of the zone of inhibition (ZOI) was measured. The observation 
is based on two separate experiments with four replicates.  Diamonds and squares indicate ZOI greater 
than or less than 10 mm in diameter, respectively.  (B) The presence of smb locus in 16 different S. 
mutans strains. Analysis of PCR products of smbAB genes by agarose gel electrophoresis. Solid circles 
indicate the strains that are susceptible to Smb inhibition (Table 6). The observation is based on at least 
three independent experiments. 
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Table 5: Sensitivity of various Gram-positive bacteria to Smb 
 
Species (indicator strain)  Group    Zone of inhibition diameter (mm) 
                  GS-5  !smbAB 
 
S. uberis (UT387)   Pyogenic  26.0 ± 2.0 12.0 ± 1.0  
S. agalactiae (NEM306)   Pyogenic  18.0 ± 0.5 4.0 ± 1.0  
S. agalactiae (A909)   Pyogenic  19.0 ± 1.0 4.0 ± 1.0  
S. dysgalactiae (CI)   Pyogenic  26.0 ± 1.0 0.0 ± 0.0 
S. iniae (K388)    Pyogenic  31.0 ± 1.0 7.0 ± 1.0  
S. pyogenes (JRS4)*   Pyogenic  26.0 ± 1.0 9.5 ± 1.5 
S. pyogenes (AM3)   Pyogenic  24.0 ± 1.0 10.5 ± 1.5 
S. pyogenes (K32)   Pyogenic  28.0 ± 1.0 10.5 ± 1.5 
 
S. anginosus (CI)   Anginosus  16.0 ± 1.0 4.5 ± 0.5 
S. constellatus (CI)   Anginosus  10.0 ± 1.0 4.5 ± 0.5 
 
S. gordonii (DL-1)*   Mitis   9.5 ± 0.5 4.0 ± 0.5  
S. gordonii (M5)    Mitis   11.5 ± 1.5 6.5 ± 0.5 
S. gordonii (ATCC10558)  Mitis   12.5 ± 3.5 6.0 ± 1.0 
S. pneumonia  (ATCC 6303)  Mitis   10.0 ± 1.0 1.0 ± 0.5  
S. pneumonia (ATCC49619)  Mitis   11.5 ± 1.5 0.0 ± 0.0 
S. pneumonia  (ATCC43079)  Mitis   13.5 ± 0.5 1.5 ± 1.0 
S. sanguinis (SK36)*   Mitis   23.0 ± 1.0 0.0 ± 0.0 
S. oralis (NCTC7864)   Mitis   7.0 ± 1.0 0.0 ± 0.0 
S. mitis (CI)    Mitis   4.5 ± 0.5 3.5 ± 0.5 
 
S. salivarius (ATCC25975)  Salivarius  15.0 ± 1.0 6.0 ± 1.0  
S. salivarius (BAA491)   Salivarius  24.0 ± 1.0 0.0 ± 0.0 
   
S. gallolyticus (TX20005)  Bovis   12.0 ± 1.0 1.5 ± 0.5  
S. gallolyticus (BAA2069)  Bovis   22.0 ± 2.0 3.0 ± 0.5  
S. gallolyticus  (43143)   Bovis   25.0 ± 1.0 1.0 ± 0.5  
S. equines (ATCC700410)  Bovis    20.0 ± 1.0 0.0 ±0.0 
 
S. downeii (ATCC 33798)  Mutans   14.0 ± 1.0 0.0 ± 0.0 
S. sobrinus (6715)   Mutans   7.0 ± 1.0 0.0 ± 0.0 
S. sobrinus ATCC 27352   Mutans   7.0 ± 0.5 0.0 ± 0.0 
S. sobrinus ATCC33478   Mutans   5.5 ± 0.5 0.0 ± 0.0 
S. criceti AHT    Mutans   7.0 ± 0.5 0.0 ± 0.0 
S. ratti FA-1    Mutans   6.0 ± 0.5 0.0 ± 0.0 
S. ratti BHT    Mutans   9.0 ± 0.5 0.0 ± 0.0 
  
 
L. lactis MG1363   Other   20.0 ± 6.0 2.0 ± 2.0 
E. faecalis OG1X   Other   7.5 ± 0.5 3.5 ± 0.5 
L. rhamnosus (CI)   Other   22.0 ± 1.0 7.0 ± 1.0 
Staph. epidermidis 1457   Other   0.0 ± 0.0 0.0 ± 0.0 
_________________________________________________________________________________________ 
CI, Clinical isolate. *, Strains used for heterologous expression of SmbFT 
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Table 6: Susceptibility of various S. mutans strains to Smb  
____________________________________________________________________________________ 
Species (strain)     Zone of Inhibition [diameter, mm] 
       ______________________________________ 
       GS-5  !smbAB 
____________________________________________________________________________________ 
 
S. mutans UA159*      11.0 ± 1.0 2.0 ±2.0 
S. mutans NG-8*      11.0 ± 1.0 0.0 ± 0.0 
S. mutans GS-5       0.0 ± 0.0 0.0 ± 0.0 
S. mutans SP-2       0.0 ± 0.0 0.0 ± 0.0 
S. mutans  Sm3209      9.5 ± 1.5 2.5 ± 1.5 
S. mutans T8       0.0 ± 0.0  0.0 ± 0.0 
S. mutans SJ32       13.5 ± 1.5 0.0 ± 0.0 
S. mutans 8VS3       4.1 ± 1.0 0.0 ± 0.0 
S. mutans 109C*      16.5 ± 0.5 0.0 ± 0.0 
S. mutans  OMZ175*      15.5 ± 0.5 0.0 ± 0.0 
S. mutans V100       11.5 ± 1.5 0.0 ± 0.0 
S. mutans  262RF      0.0 ± 0.0 0.0 ± 0.0 
S. mutans  V403*      18.0 ± 2.0 0.0 ± 0.0 
S. mutans  UA130       2.0 ± 0.0 0.0 ± 0.0 
S. mutans  DP1         1.0 ± 0.0 0.0 ± 0.0 
S. mutans  V1       10.0 ± 1.0 0.0 ± 0.0 
___________________________________________________________________________________ 
CI, Clinical isolate. *, Strains used for heterologous expression of SmbFT 
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We found the presence of expected 420-bp size band in eight of the isolates.  As expected, these strains 
were also found immune to Smb, indicating presence of the same immune mechanism(s) in these strains 
as in the producer strain.  The only exception was V100 strain that encodes the smb locus but was 
sensitive to Smb mediated inhibition.  All other eight strains that did not produce a PCR product were all 
produced clear ZOI against Smb.  This data support the notion that the strains that encode the smb locus 
are all immune to Smb mediated killing, except strain V100. V100 is unique among the S. mutans strains 
since does not develop natural competence (data not shown).  We speculate that it does not express the 
smb locus.  
      
3.3.2. SmbFT, a putative ABC transporter complex, provides immunity against Smb.  The Smb 
encoding operon also encodes smbFT that shares high homology to a putative ABC transporter complex. 
Since ABC transporters often function as immunity proteins, we wanted to verify whether SmbFT can 
protect S. mutans from Smb mediated killing. SmbFT transporter is composed of two polypeptides. SmbT 
encodes permease component and is 238 residues long with six transmembrane domains. SmbF, on the 
other hand, encodes a 274- residues long protein with ATPase signature sequences [134].  The promoter 
for smb locus lies about 3.0-kb upstream of the smbFT genes. Sequence analysis suggests the presence of 
a weak ribosome-binding site at 5-nt upstream of smbF start codon and an overlap of nine codons 
between the smbF and smbT coding sequences (Fig 10A).  Because the promoter lies far from the smbF 
and since smbFT are linked together, we decided to express both smbFT from a low-copy plasmid under a 
heterologous promoter (P23) as a single transcript.  We selected a stable theta-replicating plasmid, 
pIB184Km [135], to clone and express smbFT.  We also replaced the native weak ribosome-binding 
sequence with a strong sequence from the gftB gene. To examine the role in immunity, we heterologously 
expressed SmbFT in five S. mutans strains that are susceptible to Smb.  These strains are UA159, NG-8, 
V403, 109c, and OMZ175.  
  
76 
 
 
 
Figure 10.   Smb and its immunity protein (A) Genomic organization of smb locus in GS 5. Regions used 
for fusion PCR for deletion constructions are shown at the bottom. Brackets indicate the regions that were 
deleted from the genome and an erythromycin resistance gene (ermB) was inserted.  Plasmid used for 
heterologous expression of smbFT (pIBM09) is shown. This plasmid contains a RBS from gftB gene and 
a P23 promoter used for smbFT expression.  Relevant sequences near the smbF start codon and the 
overlapping region between smbF and smbT is shown. Bent arrows and lollipop indicate promoters and 
transcription termination site.  Block arrows indicate gene orientation. (B). Immunity activity of SmbFT 
in S. mutans strains. GS-5 and a ΔsmbAB strain were stabbed into THY agar and incubated overnight at 
37°C under microaerophilic conditions. The plates were overlaid with soft agar containing the indicator 
strains. The ZOI of the indicator strains was evaluated after overnight incubation. The indicator strains are 
OMZ175 (left panel) and V403 (right panel) containing the vector (pIB184) or the vector with SmbFT. 
These plates are representative of three independent assays. 
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.  
 Heterologous expression of SmbFT in all the five S. mutans strains provided complete protection against 
Smb compared to the empty-vector carrying strains (Fig 10B, data not shown).  Thus our findings support 
the prediction that SmbFT indeed functions as an immunity protein against Smb.  
 
3.3.3. Inactivation of smbT makes the strain susceptible to Smb.  Since SmbFT can confer protection 
against Smb lantibiotic, we wanted to determine whether SmbFT has a redundant function in providing 
immunity against Smb in GS-5.  This is because a previous study suggests that two other factors, Bip 
(SMU.1914) and SmbG  (encoded by smb operon), also provide protection against Smb [132]. We first 
constructed a smbT-deleted mutant (ΔsmbT) in GS-5 by replacing the smbT coding sequence with a non-
polar Em resistance cassette.   We used ΔsmbT as an indicator strain in previously described plate assays 
against Smb producer. As shown in Fig. 11A, we observed that ΔsmbT is more susceptible to Smb 
compared to GS-5 strain.  The ZOI inhibition produced by ΔsmbT strain was very clear and as large as the 
ZOI produced by S. salivarius strain. This result supports that SmbFT functions primarily as an immunity 
protein in GS-5 and its absence makes the strain more susceptible to the lantibiotic.   
 
To investigate the influence of SmbFT in Smb production, we performed a plate assay to measure 
ZOI formation by ΔsmbT strain against S. salivarius indicator strain with GS-5 and ΔsmbAB as controls.   
While GS-5 produced a larger and clear ZOI including a secondary halo, the ZOI produced by ΔsmbT 
was clear and small.  On the other hand ΔsmbAB did not produce a visible ZOI. The larger secondary ZOI 
that was seen with GS-5 is not always visible and it depends on the age of the indicator culture (Fig 11B, 
data not shown).   To confirm that ΔsmbT could produce a clear ZOI, we used two other indicator strains, 
S. galolyticus and S. sanguinis. As shown in Fig 11B (right panels), ΔsmbT produced a clear ZOI in both 
the strains as compared to ΔsmbAB control, which did not produce a halo. As expected, GS-5 strain 
produced a larger ZOI with a secondary halo against both the indicator strains.  Taken together, our data 
suggest that Smb is secreted at low level even in the absence of smbT.   
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Figure 11. Sensitivity of ΔsmbT to Smb and secretion of Smb by ΔsmbT (A) Agar diffusion assays were 
carried out with GS-5 and ΔsmbAB as tester strains with GS5 and ΔsmbT as indicator strains.  (B).  
Production of Smb by ΔsmbT was verified by agar diffusion assay using S. salivarius BAA491, S. 
galllolyticus BAA2069 and S. sanguinis SK36 as indicator strains. GS-5 and ΔsmbAB was used as 
positive and negative controls, respectively.  The plates are representative of three independent replicates. 
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3.3.4. SmbFT can confer immunity in heterologous streptococcal hosts.  The oral cavity harbors over 
700 different bacterial species, and streptococci constitute the majority [41].  Many streptococci contain 
ABC transporters that are similar to SmbFT yet they are sensitive to Smb.  To verify whether SmbFT can 
confer resistance in other oral streptococci we selected a mitis group of streptococci, S. sanguinis, which 
plays a beneficial role in oral cavity and known to compete with S. mutans for subsequent colonization 
[103,105]. Another reason for selecting S. sanguinis was that the organism is naturally competent and 
therefore easy to manipulate [136].  When we overexpressed SmbFT from the plasmid in S. sanguinis 
SK36, we observed a complete protection against Smb mediated killing (Fig 12). In fact, there was very 
little or no ZOI in strain overexpressing SmbFT whereas ZOI of about 20mm diameter was observed in 
strain containing the vector only (Fig 12).   
Since SmbFT conferred protection against Smb in streptococcus belonging to mitis group, we wanted to 
test whether it can confer protection in other groups.  For this, we selected the pyogenic group since all 
the four tested species produced larger and clear ZOI (Fig 9A).   We introduced the plasmid 
overexpressing SmbFT and the vector control in S. pyogens JRS4 strain, an M6 serotype strain. As shown 
in Fig. 12, overexpression of SmbFT in S. pyogenes also provided protection against Smb in S. pyogenes 
strain.   However, the level of protection was less drastic and the ΔsmbAB strain, which was included as 
control, also produced a clear ZOI in both vector and SmbFT overexpressing strain.  Nevertheless, 
SmbFT conferred protection against this lantibiotic in S. pyogenes.  Taken together, our results suggest 
that SmbFT can function as a universal immunity protein for Smb in streptococci. 
 
3.3.5. The immunity provided by SmbFT is specific toward Smb and related lantibiotics. Cross-
immunity is a rare occurrence among lantibiotic producer strains and has only been found in strains that 
produces very closely related lantibiotics, such as nukacin ISK-1 and lacticin 481 [137].  Since SmbFT 
was able to confer protection in various streptococci, we wondered whether SmbFT could provide cross-
protection against other bacteriocins.  Towards this end, we first tested against haloduracin, a two-
component lantibitic produced by Bacillus halodurans and shares structural similarity with Smb [111].    
82 
 
 
 
 
 
 
Figure 12.  SmbFT confers protection in heterologous hosts.  Agar diffusion assays were carried out with 
GS-5 and ΔsmbAB as tester strains.  The indicator strains are S. sanguinis SK36 (left panel) and S. 
pyogenes JRS4 (right panel) containing the vector (pIB184) or the vector with SmbFT. These plates are 
representative of three independent assays. 
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S. sanguinis and S. mutans V403 strains containing either smbFT expression plasmid or the vector alone 
were used as indicator strains in agar diffusion assay with 10µl of 100µM purified haloduracin (kindly 
provided by Dr. van der Donk) spotted on plate and the results are shown in Fig. 13.  Haloduracin 
produced a clear and larger ZOI in S. sanguinis containing the vector while S. sanguinis expressing 
SmbFT produced a much smaller and cloudy ZOI.  The ZOI in S. mutans V403 with the vector was much 
smaller and cloudy, suggesting that haloduracin is not very effective against S. mutans.  However, no ZOI 
was observed in V403 expressing SmbFT indicating that as in S. sanguinis, SmbFT provided protection 
against haloduracin in S. mutans.    
 
S. gallolyticus BAA 2069 possess a unique 23 kb genetic island in the genome, coding for bacteriocin-
associated genes (SGGBAA2069_c00810-c00960). These genes encode for a lantibiotic that share high 
degree of similarity with Smb and haloduracin.   Hinse et al [138] have shown that BAA 2069 strain 
indeed produces a lantibiotic that is active.  Therefore, we tested S. mutans V403, S. sanguinis SK36, and 
S. pyogenes JRS4 strains overexpressing SmbFT or containing the vector.  All the streptococci produced 
much smaller ZOI when SmbFT was present as compared to vector only strains (data not shown).   This 
indicates that SmbFT is also active against the lantibiotic produced by BAA 2069. 
 
 
We then tested whether SmbFT could provide protection against other bacteriocins.  For this we chose S. 
mutans UA159 that primarily produces mutacin IV (NlmAB, a two-component non-lantibiotic.  S. 
gordonii is generally used as an indicator strain for mutacin IV.  As shown in Fig. 13, S. gordonii with or 
without SmbFT produced similar size ZOI indicating that SmbFT could not confer protection (control 
ΔnlmAB did not produce any ZOI in either cases).  Next we checked the effect SmbFT on protection 
against purified nisin, a well-studied monopeptide lantibiotic that is structurally different from Smb.  As 
expected, SmbFT did not provide protection against nisin (data not shown).  ABC transporters are often 
associated with tolerance to various peptide antibiotics such as vancomycin and bacitracin [139].  
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Therefore, we also checked sensitivity to different cell-wall specific peptide antibiotics, such as 
bacitracin, polymyxin B, and vancomycin by disc diffusion assay.  We did not observe any noticeable 
difference between the strain containing SmbFT or the vector control (data not shown).  Taken together 
our results imply that SmbFT is specific to confer protection against Smb or closely related lantibiotics.  
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Figure 13.  Substrate specificity of SmbFT. (A) Purified haloduracin (1:1 mixture of Halα and Halβ) was 
spotted on THY plate and then overlaid with indicator strains containing the vector or the vector with 
SmbFT.  (B). UA159 and ΔnlmAB strains were stabbed into THY agar and deferred antagonism assay 
was carried out with S. gordonii DL-1 strain containing the vector or the vector with SmbFT.   GS-5 and 
ΔsmbAB strains were used as control.  Assays were repeated at least three times, and a representative plate 
is shown.  
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3.4. Discussion  
Lantibiotic producer strains possess multiple mechanisms to protect themselves against their own 
inhibitory activity. One of the most effective mechanisms that provide the maximum protection is through 
various dedicated ABC transporters.  ABC transporters that are involved in self-immunity or protection 
against other lantibitics are generally classified into multiplecategories [140]. ABC transporters such as 
NisT and SunT family members are encoded by a single polypeptide where the ATPase domain is fused 
with the permease domain.  Some members of SunT also encode an N-terminal peptidase C39 domain. 
SmbG, which was shown to confer protection against Smb [132], belongs to the SunT family.  The other 
ABC transporters families all contain two separate polypeptides one with permease activity and the other 
with ATPase function.   SmbFT, the ABC transporter that we studied here, belong to BcrAB family that 
contains two separate polypeptides.  ABC transporters belonging to BcrAB family are not extensively 
characterized except for two transporters from Bacilli [141,142].  A recent evolutionary relationship study 
indicates that BcrAB family proteins are closely related to LanFEG family transporters.  The latter family 
proteins, which contain two separate permeases (LanE and LanG) and one ATPase (LanF), are all 
involved in self-immunity of lantibiotic producing bacteria.   On the other hand BcrAB family 
transporters are involved in resistance against bacitracin [141,143]. Since the genes are encoded within 
the biosynthesis locus for bacitracin, BcrAB family proteins appear to confer self-immunity [143].  The 
SmbFT transporter that we studied here is the first example of a BcrAB family protein that is involved in 
lantibiotic resistance.  
As mentioned before the SmbFT transporter is composed of two polypeptides, SmbT, which encodes the 
permease component and SmbF, on the other hand, encodes the ATPase where two third of the N-
terminal region comprises of P-loop containing nucleoside triphosphate hydrolase signature sequences 
[144].  Although S. mutans encodes numerous permease proteins [44], a sequence similarity search with 
SmbT against the genome returned no results suggesting that SmbT encodes a unique sequence.  In 
contrary, search using SmbF as query against the genome returned several ABC transporter related 
ATPAses.  Four ATPases, SMU.238, SMU.654, SMU.1035, and SMU.1811 showed maximum similarity 
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(E-value >-30) with SmbF (data not shown).  At present we do not know whether any of these ATPases 
can form a productive complex with SmbT permease to counteract Smb.  
 
We expressed SmbFT in at least four different streptococci other than S. mutans.  In each of these 
streptococci, heterologous expression of SmbFT conferred full protection against Smb lantibiotic.  This 
means SmbFT does not need any other accessory proteins for their activity.  Alternatively, the accessory 
protein could be a highly conserved protein present all the streptococcal strains tested here.   As 
previously mentioned, lantibiotic producer strains often encode two types of transporters for full 
protection.  For example, Lactococcus lactis strain that produces lacticin 3147, a two-component 
lantibiotic similar to Smb, possesses both LtnI, a lipid anchored membrane protein, and LtnFE systems 
[77].  Draper et al [77] have demonstrated that in a heterologous system, LtnI and LntFE act 
synergistically to confer complete protection.  The smb locus does not encode any LntI homolog but it 
encodes SmbG, a SunT homolog, containing ABC transporter motif and a C39 peptidase motif.  It has 
been proposed that SmbG functions as an immunity protein against Smb [132]; however, an smbG mutant 
strain is not susceptible to Smb.  An immunity-like protein encoded by SMU.1913 (mentioned as Bip in 
ref.[132]) has also been proposed to function as Smb immunity protein.  Surprisingly, a bip single mutant 
strain is also not susceptible against Smb indicating other proteins can confer resistance.  In contrast, our 
data suggest that SmbFT alone can confer complete protection against Smb in a variety of streptococcal 
strains; all these strains neither contain SmbG nor Bip.   Therefore, unlike other lantibiotic immunity 
systems, we speculate that SmbG and SmbFT provide different functions in S. mutans.  We believe that 
the primary role of SmbG is to secrete Smb peptides from cytoplasm to the milieu and when SmbG is 
absent, the strain does not produce active Smb.  Indeed we found that a smbG mutant is unable to produce 
Smb and functionally behave like the ΔsmbAB mutant.    
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Figure 14:  Sequence alignment of two-peptide lantibiotics closely related to Smb.  The α-peptide (A1) is 
encoded by SmbB while the β-peptide (A2) by SmbA.  Other sequences were retrieved from GenBank 
and they are:  S. ratti BHT strain BHTA1 (AAZ76603) and BHTA2 (AAZ76602); Bacillus halodurans 
C-125 HalA1 (NP_241320) and HalA2 (NP_241319); and S. gallolyticus BAA 2069 SGALA1 
(YP_004287012).  The GALA2 peptide was not annotated in the BAA 2069 genome and was identified 
by analyzing the untranslated sequence near the GALA1 coding region.  Curved arrows indicate residues 
involved in putative and/or established ring structure formation and the letters inside the arrows indicate 
the ring designation in the structure. 
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 SmbB: !IGTTVVNSTFSIVL-----GNKGYICTVTVECMRNCSK!
BHTA1: !IGTTVVNSTFSIVL-----GNKGYICTVTVECMRNCQ!
HalA1: !    CAWYNISCRL-----GNKGAYCTLTVECMPSCN!
GalA1: !GWTGVAKSITSCSLLSIGLGNDGWVCTWTAECQATCR!
!" #" $"
 SmbA: !      STPACAIGVVGITVAVT-----GISTACTSRCINK!
BHTA2: !      STPACAIGVVGITVAVT-----GISTACTSRCINK!
HalA2: !GDVHQ-TTWPCATVGV--SVALC------PTTKCTSQC--!
GalA2: !      STPGCAWAAV--SAISTVSALFQITTACTTRCYHP!
 !
 !
!" #" $" %"
!"
#"
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We also believe that the primary function of SmbFT is to confer self-protection and not secretion.   This 
is because we found that the ΔsmbT mutant produced a clear ZOI against multiple strains (Fig.11) 
indicating Smb production; however, the ZOI was much smaller than the GS-5 strain.  There are several 
reasons that can explain the smaller ZOI produced by the ΔsmbT strain.  Since the strain was constructed 
by insertion of an ermB gene (erythromycin resistance), it might have interfered with the transcription of 
the downstream genes in the smb operon as a result less smbAB was produced.  Often lantibiotic 
production is under feedback inhibition and positively influenced by the immunity proteins [145,146].  
Therefore, it is also possible that SmbFT positively influences smb production.  Whether SmbFT has a 
positive role in Smb production remains to be tested.  
Our results suggest that SmbFT could confer protection not only against Smb but also against haloduracin 
and an uncharacterized lantibiotic produced by BAA 2069 (we named it as gallolacticin).  All the three 
lantibiotics share high degree of sequence similarity (Fig. 14) and probably structurally similar as well.  
All three lantibiotics are composed of two modified peptides, α and β.  While no information is available 
for Smb or gallolacticin, a detailed structure has been proposed for haloduracin that is based on mass-
spectrometry data and modeled on NRM structure of lacticin 3147 [147].  The structural information, 
together with the sequence similarity, suggests that all α-peptides have the same topology with three C-
terminal rings ([70], Fig 14).  The β-peptides appear to contain three or four rings, however the B ring is 
present only in haloduracin and absent in all others.  Since SmbFT recognized all the three lantibiotics we 
speculate that the transporter complex predominantly recognizes the conserved topology and structurally 
similar lantibiotics.  Based on this observation, we also speculate that SmbFT will confer protection 
against two-component lantibiotics that share this overall topology.   Interestingly, the β-peptides of two 
lantibiotics, lacticin 3147 and staphylococci C55 lack the first ring (A ring) but contain three other rings 
(B-D).   It would be of interest to test whether SmbFT could recognize lacticin 3147 and staphylococcin 
C55.   
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Figure 15: Multiple sequence alignment of SmbF (A) and SmbT (B) with their closest homologs.  The 
alignment was performed using Clustal-W.  Degree of shading was done using BoxShade where black 
and gray blocks indicate identical and similar amino acids, respectively. Sequences were obtained from 
GenBank (accession numbers are in parenthesis).  Strains are: S. ratti (SRAT-F, WP_003086779.1; 
SRAT-T: WP_003086777.1); S. gallolyticus (SGAL-F, YP_004287007.1; SGAL-T, YP_004287008.1); 
L. lactis (LLAC-F, YP_004761484.1; LLAC-T, YP_004761485.1); S. sobrinus (SSOB-F, 
WP_019770819.1;SSOB-T, WP_019776383.1); and S. salivarius (SSAL-F, YP_004728647.1 SSAL-T, 
YP_004728646.1) 
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SMUT-T    1 MSNKWATVLFVRPIIMKFSVFIFLMLSLLLGGGIIYSIENLKGPFQVYNIYSVFSTVSNF 
SRAT-T    1 MNNKWATVLFVRLTIVKFSVFIFLMLSLLLGGGIIYSIENLKGPFQVYNIYSVFSTVSNF 
SGAL-T    1 MKNR-KNILFLQQDICKLSTVILLLLSLISGFSIIYSRNYLSGSFRVDNIYAMYSTISNF 
LLAC-T    1 MISK-VEILFLKKDIFRVSLPIFWVLSLLSGFSIIYSREYLSGPFRVDNIYAMFSTISSF 
SSOB-T    1 MKTK-LRPIFLRQELFTKGSFVLLAITLLAGGAIIFSDVYADTHMGAQAIVAAYTTLADI 
SSAL-T    1 MKSK-LRTVFLKQECVTRSVFICLGLVALIGAIVILCDGYKGDYLGPSAIIASYSFIVDI 
 
 
SMUT-T   61 LLMYAAINAFGREFRYKTINHLRISGRSSIEIILRKLLAVEFLAILTSLVSFVEVAF-YK 
SRAT-T   61 LLMYAAINAFGREFRYKTINQLRISGRSSIEIILRKLLAVELLAILTSLVSFAEVAF-YK 
SGAL-T   60 LLIFMAVNLLGKEFKFKTINLIRISGRTAEEIVFRKLFVMVILSLLSALLVFLEVFIFEF 
LLAC-T   60 MLMYLAVSLFGKEFQYKTINMIRISNRSPLEIILRKLMVMIVVGLLTSLLAFFEVLA-EQ 
SSOB-T   60 YLIYFGVVSFGKEFQYRTINMIRSSRLSGSEVIIRKVLDGVVLSVALATFLLGELAL-YK 
SSAL-T   60 VFAYLVVSSLGREFQNRTINMIRVSSLSGREVILRKLLSFLVLSIVAATILVLELAF-YK 
 
 
SMUT-T  120 IYFNHPQIDLFEIFNHLVPAYLVYALFLFSLGSIITLVLKNSLYSFITLFLTLRLGVTIM 
SRAT-T  120 IYFNHPQIDLFEIFNHLVPAYLVYALFLFSLGSIITLVLKSSLYSFITLFLTLRLGVTIM 
SGAL-T  120 LIFKNSSMDVIRIGIDLLRSYLLYGVFLFLVGSILVLFFKNILYSFIALLLGLRLGVTVM 
LLAC-T  119 LYFGHTDVSLTSLLGKLTLSYFVYCLFLFSIGSIIVFFLKNTLFSFIFILLFLRIGVTFM 
SSOB-T  119 YVFHHPEVDFRHFAKFLYANFIIYGVFIYALANLVIFFVKNILGSFLSVYFGLPLLTFLI 
SSAL-T  119 YSVQHVDFPLWDYIRNIYIDFLLYGAFIYMVSSLLVLFVKNTLTAFVTAYFGVTGMTFFT 
 
 
SMUT-T  180 NVMNNF-ESTADLTKYIPLSFVENAFSFA--KYTPEQYVVTIVWSVALMALLPVIYRKWGYA 
SRAT-T  180 NVMNNF-ESTADLTKYIPLSFVENAFSFA--KYTPEQYVVTIVWSVALMALLPVIYRKWGYA 
SGAL-T  180 NIMGNF-EATAKLTPYIPLSFVENSFYFA--KYTVKQSIVLVIWSVLLLLILVVVYKKRGYK 
LLAC-T  179 NILSNF-PIMRPLVQYIPLSFAENSFSFA--SYTGKQTLVLVLWSLIFLSFTPRIYKKRGYE 
SSOB-T  179 AYFHDFDNVFGRAMKYVPFEYVHGKFDHG-LVYTSHEFWVLLVWTVGLVALLPLVYKKKGFV 
SSAL-T  179 LYLASLGDTMTKLMTYVPFSFMRAVFTSGQQFFSLREALVLFAWTLVLLLFAPTIYEKRAFV 
 
 
 
SMUT-F    1 MRILDIQNLNFKYGKDYVLKNINLTLEQGDILGLVGENGAGKSTLMKLISGIIPNYEGDI 
SRAT-F    1 MKILEIQNVNFKYGKDYVLKNINLTLEQGDILGLVGENGAGKSTLMKLISGIIPNYKGDI 
SGAL-F    1 MDNIIIKNLGFKYGSNLVLKDVNLTLKKGDIVGLVGKNGAGKSTFMKIISGILPGYDGNI 
LLAC-F    1 MNILTVSNLNFSYGKKRIINNGNISIESGDIVGLIGNNGSGKTTLMKLISGIIPGYSENI 
SSOB-F    1 MSVLEVNQLYFKYGKKTILEDVTFSLDKGDIVGLVGSNGAGKTTLMKIISGILPGATGKV 
SSAL-F    1 MTVLAVKGLTYSFGKQTVLDNISFTLEKGDIAGLIGNNGAGKTTLMKLVSGILAGPKDII 
 
 
SMUT-F   61 KIQAHNVGTLIEHPSLYADMTVLSNLKFYCRLFGKSYGVIDDYKYVLQVDSYLHKKVSKL 
SRAT-F   61 KIQAHNVGTLIEHPSLYADMTVLGNLKFYCRLFGKSYSVIDDYKYVLQVDSYLHKKVSKL 
SGAL-F   61 TIHANTVGVLIEEPSLYADLSVKKNLEFYCKLYNKSFSDIDKFKKILSTESFMNKKVSAL 
LLAC-F   61 IVNSKSIGVLIEEPSLYKDMTVLENLRFYCKLYRQEYDVISKYKKTLDVEAFLNKKVSKL 
SSOB-F   61 TLKASSVGALIEEPALYPHISVLRNLQFYCRLYGQDYDIIDKFKDDLDVAGYLNKKASKL 
SSAL-F   61 DLKTKTVGALIEAPALYPNMTVEANLKFYCKLYSKDYALIDRYKDELEVAAYLRRKASKL 
 
 
SMUT-F  121 SLGMKQRVGLFIALIASEEFILLDEPTNGLDPIGIKNLLDLIKKLSSEKGITFIISSHIL 
SRAT-F  121 SLGMKQRVGLFIALIASEEFILLDEPTNGLDPTGIKNLLDLIKKLSSEKGITFIISSHIL 
SGAL-F  121 SLGMKQRVGLFVALIASNEIILLDEPTNGLDPDGIQDLLNLIEELSKEFGITFIISSHIL 
LLAC-F  121 SLGMKQRIGLFVALIASNEFILLDEPTNGLDPTGIDSLLKLIKNLSLDFGITFIISSHIL 
SSOB-F  121 SLGMRQRVGLFIALIASNEFILLDEPTNGLDPKGINNLLNLIKDLAHKYGITFVVSSHIL 
SSAL-F  121 SLGMKQRVGLFIALIASDELILLDEPTNGLDPNGINSLLTLIKKLAKNHGLTFIISSHIL 
 
 
SMUT-F  181 QNLEQICNKAVLLRNHTISSLDAKKHMKYKIYHPDLSQSELICLLEDNGFDYEQNGRDII 
SRAT-F  181 QNLEQICNKAVLLRDHTISSLDAKEHMKYKIYHPDLSQSELICLLEDNGFDYEQNGRDII 
SGAL-F  181 SNLEQICNKYIILRDHTTKLIDSKK-GRYKIYAYDISQRELISLLKANEFDFEQQSQDVV 
LLAC-F  181 ENLDKVCNKNVLIRNEKLISLDSSEYMKFKIYSFEVSQSMIVECLEENKIPYEVNKRDII 
SSOB-F  181 ANLDQVCNKNFMIANQRLTSLDDGQHAKYSLYSFDTSPKDLLGLLDQYQLTYEHKGRDIL 
SSAL-F  181 SNLEQVCTKNYLLKNHKLIYLDDSNNVKYKIYTEDLSLKSLMSLLKLNGLSFERQKHDIL 
 
 
SMUT-F  241 VR--DIDAIEEMLQREKNITIQKEKISLSEVYFDEQ 
SRAT-F  241 VR--DIDAIEEMLQREKNITLEKEKISLSEVYFDEQ 
SGAL-F  240 IS--DIEEVEEFLE-NKKIKFKKEAVKISEVYFYEK 
LLAC-F  241 VSVSDIEKVESLFN-EKNISISKEKTSLSEVYFNDK 
SSOB-F  241 VT--DPAAIEAGLA-SQGIDLQFEKVGLSEVIFNED 
SSAL-F  241 VK--GLAAVKQVMD-REGIPFTYEKEGLSEVLFNEK 
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So far all the ABC transporters that belong to BcrAB family have been shown to act specifically against 
cyclic peptide bacitracin ([141,143]).  Although sequence similarity indicates that SmbFT belongs BcrAB 
family, we found that SmbFT did not recognize bacitracin, nor it recognized vacomycin and polymyxin 
B, two other cyclic peptide antibiotics. SmbFT also did not recognize nisin, a heavily modified single 
peptide lantibiotics.   A BLASP search using SmbF or SmbT peptides as query sequences against the 
GenBank database returned sequences mostly from streptococci.  The top hit sequences include S. ratti 
(strains BHT and FA-1), S. gallolyticus BAA 2069, S. sobrinus DSM20742, S. salivarius CCHSS3, and 
Lactococcus lactis (Fig 15).  Thus we propose that SmbFT and its homolog constitute an ABC transporter 
family distinct from BcrAB and specifically recognize two-component lantibiotics.   It is noteworthy to 
mention that although S. gallolyticus BAA 2069 produces gallolactacin and encodes a SmbFT homolog, 
which we named GalFT, the strain was sensitive to Smb (data not shown). Therefore, we speculate that 
while SmbFT confer protection against gallolacticin, GalFT from BAA 2069 cannot confer protection 
against Smb.  Sequence alignment between SmbF and SmbT with the corresponding GalF and GalT 
sequences identified presence of several unique amino acid residues in both GalF and GalT.  A hybrid 
approach is currently underway where we are combining SmbF with GalT and vice versa to identify the 
subunit necessary for substrate recognition and/or discrimination.  
 Although mechanisms related to protection against lantibiotics have been extensively studied, the 
molecular mechanism of lantibiotic transport is still poorly understood.  Several recent studies suggest 
that unlike general ABC transporters that transport substrates across the membranes, the ABC transporters 
related to immunity function transport specific lantibiotics from the membrane to the extracellular space 
[120,121,137].  A recent study identifies the presence of a conserved motif, termed as E-loop, in the ABC 
transporters belonging to LanFEG and BcrAB families [134].   This E-loop structure plays an important 
role in the function of these transporters and perhaps induces structural changes in the transmembrane 
domains.  Whether E-loop is involved in substrate recognition and/or binding remains to be evaluated.  
Additional structure/function studies are necessary to understand the molecular mechanism of lantibiotic 
transport by the immunity related ABC transporter systems.  
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Chapter 4:  A conserved streptococcal membrane protein, LsrS, exhibits a receptor-like function 
for lantibiotics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
97 
 
4.1. Abstract 
Streptococcus mutans strain GS-5 produces a two-component lantibiotic, Smb, which displays a broad-
spectrum inhibitory activity that includes other streptococci.  Lantibiotics must recognize specific 
receptor molecules present on the sensitive bacterial cells for inhibition.  However, so far no such receptor 
proteins have been identified for any lantibiotic.  In this study, using a powerful transposon mutagenesis 
approach, we have identified a gene in Streptococcus pyogenes that exhibits a receptor-like function for 
Smb.  The gene-encoded protein, which we named LsrS, is a membrane protein belonging to CAAX 
protease family.  We also found that nisin, a mono-peptide lantibiotic, requires LsrS for its optimum 
inhibitory activity.  However, we found that LsrS is not required for inhibition by haloduracin and 
galolacticin, both these are two-peptide lantibiotics closely related to Smb.  LsrS appears to be a well-
conserved protein that is present in many streptococci including S. mutans.   Inactivation of SMU.662, an 
LsrS homolog, in S. mutans strains UA159 and V403 rendered the cells refractory to Smb-mediated 
killing.   Furthermore, overexpression of LsrS in S. mutans causes the cells to be more susceptible to 
Smb.  Although LsrS and its homologs encode CAAX protease domain, we demonstrate that inactivation 
of the putative active sites on the LsrS protein has no effect on its receptor-like function.  This is the first 
report describing a highly conserved membrane protein that displays a receptor-like function for 
lantibiotics.    
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4.2.  Introduction 
Lantibiotics are a group of ribosomally synthesized small peptides containing bactericidal or 
bacteriostatic activity.  These peptides are post-translationally modified involving multiple residues 
[70,107,115,148].   In general, lantibiotic synthesis operon encodes various enzymes that dehydrate most 
of the serine and threonine residues to dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively.  
When cysteine residues are present in the vicinity, Dha and Dhb can form thioetherlinked lanthionine and 
3-methyl lanthinoine bridges, respectively.  Occasionally, Dha, Dhb and other modified residues can be 
present as unlinked residues [for reviews see [70,71,108-110]].   On the basis of the biochemical activities 
of the modifying enzymes lantibiotics are grouped into three classes [70].  Lantibiotics that belong to 
class I include nisin, streptin, and Pep5, and are modified by two enzymes, LanB and LanC [71,149].  
Class II lantibiotics are generally globular peptides with the prototype lantibiotics mersacidin and 
cinnamycin that modified by a single enzyme often referred to as LanM-type enzyme.  Class II 
lantibiotics also include two-component lantibiotics (such as lacticin 3147, plantaracin W, and 
haloduracin) and the antimicrobial activity requires synergistic interaction of both peptides [111,112,150].   
Class III lantibiotics, such as SapT and SapB, constitute an emerging group of lantibiotics that has mainly 
morphogenetic functions and displays very limited antibacterial activities [2,71,113,114].  
Based upon their mode of action, lantibiotics can also be classified into several categories.  Lantibiotics 
such as Pep5 directly targets the bacterial membrane to form pores that leads to release of ions and 
molecules from the sensitive bacteria, eventually leading to cell death [151].   Other lantibiotics such as 
mersacidin and nukacin ISK-1 bind to lipid II and thereby inhibit peptidoglycan biosynthesis in the target 
bacteria, a mechanism similar to that of vancomycin that also binds to lipid II [107,152].  Lantibiotics 
belonging to the next category function by a complex double mode-of-action mechanism where they 
inhibit cell wall biosynthesis by binding to lipid II molecules as well as create pore formation in bacterial 
membranes.  Often both functions can be combined into a single polypeptide as in nisin and 
epidermin [153,154].  However, a combination of two functionally specialized peptides, known as two-
peptide lantibiotics, is required for the activity. Two-peptide lantibiotics contain a globular α-peptide with 
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homology to mersacidin that binds to lipid II and an elongated β-peptide that forms a complex with the α-
peptide bound lipid II complex. Subsequently the β-peptide forms a pore by inserting inside the bacterial 
membrane [155,156] 
The lactic acid bacteria such as enterococci, lactococci, and streptococci secrete a wide range of 
lantibiotics with variable spectra of inhibition [72,109,115-117,157].  Among the lantibiotics, nisin, 
which is secreted by lactococci, is one of the most well-studied and widely used lantibiotics [72,116].  
Nisin has a broad range of inhibitory spectrum and can inhibit several gram-positive bacteria including 
Staphylococcus aureus, Listeria monocytogenes, and as well as a variety of streptococci and enterococci 
[158,159].  Furthermore, nisin can inhibit Bacillus spore outgrowth and germination [160].  Among the 
two-peptide lantibiotics, lacticin 3147, which is also secreted by some strains of lactococci, inhibits many 
gram-positive bacteria including L. monocytogenes, S. aureus and Clostridium difficile in addition to 
streptococci, enterococci and mycobacteria [161,162].  
Streptococcus mutans, an oral lactic acid bacteria and a major causative agent of dental caries in humans, 
secretes several types of lantibiotics, commonly known as mutacins [64,122-128].  Most of these 
lantibiotics such as mutacin I, II, and III (1140) are monopeptide and presumably function like nisin or 
mersacidin.  The only two-peptide lantibiotic so far identified in S. mutans is Smb produced by GS-5 and 
some other strains [126,131].  Although the lantibiotic mutacins are widely present in S. mutans [86,128], 
surprisingly the first sequenced reference strain UA159 does not encode any lantibiotic, it only encodes 
non-lantibiotics [44].  It appears that S. mutans has acquired many mutacins encoding genes by horizontal 
gene transfer mechanism.  For example, the strains that produce mutacin II contains the mut operon that is 
inserted after the alanyl t-RNA synthetase (ats, SMU.650) in the corresponding UA159 genome [128].  
Likewise, the smb locus that encodes genes necessary for Smb biosynthesis appears to be integrated in 
between SMU.1942 and syl locus.  
The frequency of the presence of smb locus among various S. mutans clinical isolates has not been 
systematically studied.  However, we recently showed that as many as 50% S. mutans isolates in our 
laboratory collection encode the smb locus [163].  Although very little is known about the structure or the 
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mode-of-action of Smb, primary sequence analysis suggests that Smb is similar to lacticin 3147 and 
haloduracin [163].  Smb also has a broad inhibitory spectrum.  It can inhibit growth of streptococci 
belonging to all six phylogentic groups as well as lactococci and enterococci [91,163]. However, it 
appears that Smb may not inhibit Staphylococcus epidermidis and Bacillus subtilis [91,163].   
 
One of the streptococci that Smb very efficiently inhibits is the human pathogen S. pyogenes, also known 
as group A streptococcus (GAS).  GAS causes a wide variety of diseases, including relatively mild and 
self-limiting infections of the throat and skin as well as life-threatening invasive diseases like septicemia, 
myositis, necrotizing fasciitis, and streptococcal toxic shock syndrome (for recent reviews, see reference 
[164,165].  Earlier observations suggest that S. pyogens and other sensitive bacteria express cell surface 
molecules that can act as receptors [166,167].  Theses molecules are different from the surface polymers 
such as group and type antigens [89].  The study by Perry and Slade [167] suggests that a partially 
purified fraction of sonicated extracts of S. pyogenes can inhibit the lantibiotic activity produced by GS-5 
strain presumably because a receptor-like molecule sequesters one or both the peptides.  In this study, we 
attempted to identify a receptor molecule in S. pyogenes for Smb by using a transposon mutagenesis 
approach. We identified a previously uncharacterized membrane protein that exhibits a receptor-like 
function for Smb. 
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4.3. Results 
 
 
4.3.1 Identification of a receptor gene in S. pyogenes   
A previous study indicated that S. pyogenes might encode some cell surface proteins that function as 
receptor for the lantibiotic Smb [167]. We wanted to identify the genes that encode those putative 
receptor molecules. Towards this end, we used the insertion sequence ISS1 because it randomly inserts 
into the genome of gram-positive bacteria, including various streptococci and because it rarely inserts 
itself more than once into the same cell [96,168-171].  We introduced this transposon into JRS4, an M6 
serotype strain, on pGhost9::ISS1, a plasmid whose replication is temperature sensitive [172]. An 
erythromycin-resistant (Emr) transformant containing pGhost9::ISS1 was grown overnight at 30°C, and 
Emr colonies containing the transposon were isolated at 37°C.  We reasoned that inactivation of a receptor 
molecule on GAS would produce a strain that would be recalcitrant to Smb-mediated inhibition.  We 
plated a transposon library on THY agar plates that were previously stabbed with S. mutans GS-5 strain 
that produces lantibiotic Smb.   While most of the stabbed GS-5 produced clear zones of inhibition (ZOI) 
with diameters of 24±1 mm, three stabbed cultures produced ZOI each with a single colony that grew 
inside the halo.  Using an inverse PCR method, as described in Material and Methods, we attempted to 
identify the ISS1 insertion sites in these survivor mutants that grew inside the halo.  Two of the insertion 
sites were located within the SPy1384 genes (M1 GAS SF370 is the reference strain) while the insertion 
site could not be determined for the third mutant.   
 
SPy1384 encodes a polypeptide of 231 residues; the ISS1 insertions occurred in this gene at codon 
positions 8 and 148 (Fig 16).  We renamed this gene as lsrS for lantibiotic Smb receptor like function in 
streptococci.  It appears that lsrS is the last gene of a three-gene operon.  SPy1386, which encodes a 
putative transcriptional regulator protein (71aa) with a Helix-Turn-Helix XRE-family like motif and 
SPy1385, which encodes a hypothetical protein with DUF3169 domain, are the two other genes in the 
operon.  Just upstream of the operon is alaS gene that encodes alanyl-tRNA synthetase.  An intergenic 
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region of 259-bp lies between alaS and SPy1386 loci.  Analysis by BPROM (Softberry) software indicate 
the presence of a -35 box (TTGTCA) and a -10 box (TACAAT) within at a position 250-bp upstream of 
the ATG start codon of SPy1386 (Fig 16).  
To confirm that lsrS indeed plays a role in Smb mediated inhibition, we selected the mutant strain 
(IBSA68) in which ISS1 was inserted at the 148th codon.  We generated a clean mutant derivative strain 
(IBSA70) by curing the integrated pGhost9:ISS1 plasmid from strain IBSA68 to create IBSA70.  We also 
cloned the lsrS gene in plasmid pIB184-Km under a heterologous promoter (P23) for complementation 
purposes.  Both the vector plasmid (pIB184-Km) and the complementing plasmid (pIBA35) were 
introduced into IBSA70.  The vector plasmid was also introduced into JRS4 for uniformity.  These strains 
were then tested against GS-5 for sensitivity.  As shown in Fig 16, IBSA70 carrying only the vector 
plasmid produced a ZOI with a diameter of 18±1 mm where as JRS4 with the vector plasmid produced a 
ZOI with a diameter of 24±1 mm, about 40% reduction in the total area of inhibition in the mutant 
strain(Fig 16).  When we complemented IBSA70 with the plasmid pIBA35 carrying the lsrS, the ZOI 
became 25±1 mm in diameter suggesting that the observed reduction in ZOI is indeed due to inactivation 
of lsrS. 
 
4.3.2. LsrS plays a role in nisin and tunicamycin sensitivity 
Smb is a two-component lantibiotic and like other lantibiotics, it is expected to interact with the lipid II 
molecules.  Because LsrS is involved in the optimum function of Smb to inhibit S. pyogenes, we wanted 
to test whether LsrS is also involved in inhibition by other two-component lantibiotics.  For this purpose, 
we selected haloduracin, a well-characterized lantibiotic that targets lipid II, and galolacticin that is 
produced by S. gallolyticus BAA2069 with sequence similarity to Smb [163].  As shown in Fig. 17, 
sensitivities of both JRS4 and IBSA70 strains were similar against the purified haloduracin and 
galolacticin.  This result suggests that LsrS is specific to Smb and does not recognize other two-
component lantibiotics.   
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Figure 16:  Isolation of a receptor protein for lantibiotic Smb in S. pyogenes. (A) Genetic organization of 
the receptor locus (SPy1384). SPy1384 is the last gene of a three-gene operon. The first gene, SPy1386 
encodes a putative transcription factor of HTH_XRE superfamily.  The second gene, SPy1385, encodes a 
hypothetical membrane protein with DUF3169 motif.   The site of ISS1 insertions and their relative 
positions are shown.  The bent arrow indicates the putative promoter sequence.  (B). Deferred antagonism 
assay for receptor activity.  Bacterial cultures were stabbed on THY-agar plate and incubated overnight at 
37⁰C under microaerophilic condition.  The plates were then overlaid with soft agar containing indicator 
strains.  The zones of inhibition (ZOI) of the indicator strains were measured after overnight incubation.  
The observation is based on four separate experiments and a representative area of interest is shown.  The 
ZOI values for Smb mediated inhibition are:  JRS4/pIB184, 24±1; IBSA70/pIB184, 18±1; and 
IBSA70/pIBA35, 25±1.  The length of the scale bar equals to 5mm. 
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Nisin is a one-component lantibiotic that functions similar to two-component lantibiotics, i.e. it binds to 
lipid II and inhibits cell-wall biosynthesis as well as form pores in the membrane.  Therefore, we tested 
whether LsrS could display a receptor like function for nisin.  We observed that IBAS70 produced a ZOI 
with 14±1 mm diameter while the wild type JRS4 produced a ZOI with 18±1 mm diameter, about a net 
reduction of 40% in total area.  This indicates that in addition to Smb, LsrS plays an important role, either 
directly or indirectly, for nisin recognition. 
 
Since Smb and nisin both bind to lipid II, and since LsrS is a putative membrane protein, we wanted to 
know whether inactivation of LsrS renders the cell sensitive to antibiotics that target cell-wall 
biosynthesis.  We tested antibiotics specific for lipid II synthesis such as fosfomycin (inhibits MurA), D- 
cycloserine (inhibits D-ala ligase), tunicamycin (inhibits MraY), bacitracyin (blocks lipid carrier 
recycling), vancomycin (blocks transglycosylation), and penicillin (blocks transpeptidation).  We also 
included polymyxin B and colistin, which target cell membranes.   We found that among these antibiotics, 
only tunicamycin produced a 40% smaller halo in IBSA70 as compared with JRS4 (Fig 17).  All other 
antibiotics produced similar halo in both the strains (Table7, data not shown).  This indicates that LsrS 
plays a role in tunicamycin sensitivity in S. mutans.  
 
4.3.3. LsrS homologs are present in other streptococci and function as Smb receptor 
Bioinformatics analysis suggests that LsrS belongs to COG1266, a highly conserved family predicted to 
encode a zinc dependent CAAX prenyl metalloprotease domain.   Furthermore, the C-terminal region of 
LsrS contains a domain called Abi (abortive infection, Pfam02517), which is a subfamily of CAAX 
protease.  A BLAST-P search showed that LsrS is present in all the sequenced S. pyogenes genomes.  
Furthermore, the search also fetched numerous streptococci including many oral streptococci with E-
values lower than -50.  Surprisingly, it appears that all the sequenced S. mutans strains also encode an 
LsrS homolog protein with an E-value of -61.  The homolog in S. mutans UA159 is SMU.662, which 
showed 41% identity and 66% similarity with the LsrS sequence (Fig 18).  
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Figure 17: Sensitivity of the lsrS mutant to various antimicrobial agents. THY agar plates containing the 
indicator strains were either pre-seeded with galolacticin producing strain (BAA2069), or spotted directly 
on the overlaid plates and incubated overnight at 37⁰C under microaerophilic condition.  Experiments 
were repeated at least three times and representative areas of interest are shown.  Both the strains also 
contain vector pIB184-Km. Bars, 5mm. 
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Table 7:  Effect of various bacteriocins and antibiotics on lsrS mutant  
 
                               Indicator Strains 
Compounds/Strains                                               ________________________________________ 
             JRS4/pIB184  IBSA70/pIB184 
Lantibiotics: 
  Smb*     24.0 ± 1.0    18.0 ± 1.0 
  Haloduracin    15.0 ± 1.0   15.0 ± 1.0 
  Gal     15.0 ± 1.0   16.0 ± 1.0 
  Nisin*     18.0 ± 1.0   14.0 ± 1.0 
 
Cell-wall antibiotics:   
  Amidinocillin (AMD10)  18.0 ± 1.0   20.0 ± 1.0 
  Bacitracin (B10)   27.0 ± 2.0   27.0 ± 2.0 
  Colistin (CL10)   9.0 ± 1.0   9.0 ± 1.0 
Cycloserine (100mg/ml)  35.0 ± 2.0   37.0 ± 2.0 
  Fosfomycin (F300)   24.0 ± 2.0   24.0 ± 2.0 
Penicillin (P2)    29.0 ± 1.0   30.0 ± 1.0 
  Polymyxin B (PB300)  12.0 ± 1.0   13.0 ± 1.0 
  Tunicamycin (5mg/ml)*  19.0 ± 1.0   13.0 ± 1.0 
  Vancomycin (V5)   17.0 ± 1.0   17.0 ± 1.0 
 
Strains producing bacteriocins: 
UA159    18.0 ± 1.0   17.0 ± 1.0 
UA159::ΔnlmAB   15.0 ± 1.0   15.0 ± 1.0 
UA159::ΔnlmC   16.0 ± 1.0   16.0 ± 1.0 
UA159::ΔnlmABC   14.0 ± 1.0   13.0 ± 1.0 
______________________________________________________________________________ 
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To study whether SMU.662 could function as a receptor protein, we selected two S. mutans strains 
(UA159 and V403) that are sensitive to Smb [163].  The entire SMU.662 coding region was replaced in 
these strains with an erythromycin resistant gene by fusion PCR and tested these strains against Smb 
mediated inhibition.   As shown in Fig 18B, inactivation of SMU.662 nearly abolished the sensitivity 
towards Smb lantibiotic in both the strains.  This finding suggests that SMU.662 indeed encodes a 
receptor like protein for Smb.  
We also tested whether SMU.662 can be effective against haloduracin, galolacticin, and nisin.   However, 
we found no difference between the wild type and the SMU.662 inactivated strains (data not shown).  
Thus, at least in S, mutans, SMU.662 is very specific and only recognizes Smb.  Furthermore, we also 
observed that SMU.662 deleted strains were as susceptible to tunicamycin as their isogenic wild type 
strains. Therefore, it seems that although SMU.662 recognizes Smb for lantibiotic activity, the LsrS 
protein in S. pyogenes might have additional functions that are absent in SMU.662.   
 
4.3.4. Overexpression of LsrS in a heterologous host increases sensitivity 
It appears that Smb produced a smaller ZOI in S. mutans than in S. pyogenes strains.  We speculated that 
SMU.662 might not function as efficiently as LsrS, therefore we decided to overexpress LsrS in UA159.  
When we used UA159 containing pIBA35, we observed that the ZOI was increased about 2.5 times as 
compared to UA159 containing the vector plasmid (Fig. 19).  To rule out the possibility that observed 
effect is not a strain specific phenomenon, we also used V403 strain and observed the increased ZOI 
when LsrS was overexpressed.   Taken together, these results suggest that LsrS can efficiently function in 
heterologous host and overexpression can lead to increased sensitivity. 
Since LsrS deficient S. pyogenes strains showed decreased sensitivity towards nisin and tunicamycin, we 
wanted to test whether overexpression of LsrS in S. mutans makes the strain more sensitive to these 
compounds.  We found that LsrS, when expressed in S. mutans, does not affect the sensitivity toward 
these reagents.  This result indicates that in S. pyogenes, additional proteins, which are absent in S. 
mutans, are necessary for the observed LsrS functions.  
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4.3.5. Protease activity of LsrS is not required for the receptor-like function 
In eukaryotes, Abi-domain containing proteins are known to be involved in protein prenylation [173].  
These membrane proteases belong to a zinc metalloprotease family and cleave within CAAX of the 
substrate (A denotes an aliphatic residue where as X denotes one of several allowed residues that dictates 
the specificity of prenyltransferases).  Abi-domain itself encodes four transmembrane helices (TH) with 
the conserved active site residues.   The catalytic glutamic acids in motif 1 and histidines in motif 2 and 4 
are predicted to coordinate zinc ions (Fig 18A).   We used TMpred and TopPred2 to determine the 
membrane topology of the LsrS and as shown in Fig 5A, LsrS appears to contain six THs.  We verified 
the orientation of TH3 and TH4 with the help of LacZ translational fusions at positions M74 and V148 
(Fig 20).   E. coli XL-1 strain containing these translational fusions generated blue color colonies on agar 
plate containing X-gal, suggesting that the predicted TH orientations correlate with the experimentally 
verified ones.   
We then tested whether the protease-like mechanism of LsrS is necessary for the receptor function.  For 
this, we made alanine substitutions at the conserved glutamic acids at positions 145 and 146, and histidine 
residue at position 178 described as critical for the metalloprotease activity with alanine residues 
(EE145/146AA, pIBA44; and H178A, pIBA45).  As shown in Fig 20B, both the mutations in the 
conserved active site residues of LsrS have no effect on the receptor activity in S. pyogenes or in S. 
mutans.  Thus, the putative protease activity of LsrS is not necessary to exhibit the receptor-like 
functions.  
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Figure 18: Deletion of lsrS homolog in S. mutans makes the strains resistant to Smb-mediated inhibition.  
(A). Multiple sequence alignment of LsrS and its homolog from various streptococci.  Sequences were 
aligned with Clustal-W and the degree of relatedness was displayed with BoxShade where black and gray 
indicate identical or similar residues, respectively.  Sequences were obtained from GenBank (accession 
numbers are in parenthesis).  The strains are: S. pyogenes (GAS, NP_269484), S. mutans (SMU, 
NP_721090), S. gordonii (SGO, YP_001449790), S. sanguinis (SSA, YP_001034746), and S. gallolytics 
(SGG, YP_004287423).  The four conserved putative metalloprotease motifs along with the active side 
residues (asterisks) are also indicated.  (B). Deferred antagonism assay using two S. mutans isolates and 
their mutant derivatives.  Assays were carried out with GS-5 and ΔsmbAB as tester strains as described in 
figure 1 and repeated at least four times.  The length of the scale bar equals to 5mm. 
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4.4. Discussion 
One of the noteworthy features of bacteriocins, specifically lantibiotics, is that the peptides are highly 
potent and active in the nanomolar range.   On the other hand antimicrobial peptides produced by human 
and animal (such as defensins and LL-37) are active in the micromolar range, a difference of 1,000-fold 
in the concentration [155,174].  It is assumed that the primary reason for this extreme potency is due to 
the fact that bacteriocins recognize specific receptors on the target cells while antimicrobial peptides of 
eukaryotic origin interacts non-specifically with their targets.   This assumption was first validated by the 
identification of mannose-phosphotransferase system (Man-PTS) as a receptor for some non-lantibiotics 
(class II) belonging to pediocin-like bacteriocins of sub-class IIa [79], and also for some non-pediocin-
like linear bacteriocins of subclass IId such as lactococcin A and B [175].   Subsequently, another sugar 
transporter, a maltose-ABC transporter, was also found to be required in target cells for sensitivity to 
garvicin ML, a circular bacteriocin belonging to subclass IIc [176].    Furthermore very recently, Uzelac 
et. al. [177] have recently identified a membrane bound Zn-dependent metaloprotease in L. lactis that 
seems to act as a receptor for yet another non-lantibiotics, LsbB, produced by some strains of L. lactis.   
So far no receptor molecules have been identified for lantibiotic peptides including nisin, one of the most 
extensively studied lantibiotics.   In the present study we report the discovery of a new protein, LsrS, 
employed by Smb to target sensitive strains.  
 
The locus that encodes lsrS is organized in a three-gene operon and is present in all the sequenced S. 
pyogenes strains.  A BLAST-P search with LsrS as query against the S. pyogenes genomes did not return 
any other proteins suggesting that LsrS does not have any paralogs.   The inactivation of lsrS generated 
about 40% reductions in ZOI, but did not completely abolish the sensitivity to Smb.  This indicates that in 
S. pyogenes, LsrS may not be the only protein with receptor like function.  Since no other LsrS paralogs 
are present in S. pyogenes, we speculate that Smb utilizes other molecules unrelated to LsrS as receptors 
to inhibit this organism.  To this line, it is noteworthy to mention that Perry and Slade [167] first isolated 
an inhibitory factor with a molecular weight of 93-kd from S. pyogenes strain E14 (a sensitive strain) that 
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neutralizes bacteriocins produced by GS-5.   Soon after, Franker [166] isolated another factor, which is 
74-kd, from S. pyogenes strain MJP-2 (also sensitive to GS-5) that also demonstrates inhibitory activity 
against GS-5.  The exact identities for both the factors are not known and we speculate that these factors 
might act as additional receptors for Smb.   
 
We observed that LsrS has a receptor like activity for Smb and not for other closely related two-peptide 
lantibiotics, such as haloduracin and galolacticin (Fig 17).  This was surprising to us since the immunity 
protein, SmbFT, can recognize all the three lantibiotics.  While haloduracin and galolacticin are 
structurally similar to Smb, several differences in the sequence also exist.  We speculate that some critical 
residues that are present in either one or both the components of Smb might be important for peptide-
receptor interactions, and those critical residues are absent in haloduracin and galolacticin.   Since these 
two lantibiotics inhibit S. pyogenes very efficiently, they might utilize other cell-surface molecules as 
receptors.    
 
In contrast, we found that LsrS facilitates nisin activity.  This was also surprising since nisin, which is a 
mono-peptide lantibiotic, has very little sequence or structural similarity with Smb.    Furthermore, the 
mechanism of inhibition by nisin and two-peptide lantibiotics is different.  In the case of two-peptide 
lantibiotics, the α-peptide component interacts with the lipid II that most likely involves the mersacidin-
like binding motif and form a complex. The β-peptide then binds to the α-peptide/lipid II complex and 
adopt a transmembrane conformation to form a defined pore.   Although LsrS displays a receptor like 
activity for both nisin and Smb, the molecular mechanism might be very different.  It is possible that an 
accessory protein acts as the primary receptor for nisin and the function of LsrS is to enhance or stabilize 
the interaction.  We speculate this because, when we overexpressed LsrS in S. mutans, it did not enhance 
the nisin-mediated inhibition, only the Smb-mediated inhibition was enhanced (Fig 19, data not shown).  
Since in S. pyogenes, the LsrS encoding gene is genetically linked to SPy1385, it is possible that SPy1385 
might be involved in nisin recognition.  SPy1385 is a hypothetical protein that is present in all the 
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sequenced S. pyogenes strains that encodes LsrS.  In fact the entire operon is very highly conserved in S. 
pygenes and other pyogenic streptococci. When we performed a BLAST-P search, we did not find any 
Spy1385 homolog in S. mutans, strengthening our hypothesis.   Furthermore, SPy1385 contains six 
transmembrane helices (data not shown) and thus it is also appears to be a membrane protein.   We also 
found that pyogenic group of streptococci are more sensitive to nisin as compared to mutans group (data 
not shown).  Thus, we believe that for pyogenic group of streptococci, both LsrS and SPy1385 play an 
important role for nisin-mediated inhibition.   
 
In addition to forming pores in the membrane, both nisin and Smb interfere with the cell-wall 
biosynthesis.  Therefore we tested the susceptibility of LsrS-deficient strains to various antibiotics that 
target enzymatic steps leading lipid II biosynthesis and post lipid II pathways leading to cell-wall 
formation.   To our surprise, except for tunicamycin, we did not find any significant differences in the 
sensitivity to any other antibiotics including vancomycin that also binds to lipid II (Table 7).  Thus, we 
speculate that LsrS has no negative effect in overall cell-wall synthesis.   However, we found that LsrS-
deficient S. pyogenes strains were significantly resistant to tunicamycin action.  The chemical 
composition of tunicamycin is complex and it contains uracil, N-acetyl glycosamine, an 11-carbon 
aminodialdose called tunicamine, and a fatty acid linked to the amino group.  Tunicamycin inhibits the 
enzymatic activity of MraY, the phospho-MurNAc-pentapeptide translocase that catalyzes the synthesis 
of lipid I in the conserved pathway for peptidoglycan biosynthesis.  Since MraY is also a transmembrane 
protein, it is possible that LsrS, either alone or in combination with other proteins, interferes with the 
MraY activity in S. pyogenes.  Hence, in the absence of LsrS, the enzymatic activity of MraY is 
enhanced.  Alternatively, LsrS itself acts as a receptor for tunicamycin.  We believe that this latter 
possibility is unlikely because when we overexpressed LsrS in S. mutans, we did not observe any change 
in tunicamycin sensitivity (data not shown). 
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Figure 19:  Overexpression of LsrS in S. mutans causes increased sensitivity.  Deferred antagonism 
assays were carried out with GS-5 and ΔsmbAB as tester strains and were performed as described in 
figure 16.  These plates are representative of three independent assays.  The length of the scale bar equals 
to 5mm. 
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Figure 20:  Putative protease activity is not required for LsrS activity.  (A) Proposed transmembrane 
topology of LsrS.  The hydrophobicity plots predicted from TopPred 2, TM-Pred and TMHMM, are 
similar. The predicted six putative transmembrane α-helices are indicated.  The positions (residues) for 
LacZ fusions are shown. The residues with dark background are putative active sites for the CAAX 
protease activity.  (B-C). Site-directed mutations in the conserved active site motifs do not affect LsrS 
receptor function in S. pyogenes (B) and S. mutans (C).  Deferred antagonism assays were repeated at 
least three times, and representative plate areas are shown.  
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In S. pyogenes, the lsrS is encoded by a three-gene operon (Fig. 16).  Our bioinformatics searches found 
that the entire operon is present in all the sequenced strains of S. pyogenes.   We also found that this 
operon is present in some of isolates of S. anginosus, S. constellatus, S. dysgalactiae, S. pneumoniae, and 
S. suis.  Since these streptococci are pathogenic, we speculate that in addition to receptor like function for 
Smb, the genes encoded within this operon might play a role in virulence.  Additional experiments are 
required to determine the true role of the genes encoded by this operon.  
 
While the operon that encodes LsrS is present in a handful of streptococci, a BLAST-P search with LsrS 
as query yielded several additional streptococci with an E value of -35 or less.   The streptococci that we 
found are S. gallolyticus, S. intermedius, S. mutans, and S. sangunis.  Apart from streptococci, the only 
other organism that we found is Carnobacterium sp 17-4, a lactic acid bacterium often associated with 
seafood and dairy products.   However, LsrS showed the highest degree of homology (E-60) to SMU.662 
and its counterpart encoded by various S. mutans strains.  This was surprising to us since Smb is also 
secreted by S. mutans.   We showed that SMU.662 alone could function as a receptor for Smb and 
deletion of SMU.662 makes the strains insensitive to Smb.  Two recent large-scale genome-sequencing 
studies indicate that SMU.662 is a part of the core genome [65,178].  Furthermore, the upstream region 
[SMU.651-SMU.658] and the downstream region [SMU.681-SMU.687] appear to be genomic islands 
and are present in some but not all S. mutans strains [179].  Whether SMU.662 is only a receptor for 
lantibiotics or it plays a role in other biological processes remains to be evaluated. 
 
LsrS is a member of a highly conversed protein family with a putative CAAX prenyl protease domain.  
This family, which is recently renamed as CPBP (CAAX protease and bacteriocin-processing enzymes), 
encompasses more than 5000 proteins [180].   Members of the CPBP family are involved in diverse 
biological functions.  For example, Kjos et. al. have shown that SkkI functions as a bacteriocin immunity 
protein for sakacin secreted by Lactobacillus plantarum [82].  These authors have also shown that 
protease activity is necessary for the immunity function.  In S. pneumonia, PcnO is both necessary for the 
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production of bacteriocin Pnc as well as involved in the immunity against Pnc [181].  The exact 
mechanism by which PncO regulates bacteriocin production or mediates immunity is currently unknown.  
CPBP proteins are also shown to be involved in expression of surface proteins containing YSIRK signal 
peptide as in the case of Staphylococcus aureus Spd proteins [182].  Recently, Frion and colleagues have 
shown that in S. agalactiae, a CPBP protein, Abx, forms a signaling complex with the histidine kinase 
CovS and regulates expression of virulence factors [183].  The number of CPBP family proteins varies 
greatly depending on the organism.  For example, while S. pyogenes encodes only two or three CPBP 
family proteins (depending on the isolates), some streptococci, such as S. sanguinis, contain as many as 
21 CAAX-family proteins and the roles of most of these proteins remain largely unknown.  In this study 
we added another role for a CPBP family protein to the growing list of functions. 
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Chapter 5: Regulation of smb: auto-regulation and identification of a new regulator SMU.1704 
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5.1. Abstract 
  
 
A post translationally modified two-peptide lantibiotic, Smb, is produced by Streptococcus mutans strain 
GS-5.  The structural genes, smbA and smbB, are part of a seven-gene cluster: smbM1-F-T-M2-G-A-B. 
Unlike other lantibiotic biosynthesis operons, the smb locus does not encode any regulator that might act 
as autoregulator. In the present study we showed that the promoter of this locus is auto-regulated by the 
mature Smb peptides. We observed that the transcription levels of the smbM1 (encoding a modification 
enzyme), smbF (encoding an immunity protein), and smbG (encoding transporter) are all reduced more 
than two-fold in a smbAB deleted strain.  As expected, the smbAB mutant strain was more sensitive to 
Smb compared to the wild type strain.  This increased sensitivity to Smb was also apparent in a smbG 
mutant strain, presumably because the strain is unable to secrete the mature Smb and thus unable to 
autoinduce the operon. To identify other potential regulators for this operon, we performed a transposon 
mutagenesis assay using a reporter fusion with the promoter of the operon.  We found several insertions 
on various components of the Com pathway, which is known to regulate smb.  We also obtained 
insertions in five hypothetical protein encoding genes.  Two of them, SMU.1704 and SMU.1706 appear 
to be organized in an operon.  The first gene, SMU.1704 encodes a PadR family regulator, while 
SMU.1705 and SMU.1706 both encode putative membrane proteins.  Deletion of SMU.1704 generates a 
strain that produces a lower amount of Smb compared to GS-5.  We also found that the SMU.1704 
deleted strain is more susceptible to Smb. Taken together our results provide preliminary evidences for a 
novel example of bacterial signalling mediated by a two-peptide lantibiotic Smb.  Our results also show 
that a new regulator and perhaps a new regulatory pathway may control smb expression. 
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5.2. Introduction 
 Lantibiotics are small, ribosomally synthesized peptides with antimicrobial properties.  These peptides 
are postranslationally modified and contain polycyclic thioether amino acids lanthionine or methyl 
lanthoinine as well as unsaturated amino acids dehydroalanine and 2-aminoisobutyric acid.  Gram-
positive organisms including lactic acid bacteria such as streptococci, lactococci, and enterococci 
predominantly secrete lantibiotics.  Lantibiotics produced by Gram-positive bacteria are relatively broad 
spectrum and are relatively resistant to heat and protease degradation.  These properties of lantibiotics 
have generated significant attention in the pharmaceutical industry to explore the possibility to use as an 
alternative to antibiotics to treat infections.  To increase the yield of this natural bacteriocin one needs to 
increase the production by manipulating the regulation of the biosynthetic genes.   
 
Regulation of lantibiotic has been well studied for nisin operon.  Nisin has been widely used in the food 
industry over 50 years and it is perhaps the most extensively studied lantibiotics.  Nisin, a mono-
component lantibiotic, is encoded by nisA, which is a part of an 11-gene cluster containing all the genes 
needed for the production of modified active nisin (Fig 7).  Besides the structural gene, this locus contains 
genes encoding modification enzymes, transporters, immunity proteins, and regulators.  A two-
component signal transduction system, NisRK, encoded within the locus is shown to regulate the 
expression of nisA.  The matured nisin peptide itself acts as a signal to activate the sensor kinase, NisK, to 
induce the expression in a quorum dependent manner.  Interestingly, over expression of the response 
regulator, NisR, alone was sufficient to induce the operon.   A similar observation was made in case of 
lantibiotic epidermin where overexpression of EpiQ (response regulator) increases epidermin 
transcription [184].   However for subtilin production the presence of both the sensor kinase SpaK and the 
response regulator SpaR are necessary [185].  Infact in most cases, a two-component system is associated 
and often essential for lantibiotic expression.   The production of lantibiotic is also growth phase 
dependent as in the case of plantaracin A and subtilin [186]. But the signal necessary for the growth phase 
dependent regulation has not been identified.   
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S. mutans GS-5 is a highly virulent strain that is known to produce a two-peptide lantibiotic named Smb.  
The Smb biosynthetic operon contains seven genes (smbM1, -F, -T,-M2, -G, -A, and -B) and is regulated 
by ComDE two-component system that responds to competence stimulating peptide (CSP), a quorum 
sensing molecule. The locus that encodes ComDE and CSP (comC) is located elsewhere in the genome 
and genetically unlinked. In addition to the smb operon, ComDE system regulates several other operons.  
Previous studies have shown that smb operon contains two promoters, one upstream promoter (P1) that 
drives the expression of all the seven genes and one down stream promoter (P2) that drives the last two 
structural genes smbAB.  ComDE appears to regulate (positively) only the P1 promoter and the effect on 
P2 promoter is unknown.  
 
A previous study showed that smbG, the fifth gene in the operon, can provide resistances in the organism 
against some antimicrobial substances [126].  However, the authors did not observe any increase in 
sensitivity in the smbG deficient strain [132].  They observed sensitivity only when the indicator strain 
contained two mutations, one in the promoter of smb and another in an unrelated immunity protein (Bip) 
expressed from a different region in the chromosome.  However, we showed that SmbFT ABC transporter 
complex alone can provide immunity against Smb and a strain devoid of smbT is sensitive to Smb 
(Chapter 3).  Since SmbG contains a protease motif, it might be involved in the processing and transport 
of mature peptide Smb. 
 
The present study shows that the mature peptide Smb functions as a signaling molecule to induce its own 
expression.  Since the smb locus does not encode any two-component regulatory system, a search for the 
regulator involved in mediating the signal to the promoter identified a new protein. This regulator is 
predicted to be a PadR family protein. We show that this protein positively influences the production of 
Smb. 
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Figure 21:  Genetic organization of smb locus and construction of the smbAB mutant (A).  The locus 
encodes seven genes that are transcribed from a major promoter, P1.  Another promoter (P2) that is 
located just downstream of the fifth gene, smbG, and putatively transcribes smbAB genes.  A rho-
independent terminator maps downstream of the smbAB genes.  (B). PCR verification of ∆smbAB mutant.  
The mutant was created by gene replacement with an kanamycin resistant cassette.   
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5.3. Results 
5.3.1. Inactivation of the structural genes and evaluation of the mutants for susceptibility to Smb. 
Since nisin works as a signaling molecule to activate its own locus we wanted to examine whether the 
structural genes smbA and smbB are also involved in enhancing transcription of its own locus. Because 
the immunity protein (SmbFT) is also encoded in this locus, we wanted to test the sensitivity of the strains 
lacking smbAB against GS-5. We inactivated both the structural genes by gene replacement with a Km 
resistance cassette.  The mutant was evaluated as a tester strain against Smb produced by GS-5.  Indeed 
the smbAB mutant (IBSA63) showed increased susceptibility to Smb.  This result suggests that the smbAB 
genes are necessary for complete protection of the producer strain.  
 
5.3.2. Induction of P1 (smb) by SmbAB functioning as a signal.  To further verify whether Smb  
functions as a signaling molecule to activate the promoter P1, we performed semiquantitative RT-PCR of 
the three following genes - smbM1, smbT, and smbG form GS-5 and the mutant strain IBSA63.  We 
found that expressions of all three genes were at least two-fold reduced in the mutant strain compared to 
the wild-type GS-5.  Growth of both the strains was measured for any apparent growth defect.  We 
observed that both strains grew equally well at 37°C.  This finding indicates that the matured form of Smb 
functions as a signal to activate its own locus.   
 
5.3.3. Effect of putative transporter SmbG on promoter activation.  The smb locus contains only two 
ABC transporters, the SmbFT complex and SmbG.  We showed that SmbFT functions as an immunity 
protein for Smb.  Here we propose that the other ABC transporter, SmbG, which contains a cysteine 
protease domain, is the exporter of the processed Smb. We wanted to verify if the smbG mutant (IBSA89) 
is also sensitive to Smb like IBSA63.  We observed that this mutant is more sensitive to Smb than GS-5.   
Moreover, when we compared the susceptibility with the smbFT mutant (IBSA77), we found that 
IBSA89 is not as susceptible as IBSA77.  This observation suggests that SmbFT is expressed at a basal 
level even in the absence of Smb signaling. 
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5.3.4. Identification of positive regulators for P1 (smb).  To understand the smb promoter regulation 
further, we constructed a Psmb-gusA reporter strain (IBSA71) and subjected this strain to ISS1 
mutagenesis. Since we wanted to identify positive regulators for this promoter, we selected mutants that 
produce white or pale blue color colonies on X-Gluc plate.  We screened approximately 6000 colonies of 
which 45 colonies were either pale blue or white.  Among the 45 colonies, only 20 were defective in 
mutacin production.  These colonies were analyzed further to identify the ISS1 insertion site.  We 
classified the mutants into two groups.  The first group contains mutants that were mapped in the genes 
involved in the ComDE signaling pathway.  These genes are: comD (the histidine kinase), comE (the 
response regulator), nlmTE (the transporter of CSP) and sepM (the protease that processes CSP to its 
active form).  For each of these genes, at least one mutant was identified and in some cases two 
independent insertions were obtained (comD).  The second group includes genes that are annotated as 
hypothetical proteins.  These genes are SMU.831, SMU.833, SMU.1077, SMU.1704, and SMU.1706.  
Interestingly, two independent isertions had ocurred into a SMU.1706.  The operon that encodes 
SMU.1706 is a three-gene operon.  The first gene of this operon, SMU.1704, is a putative PadR family 
regulator and we obtained an insertion into this gene.  The following two genes are SMU.1705 and 
SMU.1706; both encode putative membrane bound proteins.  Since, competence related genes including 
ComE are known to activate the P1 promoter we did not study them further, rather we decided to focus on 
the uncharacterized operon SMU.1704-6 that we identified.   
 
We inactivated the regulator, SMU.1704, by gene replacement (IBSA72).  We also constructed a strain 
where we replaced the entire SMU.1704-6 locus with an Em cassette (IBSA81).  We tested whether 
IBSA72 produces less Smb compared to GS-5 and is more sensitive to Smb.  We observed that IBSA72 
indeed produces less Smb compared to GS-5 (Fig 25) and is more susceptible to Smb (data not shown).  
However, IBSA81 seemed to produce a slightly lower amount of Smb compared to GS-5 on agar plate.  
This observation suggests that this newly identified operon SMU.1704-6 might act as a positive regulator 
of the P1 promoter.  Further experiments are required to confirm whether P1 expression is directly 
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regulated by SMU.1704 protein, or indirectly regulated by one or more gene products encoded by this 
operon.    
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Figure 22:  Growth characteristics and gene expression profile of the wild type and the smbAB mutant. 
(A). RNA was isolated from the wt and the mutant strains and subjected to semiquantitative RT-PCR 
analysis to measure the relative amounts of the targeted genes as shown.  The experiment was performed 
twice. (B). Analysis of growth of the wt and the mutant in THY broth at 37◦C under microaerophilic 
condition. The experiment was repeated twice.  (C). Schematic diagram showing the smb operon.  Genes 
used for RT-PCR analysis are shown with vertical arrows.  
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Figure 23: Susceptibility of smbAB deletion mutant to Smb.  Deferred antagonism assays were performed 
as described in Chapter 2.  The plates were overlaid with either GS5 or the mutant starin.  A diffused ZOI 
is clearly visible in case of the ∆smbAB strain.  The experiments were performed twice. 
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Figure 24. Susceptibility of smbG mutant against Smb. Deferred antagonism assay using the wild type 
and two mutant strains.  Indicator strains were overlaid on THY agar plates that were pre stabbed with 
GS5 and ∆smbAB.  Note, ∆smbG strain clearly produces a diffused ZOI, whereas ∆smbT strain produces 
a clear ZOI. 
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Figure 25:  Assessment of the role of SMU.1704 -1706 operon in smb promoter (P1) expression. (A). 
Schematic diagram of the SMU.1704 -1706 operon.  A putative promoter like sequence is shown with the 
bent arrow.  Site for two ISS1 insertions are also shown with inverted triangles. (B). Deferred antagonism 
assay with ∆SMU.1704 (IBSA72) and ∆SMU.1704 -1706 (IBSA81) strains as indicator.  (C). Growth 
kinetics of the wt and two mutants were measured in THY broth at 37◦C under microaerophilic condition.  
Experiments were performed twice. 
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Figure 26.  A working model for smb promoter regulation.  In this model we predict SmbG (yellow oval) 
is the transporter that secretes the matured Smb peptides.  Whether SmbA and SmbB peptides are 
secreted individually or as a complex is not known.  The mature Smb peptide then binds to an unknown 
sensor protein, most probably a sensor kinase (green oval) to activate the cognate response regulator, 
which in turn induces P1 promoter.  Since SMU.1704 is a transcriptional regulator, we speculate that 
SMU.1704 also directly regulates this operon.  The P1 promoter is also directly regulated by ComDE 
pathway.  However, we believe Smb does not interact with ComDE pathway.   The exact function of 
SMU_GS5_02915 (the receptor, SMU.662) in the smb regulation is unknown.   
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5.4. Discussion 
 
Nisin and subtilin are two well-studied lantibiotics that are involved in self-regulation.  It was known that 
both nisin and subtilin regulate their promoters by working as a signaling molecule through a two-
component system.  However, to our knowledge, the role of a two-peptide lantibiotic working as a 
signaling molecule to activate its own transcription has never been reported.  In the present study, we 
wanted to test whether Smb is functioning as a signaling molecule for its own promoter.  We observed 
that smbAB inactivated strain was susceptible to exogenous Smb produced by GS-5.  This indicates that 
the P1 promoter of smb is autoregulated by Smb.  Either the intracellular Smb prepeptides or the secreted 
form of matured and processed Smb promotes the transcription induction of the smb operon.   
 
Because we observed increased sensitivity of the smb mutant against GS-5, we wanted to examine 
whether the immunity protein SmbFT expression is reduced and therefore becomes sensitive to Smb.  We 
also wanted to verify whether the transcription of the whole locus is reduced.  Our semiquantitative RT-
PCR data show that the expression of smbM1 (the modification enzyme), smbF (the immunity complex 
protein), and smbG (the putative transporter) are reduced two-fold in the smb mutant strain.  This 
indicates that Smb signaling enhances the expression of the genes encoded in the operon.  In other words, 
without Smb signaling, genes in this operon are expressed at a basal level.   We also observed that smbG 
(a putative transporter) mutant strain, which is deficient in secreting mature Smb, is sensitive as the smb-
deficient strain.  This suggests that the secreted mature form of Smb and not the intracellular form of Smb 
is involved in the signaling.  Moreover, we also observed that the smbT-deficient strain is significantly 
more sensitive to Smb compared to the smb- or smbG-deficient strains (Fig 25).  This indicates that Smb 
signaling only enhances the expression of the operon encoding the immunity protein SmbFT.   
S. rattus is very closely related to S. mutans and belongs to mutans group of streptococcus.  S. rattus 
encodes a two-peptide lantibiotic operon, bhtA, which is nearly identical to smb except that the bhtA locus 
also encodes a regulator protein encoding gene upstream to the operon locus.  This regulator protein most 
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probably regulates the expression of bhtA operon. In the case of smb operon, since the regulator is absent, 
we speculate that ComDE maintains a certain level of expresssion of Smb.  When the cells reach a certain 
density or when the extracellular concentration of Smb reaches a certain threshold, Smb positively 
autoregulates its own expression.    
 
Finally, our transposon mutagenesis study identified several activators of the P1 promoter.  Since we 
identified several genes that belong to the ComDE pathway and since ComDE pathway genes are known 
to regulate P1 promoter, it indicates that our screening method was successful for the identification of the 
activators.   Interestingly, we identified a new operon SMU.1704-6 that is involved in the activation of 
this operon.  We observed that the SMU.1704 mutant strain is deficient in Smb production. Furthermore, 
the mutant strain is also susceptible to Smb like the smb-deficient strains (data not shown).  Altogether, 
this observation suggests that the putative PadR family repressor SMU. 1704 regulates the P1 promoter.  
The exact mechanism by which SMU.1704 regulates the P1 promoter is currently unknown.  Since both 
SMU.1705 and SMU.1706 encode membrane bound proteins, we speculate that these two proteins might 
form a complex and function as a sensor.   When this complex recognizes appropriate signals, they 
activate SMU.1704.  This activated SMU.1704 then induces the smb operon.  Alternatively, SMU.1704 
might function with a yet to be indentified partner sensor protein.  In this regard, SMU.1704 might 
function the same way as the unusual two-component system Stp/Stk where the partner protein is 
unknown.   Further experiments on SMU.1704 might unravel a new regulatory pathway in bacteria (Fig 
26). 
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Chapter 6: Conclusions and Discussions 
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Both one- and two-peptide lantibiotics are potential alternatives to the already existing antibiotics in the 
market.  However, lantibiotics have not been properly explored for therapeutic purposes in the healthcare 
industry. The emergence of multidrug-resistant bacteria generated a renewed interest in these naturally 
existing antimicrobials because the lantibiotics use different targets on bacteria than the commercially 
available antibiotics. Usually, most of the lantibiotics use the lipid II as their docking molecule to inhibit 
the target cells.  But the initial binding sites on lipid II for lantibiotics and antibiotics such as vancomycin 
are different. Thus, lantibiotics has even the potential for treatment against vancomycin-resistant 
enterococcus (VRE) or vancomycin-resistant S. aureus (VRSA).   
 
Among the lantibiotics, it is not known whether two-peptide lantibiotics are more potent than the one-
peptide ones.  One-peptide lantibiotics such as mersacidin or actagardin can bind to lipid II and inhibit 
cell wall biosynthesis.  In contrast, two-peptide lantibiotics such as lacticin 3147 (Ltnα and Ltnβ) contains 
a lipid II binding component, Ltnα, which inhibits cell wall biosynthesis.  The second component, Ltnβ, 
can act synergistically to form pores in the target cell membrane and cause ion loss leading to rapid cell 
death.  In general the two-peptide lantibiotics are more potent and have wider inhibitory spectra.   For 
example lacticin 3147 has much wider inhibitory spectra than mersacidin.  However, nisin, which is a 
one-peptide lantibiotic, is an exception and can inhibit a wide range of organisms.  This is because nisin 
can inhibit both the cell-wall biosynthesis and can form pores in the target cell membrane.   Two-peptide 
lantibiotics could provide additional options to generate mutations aiming to improve the potency. For 
one-peptide lantibiotics the options to improve the potency by mutagenesis is theoretically limited to half.   
Furthermore, the modification enzymes may not be able to recognize or modify if too many residues are 
changed in a single peptide.  Furthermore two separate peptides provide lantibiotics a chance to pair with 
a homologous counterpart from another two-peptide lantibiotic to create a hybrid lantibiotic with much 
wider inhibitory spectra, increased potency and/or stability.  Smb, the two-peptide lantibiotic that we 
studied here, has not been explored for bioengineering purposes.  Moreover, to our knowledge Smb has 
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never been extensively studied for its activity or never been paired with another two-peptide lantibiotic 
for enhanced potency.  
 
Smb is naturally very potent and has a broad inhibitory spectrum that includes most pathogenic 
streptococci such as S. pyogenes, S. agalactiae, and S. pneumoniae.  Few other less pathogenic 
streptococci, such as S. dysgalactiae (causes osteomyletis) and S. gallolyticus (causes encodcarditis and 
perhaps colon cancer), are also inhibited by Smb (Chapter 3).  Furthermore, Smb is active against many 
commensal but opportunistic viridians group of streptococci including many S. mutans isolates, and these 
viridans streptococci can cause systemic infections leading to infective endocarditis.  Based on the 
inhibitory spectra it appears that the natural form of Smb carries a strong therapeutic potential.   
 
To evaluate the therapeutic applicability of Smb, it is fundamental to understand how Smb recognizes and 
inhibits the target organisms.  An organism becomes a target when it carries a receptor for the lantibiotic 
and at the same time lacks the immunity protein necessary for protection against the lantibiotic (Fig 27). 
Identities of neither of these molecules were known for Smb.  In addition, how S. mutans regulates the 
level of Smb production during initial colonization and how the organism sustains bacterial warfare in the 
dental plaque are also unknown.  Our study is the first to shed some lights on these various unexplored 
questions.   
 
Lantibiotics are generally purified from the culture supernatant of the producer strain, but the yield of the 
purified product is often not high enough for economic benefit.   In many cases, lantibiotics are purified 
from agar media for better yield, presumably because the lantibiotics are expressed in higher amounts in 
solid media than in liquid broth.  However, an alternative production strategy is to over express the 
immunity protein leading to higher secretion of the cognate lantibiotics [146]. In this dissertation work, 
we identified SmbFT as the immunity protein for Smb (Chapter 3).  We also verified that over expression 
of SmbFT in GS-5 leads to increased ZOI indicating increased Smb production (preliminary observation).  
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Identification of the cognate immunity protein for Smb also opens up new avenues of research.  For 
example, it is now possible to explore various mutated forms of SmbFT for better protection against Smb.   
However, if a more potent bioengineered form of Smb is developed in the future, it has to be kept in mind 
that the immunity protein also needs to be modified accordingly to provide proper protection to the 
producer strain.  Identifying the critical residues on SmbFT required for lantibiotic recognition as well as 
for protection will provide the necessary information for such modifications.  These studies will further 
explore the therapeutic potential of Smb lantibiotic beyond the natural limits. 
 
To our surprise we found that SmbFT can confer cross-protection against related lantibiotics such as 
haloduracin and gallolacticin.  We speculate that in a given multispecies community there are bacteria 
that are protected from each other’s bacteriocins to coexist together and to employ a concerted inhibitory 
effect against their competitors. This group of bacteria are perhaps metabolically diverse and do not 
compete within themselves for nutritional resources.  We also found that SmbFT alone is sufficient to 
provide protection against Smb in S. sanguinis, a cocolonizer of S. mutans.   If S. sanguinis, which is 
naturally competent, acquires just the smbFT or the entire smb locus by horizontal gene transfer, then S. 
mutans will not be able to inhibit S. sanguinis.  We speculate that S. mutans might use other strategies, 
such as interfering with the competence of S. sanguinis, so that the Smb is still active against this 
organism. 
 
Cross-immunity conferred by an ABC transporter complex has been reported previously.  A 
staphylococcin C55 producer S. aureus strain is also cross immune to lacticin 3147 produced by L. lactis.  
Therefore, a repository of Smb or lacticin 3147 resistant strains, other than the expected producer 
organisms, exist in the nature and perhaps are present in the same environmental niches [187]. If a given 
lantibiotic is considered for therapeutic purposes, it is necessary to consider the resistance problems 
before hand so that a proper strategy can be developed to counter act the emergence of resistance due to 
cross-immunity.   
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Although the exact mode of action for SmbFT was not characterized in this study, an equivalent system 
encoded by NisFEG has been shown to export the membrane-inserted nisin to the outer milieu.  An 
additional protein, NisI, sequestrates the extracellular expelled nisin and prevents their reinsertion into the 
membrane.  For SmbFT it is currently unknown what prevents Smb from coming back to the membrane 
once it is exported outside, since the smb locus does not encode a sequestering protein like NisI.  We 
speculate that the exporter protein SmbG that is involved in the secretion and processing of Smb might 
provide a sequestration function.  This is because SmbG bears a large extracellular domain that might be 
suitable for binding the expelled Smb and prevent its re-association with the membrane.  Alternatively, 
Bip, a membrane protein that was proposed by Kuramitsu’s group to function as an immunity protein, 
might function as a sequestration protein and prevent Smb to re-associate with the membrane.  However, 
this is just a speculation that needs to be verified experimentally.  
 
Although it is known that immunity proteins can enhance the production of cognate lantibiotics, the exact 
mechanism of enhanced production has not been evaluated at the molecular level.  Some immunity 
proteins such as BceAB type ABC transporter interact with a signal transduction pathway and regulate the 
production of bacteriocin [139].  In case of BceAB, the transmembrane domain of the transporter 
complex interacts with the histidine kinase present at the membrane and this interaction is necessary for 
the signal transduction that ultimately regulate bacteriocin production.  Interestingly, the ATPase activity 
of the immunity protein is also necessary for the signaling.  It seems that when the immunity protein 
exports out the bacteriocins from the membrane, the ATPase activity influences the sensor kinase to 
activate transcription therefore more immunity protein is produced.  We also observed that when SmbFT 
is over expressed Smb production is also increased; however, the detailed molecular mechanisms by 
which SmbFT influences Smb production remains to be explored. 
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In general, lantibiotics have a very well defined inhibitory spectra and this led us to believe that the target 
selectivity is due to specific interaction between the lantibiotic and a receptor-like component on the 
target organism.  Lipid II is still essential for inhibition but the absence of a particular receptor or 
receptor-like protein makes an organism resistant (Figure 27).  Identification of a receptor for a non-
lantibiotic bacteriocin such as pediocin is a very recent event; although, the pediocin-like bacteriocins 
were discovered decades ago.  No receptors or receptor-like proteins have been identified for any 
lantibiotics despite the intense research in this area.  In this work, we have identified a protein with 
receptor-like function towards Smb (Chapter 4).  This protein, which we named LsrS, is a zinc 
metalloprotease and shows a receptor-like function in S. pyogenes for Smb.  The molecular mechanisms 
by which LsrS causes Smb mediated toxicity are currently unknown.  However, we speculate that the 
LsrS-Smb interaction is direct since we isolated an lsrS-deficient mutant colony as a survivor inside the 
ZOI of Smb.  Although, the ZOI in S. pyogenes was not reduced to zero, the ZOI was reduced to zero in a 
SMU.662 mutant of S. mutans V403.  Since the lsrS-mutant of S. pyogenes produced a moderate ZOI it is 
possible that this organism encodes multiple receptors or receptor-like proteins for Smb, while S. mutans 
encodes only one.  Since all the members of pyogenic group of streptococci that we tested produced 
consistently larger ZOI compared to the other organisms, we speculate that pyogenic streptococci perhaps 
encode multiple receptors for Smb.  Furthermore, the streptococci tested in this study were sensitive to 
Smb because of the presence of the receptor or receptor-like proteins although some encode homologs of 
the immunity protein as evident from our in silico searches.  These immunity-like proteins either are 
pseudogenes or do not recognize Smb.   Surprisingly, we found that the Smb producer strain GS-5 also 
encodes the receptor protein (SMU_GS5_02915).   Our preliminary studies suggest that this protein 
shows receptor-like function.  At present we do not know the reason why a producer strain also encodes 
the receptor.  Since LsrS is the only receptor so far identified, we do not know how frequent is the 
presence of both the receptor and the cognate lantibiotic in bacteria.  One possibility is that when the 
producer strain encodes a receptor, the receptor may handover the lantibiotic immunity proteins. We 
speculate that the immunity proteins and receptors reside on the producer membrane juxtaposed to each 
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other to efficiently handover the receptor bound Smb to SmbFT for export.  Furthermore, it is possible 
that the presence of receptor bound to Smb might negatively influence the secretion of Smb.   Future 
studies will unravel the significance of the presence of receptors in producer organisms. 
 
LsrS is a CAAX family protease that belongs to CPBP subfamily.  CBPB subfamily proteins are widely 
present in bacteria but they are very poorly characterized.  Only a handful of CPBP proteins have been 
experimentally characterized and they show a diverse range of functions.  These CBPB proteins contain 
various functional domains at the N-terminal side, which are not characterized.  So far the identified 
receptor proteins for unmodified bacteriocins are sugar transporters and the most recent one is a zinc 
metallo-protease.  These proteins are all well conserved in bacteria.  LsrS is also a conserved protein and 
its presence in the producer strain indicates that the lantibiotics, in addition to killing activity, may 
possess a signaling activity to regulate various cellular functions that are needed for the growth in the 
multispecies community. Deciphering this signaling pathway mediated by lantibiotics within and beyond 
the producer population might open up new avenues in bacteriocin research. 
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Figure 27:  A model for Smb mediated inhibition.  The SmbG transporter protein secretes Smb to the 
outside.  Accumulated Smb is then recognized by a cell-surface receptor protein, SMU_GS5_02915 
(SMU.662), which probably interacts with the immunity complex, SmbFT (an ABC transporter) that 
pumps out the Smb before it can exert its inhibition.  The target cells that contain only the receptor 
protein, and not the immunity protein, will be killed.  For example, S. pyogenes which conatins LsrS but 
not the immunity protein is susceptible.  Whereas Smb will not inhibit cells containing both the receptor 
and the immunity proteins.    Similarly, cells that are devoid of both the receptor and the immunity 
proteins are also refractory to Smb mediated inhibition.    
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Abstract 
Streptococcus mutans, a principal causative agent of dental caries, is considered to be the most cariogenic 
among all oral streptococci.  Of the four S. mutans serotypes (c, e, f, and k), serotype c strains 
predominate in the oral cavity.  Here we determine the complete genome sequence of S. mutans GS-5, a 
serotype c strain originally isolated from human carious lesions, which is extensively used as a laboratory 
strain worldwide.    
 
Text 
Streptococcus mutans, a colonizer of the supragingival tooth-surface, is a part of a complex microflora 
comprising ~700 species.   To maintain its dominant presence and to cause dental caries, this acidogenic 
and aciduric organism can drastically and quickly reduce the pH of its surrounding leading to 
demineralization of tooth enamel (10).  S. mutans also secretes antimicrobial peptides (mutacins) to 
suppress the growth of other competing species.  Of the four serotypes of S. mutans, the predominant oral 
isolates are of serotype c (14).  GS-5 is a representative serotype c strain originally isolated from carious 
lesions forty-five years ago (7), and has been extensively used in genetic and biochemical studies of 
virulence (10). This strain also produces a unique two-peptide lantibiotic mutacin, known as SmbAB (17), 
which is encoded by only ~8% of the isolates (16).  Recent completion of three S. mutans genome 
sequences (UA159, NN2025, and LJ23; (1, 2, 13), indicates a large degree of diversity and genome 
rearrangement within the species.   Here we determine the complete genome sequence of GS-5, which 
will allow us to gain further insight into overall genetic variation in S. mutans. 
 Genome sequencing was performed using a combination of strategies that include Illumina GA-IIx 
and Roche GS-Jr. technology at Cofactor Genomics (St. Louis, USA).  Illumina sequencing used two 
genomic libraries SIPE (~300bp) and LIMP (~3-kb), which generated ~21 and ~15 million paired reads, 
respectively.  Roche 454 GS-Jr. generated 142,832 reads (average length ~450nt) that covered ~26X of 
the entire genome.  Several assembly procedures were applied and manual editing was performed with the 
454 GS-Jr. data. Remaining gaps and unassertive assembled regions were verified by PCR/ABI 
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sequencing to obtain a single contig onto which Illumina data were subsequently mapped for further 
refinement.  The genome was annotated using IGS Annotation Engine (5) and The NCBI Prokaryotic 
Genomes Automatic Annotation Pipeline (PGAAP) was employed for submission 
(http://www.ncbi.nlm.nih.gov/genomes /static/Pipeline.html). 
GS-5 genome encodes a 2,027,088-bp circular molecule with a G+C content of 36.8%. The sequence 
information is consistent with a previously generated physical map of the GS-5 genome (3).  Putative 
origin of replication was mapped near position 1553-nt by OriFinder (6).  GS-5 harbors 65 tRNA genes, 
15 rRNA genes, and 1985 CDS.  Among the CDS, 91 exported-proteins, 23 lipo-proteins, 11 wall-
proteins, and 462 membrane-proteins were identified by SLEP (8). No putative phages or prophages were 
predicted by Prophinder (12).  However, two complete and one incomplete CRISPRs (clustered regularly 
interspaced short palindromic repeats), and numerous insertion sequences were identified with 
CRISPRFinder (9) and ISfinder (15), respectively. Furthermore, in addition to SmbAB, at least ten other 
putative mutacins were also identified by BAGEL2 (4).  Several large (>1.0-kb) duplicated regions were 
identified in the genome by REPuter (11).  Sequence alignment indicated that genome rearrangement 
occurred between GS-5 and NN2025 across the replication axis, but not between GS-5 and UA159.  The 
GS-5 complete genome will allow for in depth comparative genomics to unravel the extent of genome 
rearrangements and dynamics in S. mutans and to better understand the adaptive life style of this 
pathogen. 
 
NUCLEOTIDE SEQUENCE ACCESSION NUMBER:  The complete genome sequence of S. mutans 
GS-5 was deposited in GenBank under the accession number CP003686. 
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